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SUMMARY: 
The  project  was  concerned  with  the  construction  of  defined  attenuated 
derivatives  of  P.  multocida  serotype  B:  2  strains,  causative  agents  of 
haemorrhagic  septicaemia,  and  attempts  were  made  to  construct  defined 
mutations  in  genes  such  as  aroA,  cya,  and  galE  loci  that  have  been  used  to 
induce  attenuation  in  other  bacterial  strains. 
Mutants  defective  in  the  aroA  gene  were  constructed  by  allelic  exchange  of 
the  locus  in  the  chromosome  of  the  wild-type  strains  with  a  cloned  aroA  gene 
interrupted  with  a  cassette  encoding  kanamycin  resistance  (KmR).  The  aroA 
defective  strains  were  confirmed  by  PCR,  Southern  blotting,  lack  of  growth 
on  minimal  medium  and  by  enzyme  assay. 
KmR-inactivated  aroA  mutants  JRMT1  and  JRMT2  strains  derived  from  P. 
multocida  85020  and  Quetta  strains,  respectively,  were  highly  attenuated  in  a 
mouse  model,  with  an  LD50  >_  108  C.  F.  U.  /mouse  after  injection 
intraperitoneally  (i.  p.  ).  In  contrast,  the  wild-type  strains  had  LD50  <50 
C.  F.  U.  /  mouse  by  this  route.  Vaccination  once  by  the  i.  p.  route  or  twice  by 
the  i.  n.  route  with  these  aroA  mutants  gave  complete  protection  to  the  mice 
against  subsequent  challenge  i.  p.  with  10,000  LD50  of  the  homologous  wild- 
type  strain  or  1000  LD50  of  the  heterologous  wild-type  strain.  Vaccination 
with  these  by  the  s.  c.  route  was  not  protective.  When  high  doses  of  the 
attenuated  strains  were  inoculated  by  the  i.  p.  or  i.  n.  routes,  there  was  some 
spread  to  the  internal  organs  but  the  organisms  were  cleared  by  24  and  72  his 
respectively.  In  contrast,  the  wild-type  parent  strains  spread  rapidly  and 
multiplied  in  high  numbers  and  killed  the  mice  by  24  and  96  hrs  respectively. XXVI 
Attempts  were  made  to  construct  cya  mutants,  by  insertion  of  KmR  or  ApR 
cassettes  into  the  cya  gene  by  allelic  exchange,  but  this  was  only  partially 
successful.  Only  a  single  cya::  KmR  clone  that  produced  the  correct  predicted 
size  bands  by  Southern  blot  hybridisation  was  obtained  with  the  Quetta  strain. 
This  strain  showed  some  attenuation,  with  an  LD50  about  1000  C.  F.  U.  / 
mouse  by  the  i.  p.  route,  but  did  not  provide  any  protection  in  the  mouse 
against  challenge  with  the  wild-type  parent  strain.  Also,  insertion  of  a  KmR 
cassette  into  the  galE  locus  did  not  prove  to  be  successful  and  no  strains  were 
obtained  with  the  predicted  genotype. 
For  construction  of  a  marker-free  aroA  mutant,  different  procedures  were 
attempted.  These  included  selection  against  the  vector  and  combinations  of 
repeated  subculturing  and  auxotrophic  enrichment,  but  these  were 
unsuccessful.  Finally,  for  the  first  time  in  Pasteurella  strains,  the  sacB  gene 
was  used  successfully  as  a  positive  selection  marker.  A  broad-host-range 
suicide  plasmid  pJRMT30  containing  the  sacB  gene  of  Bacillus  subtilis  was 
constructed  for  use  in  the  positive  selection  for  marker-free  construction  in 
Gram-negative  bacteria.  P.  multocida  cells  containing  pJRMT30  do  not  grow 
on  a  medium  containing  5%  (w/v)  sucrose  and  loss  of  the  plasmid  can  be 
monitored  by  the  capacity  to  grow  on  this  medium.  With  this  procedure, 
marker-free  aroA  mutants  of  P.  multocida  85020  and  Quetta  strains,  JRMT12 
and  JRMT13  respectively,  were  constructed.  These  two  deleted  aroA  mutant 
strains  showed  attenuation  and  protection  properties  similar  to  the  KmR- 
interrupted  aroA  mutants.  This  strategy  was  not  successful  however  for 
construction  of  a  deleted  galE  mutant. 
The  P.  multocida  strain  85020  and  its  aroA  mutant,  JRMTI,  were  tested  in 
a  phagocytosis  assay,  with  a  macrophage-like  cell  line,  to  examine  the  uptake XXVI 
and  survival  of  the  strains  within  the  intracellular  environment.  Both  strains 
were  taken  up  into  the  macrophage-like  cells  but  the  aroA  strain  JRMTI  was 
able  to  enter  more  efficiently  than  its  wild-type  parent  strain.  Both  wild-type 
and  mutant  were  able  to  survive  for  at  least  2  hrs  in  the  phagocytic  cells. i 
1.  INTRODUCTION 
1.1.  The  family  Pasteurellaceae 
As  reviewed  by  Bisgaard  (1995),  the  family  Pasteurellaceae  pohl  1981  was 
conceived  to  accommodate  a  large  group  of  Gram-negative  chemoorgano- 
trophic,  facultatively  anaerobic,  and  fermentative  bacteria  including  the  genera 
Pasteurella,  Actinobacillus,  Haemophilus  and  several  other  groups  of 
organisms  that  exhibit  complex  phenotypic  and  genotypic  relationships  with 
the  aforementioned  genera. 
1.2.  The  genus  Pasteurella 
DNA:  DNA  hybridisations  have  shown  that  this  genus  consists  of  at  least  11 
species  some  of  which  have  not  yet  been  named.  The  Pasteurella  sensu  stricto 
includes  Pasteurella  multocida  with  3  subspecies  (multocida,  septica,  and 
gallicida),  P.  dagmatis,  P.  gallinarum,  P.  canis,  P.  stomatis,  P.  avium,  P. 
volantium,  P.  anatis,  P.  langaa  and  Pasteurella  species  A  and  B.  Species  and 
taxa  excluded  from  the  genus  include  [P.  ]  aerogenes,  [P.  ]  haemolytica 
biotypes  A  and  T,  P.  multocida  biotype  1,  [P.  ]  pneumotropica  biotypes  Heyl 
and  Jawetz,  [P.  ]  testudinis,  [P.  ]  urea,  and  the  SP-group.  The  bacteria  in  [P.  J 
haemolytica  biotypes  A  and  T  have  been  reclassified  by  taxonomists  twice 
since  1990.  The  former  T.  biotype  is  now  P.  trehalosi  and  the  A  biotype  has 
been  placed  in  a  new  genus,  Mannheimia  (Angen  et  al.,  1999).  The  majority  of 
the  old  Pasteurella  haemolytica  A  biotype  serotypes  are  now  known  as 
Mannheimia  haemolytica. 
In  Bergey's  Manual,  the  genus  Pasteurella  is  listed  under  the  heading 
"Gram-negative  Facultatively  Anaerobic  Rods:  Genera  of  Uncertain 2 
Affiliation"  as  type  genus  of  the  family  Pasteurellaceae.  The  type  species  of  the 
genus  is  P.  multocida  and  has  now  been  widely  accepted. 
Bacteria  included  in  the  genus  Pasteurella  are  commensal  and  occasional 
pathogens  of  many  species  of  domestic  and  wild  animals.  The  principal 
characteristics  of  members  of  the  genus  are:  small,  Gram-negative  rods  or 
coccobacilli  with  size  ranging  from  0.3-1.0  µm  in  diameter  and  1.0-2.0  gm  in 
length,  non-motile,  facultatively  anaerobic,  and  they  display  a  characteristic 
bipolar  staining  with  either  Leishman  or methylene  blue  stains.  The  organisms 
do  not  grow  on  MacConkey's  agar  and  they  are  non-haemolytic  on  blood  agar. 
On  nutrient  agar  they  produce  fine,  translucent  colonies  with  a  characteristic 
musty  odour.  P.  multocida  organisms  are  oxidase,  catalase  and  indole  positive. 
They  ferment  sugars  such  as  glucose,  sucrose,  sorbitol  and  mannitol  with  acid, 
but  with  no  gas  production.  Lactose,  maltose  and  salicin  are  not  fermented, 
while  variable  fermentation  results  are  obtained  with  arabinose,  trehalose  and 
xylose.  Gelatin  is  not  liquefied. 
1.3.  The  species  Pasteurella  multocida 
Pasteurella  multocida  has  been  recognised  as  an  important  veterinary 
pathogen  for  over  a  century,  and  its  importance  as  a  human  pathogen  causing 
bite  wounds,  respiratory  diseases  and  infections  of  the  central  nervous  system 
(Fredriksen,  1989)  has  been  increasingly  recognised  in  the  last  50  years.  The 
organism  can  occur  as  a  commensal  in  the  naso-pharyngeal  region  of 
apparently  healthy  animals  and  it  can  be  either  a  primary  or  secondary  pathogen 
in  disease  processes  of  a  variety  of  domestic  and  wild  mammals  and  birds. 
Distributed  throughout  the  world,  it  has  been  found  among  many  varieties  of 
both  terrestrial  and  aquatic  species  of  mammals  and  birds  (Rimler  and  Rhoades, 
1989). 3 
1.3.1.  Cell  morphology  and  staining 
P.  multocida  is  a  non-motile,  non-sporogenous  coccobacillus  or  short  rod, 
which  stains  Gram-negative.  Cells  can  occur  singly,  in  pairs  and  occasionally 
as  chains  or  filaments.  In  tissues,  exudates  and  recently  isolated  cultures,  the 
bacterium  shows  bipolar  staining  with  Giemsa  or  Wright's  stain.  Cells  usually 
measure  0.2-1.25  pm  in  length  but  after  repeated  subculture  they  tend  to 
become  pleomorphic. 
Virulent  strains  of  P.  multocida  are  usually  capsulated  and  their  capsules 
can  be  seen  in  organisms  isolated  from  tissues  of  diseased  animals  and 
laboratory  cultures.  The  capsules  are  composed  of  carbohydrate  and  differ  in 
size  and  chemical  composition  amongst  the  varieties  of  P.  multocida.  They  are 
frequently  lost  upon  repeated  subculture.  Several  techniques  have  been  used  to 
demonstrate  capsules  for  light  microscopy.  The  alcian  blue,  Congo  red  and 
crystal  violet  methods  have  been  used  for  direct  staining  while  the  Jasmin  and 
Indian  ink  methods  have  been  used  for  indirect  staining  (Rimler  and  Rhoades, 
1989).  Recently,  the  capsule  has  been  demonstrated  to  be  an  important 
virulence  factor  (Boyce  and  Adler,  2000). 
1.3.2.  Colonial  morphology 
Generally,  description  of  colonies  is  made  from  18-24  hrs  cultures  grown 
aerobically  at  35-37"C  on  enriched  media.  Under  these  conditions,  colonies 
usually  range  in  size  from  1.0  to  3.0  mm  in  diameter.  Ordinary  cultures  on  agar 
media  may  develop  into  either  or  both  of  two  principal  colony  forms,  mucoid 
and  smooth.  Rough  colony  forms  are  encountered  infrequently. 
The  largest  smooth  colonies  are  mucoid  and  they  are  composed  of 
capsulated  cells.  The  mucoid  characteristic  can  range  from  cultures  whose 
colonies  are  discrete,  circular,  and  convex  and  have  a  slight  mucus-like 
consistency  to  cultures  whose  colonies  are  confluent,  markedly  moist  and 4 
viscous.  Smooth  colonies  are  composed  of  capsulated  or  noncapsulated  cells. 
They  are  discrete,  circular  and  convex.  Rough  colonies,  which  consist  of 
filamentous  noncapsulated  cells,  have  been  described  as  being  flat  with  slightly 
raised  central  papillae  and  flattened  irregularly  serrated  edges  or  discrete, 
raised,  circular,  rough  and  slightly  dry  (Rimler  and  Rhoades,  1989). 
Colonial  morphology  on  transparent  media  observed  in  obliquely  transmitted 
light  with  a  stereomicroscope  is  a  useful  characteristic  for  the  study  of  P. 
multocida.  Colonies  refract  the  light  in  a  manner  that  helps  distinguish  variants. 
Except  for  watery  mucoid  colonies,  which  appear  grey,  colonies  consisting  of 
capsulated  cells  display  a  yellowish-green,  bluish  green  or  pearl-like 
iridescence.  Composition  of  the  medium  determines  the  degree  and  type  of 
iridescence  to  a  certain  extent.  Colonies  that  consist  primarily  of  noncapsulated 
cells  are  not  iridescent  and  appear  blue,  greyish-blue,  or  grey.  Dissociation, 
which  is  manifested  primarily  by  a  change  from  an  iridescent  to  a  blue  or 
greyish-blue  colony  form,  is  associated  with  a  loss  of  the  bacterial  capsule. 
A  characteristic  mucoid  colony  has  been  found  in  all  serogroup  A  and  a  few 
serogroup  D  strains  (See  section  1.4.4).  All  strains  of  P.  multocida  that 
produce  colonies  of  the  large  watery  mucoid  variety  have  been  found  to  belong 
to  serogroup  A.  Colonies  of  serogroup  A,  D  and  F  strains  display  a  pearl-like 
iridescence  in  oblique  transmitted  light,  except  where  watery  mucoid  colonies 
of  serogroup  A  appear  grey.  Serogroup  B  and  E  strains  produce  the  smallest 
capsules  and  form  smooth  colonies  that  usually  have  a  yellowish-  or  bluish- 
green  iridescence  in  oblique  transmittent  light. 
Dissociation  of  colonies  from  iridescence  to  non-iridescence  and  the 
concomitant  loss  of  the  capsule  of  a  virulent  strain  are  associated  with  reduction 
or  loss  of  virulence  (Heddleston  et  al.,  1964;  Penn  and  Nagy,  1974).  Capsule 
production,  iridescence  and  virulence  can  sometimes  be  regained  or  enhanced 
by  repeated  passage  in  mice  (Rimler  and  Rhoades,  1989). 5 
1.3.3.  Cellular  components 
1.3.3.1.  Capsule  antigens 
The  capsule  antigen  of  P.  multocida  responsible  for  serotype  specificity  is 
intimately  associated  with  lipopolysaccharides  (LPS),  as  well  as  non-antigenic 
polysaccharide  material  (Rimler  and  Rhoades,  1989).  Both  the  capsule-specific 
antigen  and  LPS  can  be  adsorbed  onto  erythrocytes  from  crude  cell  extracts 
(Rimler  and  Rhoades,  1989).  However,  passive  haemagglutination  tests,  with 
serum  containing  antibodies  against  the  capsule-specific  antigen  and  LPS, 
usually  show  a  reaction  only  with  the  capsule-specific  antigen  (Rimler  and 
Rhoades,  1989).  Nagy  and  Penn  (1976)  prepared  capsular  antigens  of  P. 
multocida  serotypes  B  and  E  and  showed  that  they  were  immunogenic  and 
protective  in  cattle  against  serotype  E  challenge.  However,  non-capsulate  and 
capsulate  organisms  of  serotype  A,  strain  X-73,  were  reported  to  be  equally 
effective  in  immunising  birds  against  fowl  cholera  (Heddleston  et  al,  1964). 
1.3.3.2.  Lipopolysaccharides 
P.  multocida  LPS  has  chemical  and  biological  properties  similar  to  those 
found  in  many  species  of  Gram-negative  bacteria.  As  antigens,  LPSs  have  been 
associated  with  immune  protection  of  animals  and  are  believed  to  be  the 
chemical  basis  for  the  specificity  of  the  somatic  typing  system  (Brogden  and 
Rebers,  1978). 
LPSs  have  been  purified  from  many  different  strains  of  P.  multocida.  In 
common  with  LPSs  from  bacteria  of  the  family  Enterobacteriaceae,  chemical 
analysis  has  shown  that  they  contain  lipid  A,  2-keto-deoxyoctonate,  L-glycero- 
D-mannoheptose,  glucose  and  glucosamine.  Other  sugars  encountered  amongst 
LPSs  from  different  strains  were  galactose,  rhamnose,  D-glycero-D- 
mannoheptose  and  galactosamine  (Rimler  et  al.,  1984).  Although  a  possible 
structure  for  the  heptose  region  has  been  described,  the  complete  structure  of  P. 6 
multocida  LPS  has  not  been  determined  (Rimler  and  Rhoades,  1989).  Long 
polysaccharide  chains  (0-antigen),  like  those  found  in  S-type  LPSs  of 
Salmonella  and  other  Enterobacteriaceae,  have  not  been  demonstrated  in  P. 
multocida.  Chemical  and  physical  evidence  suggest  that  typical  P.  multocida 
LPSs  are  similar  to  the  R-type  LPSs  (Rimler  et  al.,  1984;  Manning  et  al., 
1986). 
Purified  P.  multocida  LPS  is  antigenic  and  can  react  with  avian  and 
mammalian  antisera  made  against  the  whole  organism,  but  has  been  reported  to 
produce  little  or  no  active  immune  protection  for  mice  (Schmerr  and  Rebers, 
1979;  Rebers  et  al.,  1980)  or  cattle  (Erler  et  al.,  Cited  by  Rimler  and  Rhoades, 
1989)  against  challenge  with  the  homologous  organism  but  does  provide 
protection  in  chickens  (Rebers  et  al.,  1980).  In  chickens,  LPSs  from  some 
serotypes  produced  antibodies  whereas  others  did  not  (Rimler  et  al,  1984). 
Wijewardana  et  al.  (1990)  found  that  an  anti-LPS  monoclonal  antibody 
protected  mice  against  homologous  and  heterologous  challenge  with  serotype  A 
strains. 
Proteins  of  P.  multocida  are  generally  believed  to  be  important  immunogens. 
However,  with  the  exception  of  an  immunogenic  protein  toxin  from  a  serotype 
D  strain  (see  below),  purification  of  a  P.  multocida  protein  antigen  to 
homogeneity  and  its  biochemical  characterisation  has  not  been  done.  Kajikava 
and  Matsumoto  (1984)  partially  purified  proteinaceous  immunogens  found  in 
extracts  or  culture  filtrates  from  avian  strains  of  P.  multocida  and  they  found 
that  their  purified  immunogens  produced  protection  against  homologous 
serotype. 
1.3.3.4.  Neuraminidase 
Serogroups  A,  B,  D  and  E  produce  neuraminidase  (Scharmann  et  al., 
1970).  Drzeniek  et  al.  (1972)  found  that  highest  neuraminidase  activity 7 
occurred  in  serogroup  A  and  D  while  low  activity  occurred  in  serogroup  B 
strains.  Maximum  activity  occurred  between  6-10  hrs  (log  phase)  in  basal 
medium  and  at  50-70  hrs  (decline  phase)  in  complex  medium  (Drzeniek  et  al., 
1972). 
Neuraminidase  has  been  associated  with  virulence  in  other  microorganisms 
but  the  association  of  P.  multocida  neuraminidase  with  a  specific  disease 
process  or  its  role  as  a  virulence  factor  is  inconclusive.  Drzeniek  et  al.  (1972) 
indicated  there  was  no  correlation  between  virulence  in  mice  and  neuraminidase 
activity.  Both  neuraminidase  positive  and  negative  strains  of  serotype  A  were 
equally  virulent.  Muller  and  Krasemann  (Cited  by  Rimler  and  Rhoades,  1989), 
in  a  study  consisting  primarily  of  dog  and  cat  strains,  observed  that  strains  with 
rapid  in  vitro  growth  and  high  neuraminidase  activity  were  more  virulent  for 
mice  than  those  with  low  activity.  Slow  growing  strains  were  less  virulent  than 
rapid  growing  strains. 
1.3.3.5.  Hyaluronidases 
Hyaluronidases  are  enzymes  that  have  been  associated  with  invasive 
mechanisms  of  bacteria  and  helminths  (Rimler  and  Rhoades,  1994).  Several 
Gram-positive  bacteria  produce  hyaluronidase  and  it  has  been  associated  with 
their  virulence  (Rimler  et  al.,  1984).  Carter  and  Chengappa  (1980)  established 
that  serogroup  B  strains  isolated  from  cases  of  haemorrhagic  septicaemia 
produced  hyaluronidase.  Carter  and  Chengappa  (1991)  reported  that  all 
haemorrhagic  septicaemia  P.  multocida  strains  of  serotype  B:  2  produced  a 
hyaluronidase,  whereas  strains  in  serogroup  A,  D  and  E  did  not.  The  role  of 
hyaluronidase  produced  by  type  B  strains  in  pathogenesis  is  as  yet  uncertain, 
especially  in  view  of  the  fact  that  it  has  not  been  demonstrated  in  type  E  strains, 
which  also  cause  HS  (De  Alwis,  1995).  Rimler  and  Rhoades  (1994)  examined 
hyaluronidase  production  in  176  strains  of  P.  multocida  representing  different 8 
serotypes  isolated  from  different  animal  species  in  different  countries.  They 
found  that  all  82  serotype  B:  2  strains  had  activity  against  hyaluronic  acid. 
1.3.3.6.  Toxins 
Two  main  types  of  toxin  are  found  in  P.  multocida,  endotoxin  and  protein 
toxins.  Endotoxic  activity  of  P.  multocida  is  due  to  LPS,  the  structural 
component  of  outer  membrane  of  all  strains.  There  is  no  essential  difference  in 
biological  and  toxic  effect  of  P.  multocida  endotoxins  and  endotoxins  of  other 
Gram-negative  bacteria  (Rimler  et  al.,  1984). 
It  is  well  established  that  only  some  isolates  of  serogroup  A  or  D  produce  a 
dermonecrotic  protein  toxin.  Rimler  and  Brogden  (1986)  found  that  although 
toxin  production  occurs  in  different  serotype  of  both  serogroups  A  and  D,  no 
correlation  was  found  between  production  of  toxin  and  somatic  serotype.  Of 
these  serogroups,  toxin  appears  to  occur  more  often  in  serogroup  D  (Foged  et 
al.,  1987).  Antiserum,  made  against  the  toxin  from  a  swine  serogroup  D  strain, 
neutralised  the  lethal  effects  of  toxin  from  rabbit  serogroup  D  and  swine 
serogroup  A  and  D  strains  from  different  geographic  origins  (Rimler  and 
Rhoades,  1989).  Consequently,  the  toxins  of  serogroups  A  and  D  strains  seem 
to  be  antigenically  similar.  Foged  et  al.  (1987)  purified  a  proteinaceous 
substance  produced  by  a  toxigenic  type  D  strain  of  P.  multocida  and 
characterised  with  a  molecular  weight  about  143  kDa.  The  purified  P. 
multocida  toxin  showed  a  dermonecrotic  effect  in  guinea  pigs,  cytopathic  effect 
in  cultures  of  embryonic  bovin  lung  cells  and  was  lethal  to  mice.  Also  Bording 
and  Foged  (1991)  evaluated  the  immunogenicity  of  formaldehyde  detoxified  P. 
multocida  toxin  and  they  found  that  pure  toxoid  was  immunogenic  and 
protected  mice  against  challenge  with  P.  multocida  toxin.  Chanter  et  al.  (1986) 
purified  a  protein  from  sonicated  cells  of  a  serotype  D  P.  multocida  strain 
LFB3.  The  partially  purified  protein  was  cytotoxic  for  embryonic  bovine  lung 
cells,  lethal  for  mice  and  caused  turbinate  atrophy  in  pigs;  a  single 9 
intraperitoneal  injection  of  approximately  360  ng/  kg  caused  50%  turbinate 
atrophy. 
Recently,  Shah  et  al.  (1996)  investigated  the  effect  of  P.  multocida  serotype 
B:  2,5  in  macrophages  by  in  vivo  and  in  vitro  tests,  and  have  shown  that  the 
haemorrhagic  septicaemia-associated  strains  of  P.  multocida  produced  a 
vacuolating  cytotoxin.  This  cell-associated  and  extracellular  vacuolating 
cytotoxic  activity  of  P.  multocida  serotypes  B  and  E  strains  caused  large 
cytoplasmic  vacuoles  in  mouse  peritoneal  macrophages  and  in  a  mouse 
macrophage  cell  line,  and  eventually  cell  death.  In  contrast,  the  macrophage  cell 
line  treated  with  serotypes  A  and  D  strains  did  not  show  any  vacuoles. 
1.3.4.  Biotypes  of  P.  multocida 
The  species  P.  multocida  incorporates  a  heterogenous  group  of  types  with 
differences  in  pathogenicity,  host  preferences,  serological  and  antigenic 
characteristics,  and  cultural  and  biochemical  properties.  Classification  is  based 
on  the  capsular  and  somatic  antigens.  Five  main  serological  typing  systems  of 
Pasteurella  multocida  have  been  developed,  the  number  of  serotypes  identified 
by  each  method  and  the  position  of  the  haemorrhagic  septicaemia  (HS) 
serotypes  is  shown  in  Table  1. 
Isolates  from  HS  cases  were  typed  as  group  2  (Little  and  Lyon,  1943)  and 
type  I  (Roberts,  1947)  using  slide  agglutination  and  passive  mouse  protection 
test  respectively.  Carter  (1955,1961)  defined  HS  strains  as  serotypes  B  and  E. 
Namioka  and  Murata  (1961  a,  b),  with  a  combination  of  Carter  capsular  types 
and  somatic  antigen  typing,  defined  Asian  and  African  HS  strains  as  6:  B  and 
6:  E  respectively.  Heddleston  et  al.  (1972)  developed  an  agar  gel  diffusion  test 
which  found  HS  strains  to  type  as  2  and  5. 
Serotype  designation  is  thus  based  on  a  combination  of  somatic  and  capsular 
antigens.  The  more  popular  method  at  present  is  to  use  the  Carter:  Heddleston Table  1:  Methods  adopted  for  serotyping  of  Pasteurella  multocida  and  the 
position  of  the  HS  serotypes 
Position  of 
References  Technique  No.  of  tes  HS  strains 
Little  and  Lyon  (1943)  Slide  agglutination  and  passive  mouse 
1,2  and  3  2 
protection  tests 
Roberts  (1947)  Passive  mouse  protection  test  I-V  I 
Carter  (1955,1961)  "Capsular"  typing  indirect  hemaggluti- 
A,  B,  E  and  F  B  and  E 
Rimler  and  Rhoades  (1987)  nation  test  using  heat  labile  (56  C/30 
min  antigen  and  rabbit  antisera* 
Namioka  and  Murata  (1961a)  Simplified  capsular  typing  using  fresh 
A,  B,  DandE  BandE 
cultures  and  rabbit  antisera 
Namioka  and  Murata  (1961b,  c)  "Somatic"  typing  by  agglutination  test 
1-11  6 
Namioka  and  Bruner  (1963)  using  HCI  treated  cells  and  rabbit 
Namioka  and  Murata  (1964)  antisera 
Heddleston  et  aL,  (1972)  "Somatic"  typing  by  gel  diffusion  1-16  2  and  (5) 
precipitin  test  using  heat  stable  antigen 
and  chicken  antisera 
*  Originally  used  fresh  human  '0'  erythrocytes.  Subsequently  modified  by  Carter  and  Rappay  (1962) 
using  formalinised  cells,  by  Sawada  et  at.,  (1982)  using  glutaraldehyde  fixed  sheep  erythrocytes  and  by 
Wijewardana  et  al.,  (1986)  using  fresh  sheep  erythrocytes. 10 
system.  By  this  system,  the  Asian  and  African  HS  serotypes  are  designated  B:  2 
and  E:  2  respectively. 
1.3.5.  Diseases  caused  by  P.  multocida 
P.  multocida  spp.  cause  septicaemia  and  uncomplicated  or  complicated 
respiratory  diseases  in  domesticated  and  wild  animal  species.  Two  specific 
diseases  in  which  this  organism  is  the  primary  agent  are  haemorrhagic 
septicaemia  (HS)  in  cattle  and  water  buffalo,  and  fowl  cholera  in  poultry.  These 
are  major  bacterial  diseases,  of  major  economic  and  veterinary  importance 
throughout  the  world.  They  are  usually  manifested  as  either  an  acute 
septicaemia  or  a  chronic  respiratory  infection.  Strains  causing  haemorrhagic 
septicaemia  usually  belong  to  serotypes  B  and  E.  Those  of  group  A  are 
frequently  associated  with  fowl  cholera.  Serogroup  D  strains  cause  pneumonia 
in  cattle  and  atrophic  rhinitis  in  pigs  (Rutter,  1985)  and  strains  of  the  serogroup 
F  vary  in  virulence  for  turkeys  (Rimler  and  Rhoades,  1987). 
1.3.5.1.  Haemorrhagic  septicaemia  (HS) 
HS is  an  acute  septicaemic  disease  characterised  by  terminal  septicaemia  and 
high  mortality,  principally  affecting  cattle  and  buffalo,  the  latter  being 
considered  more  susceptible.  The  disease  is  distinctly  different  from  some  other 
pasteurelloses  where  Pasteurellae  play  only  a  secondary  role.  HS  is  thus 
defined  as  a  specific  form  of  pasteurellosis  in  cattle  and  buffaloes  as  much  as 
Typhoid  fever  and  Pullorum  are  specific  forms  of  salmonellosis  in  man  and 
poultry  respectively  (De  Alwis,  1992).  P.  multocida  serotype  B:  2  (6:  B)  and  E:  2 
(6:  E)  have  been  found  to  cause  HS.  In  Asia  only  serotype  B:  2  strains  have 
been  associated  with  the  disease.  In  Africa  serotype  E:  2  strains  have  been  the 
only  serotype  isolated  from  cases  of  HS,  except  for  Sudan  and  Egypt  where 
both  types  have  been  recorded  (De  Alwis,  1992).  In  North  America,  serotypes 
B:  2  and  B:  3,4  have  been  reported  as  causative  agents  of  HS  in  beef  calves  and 
bisons  (Rimler  and  Wilson,  1994).  Septicaemic  pasteurellosis  has  also  been reported  in  pigs  in  Sri  Lanka,  Thailand,  Malaysia  and  India  (Wijewardana, 
1992).  HS-causing  P.  multocida  has  been  isolated  from  goats  in  Malaysia  and 
India;  however,  these  animals  have  been  found  to  be  very  resistant  to  disease 
(Wijewardana,  1992).  Septicaemic  pasteurellosis  in  elephants  with  concurrent 
outbreaks  of  HS  in  cattle  and  buffalo  caused  by  the  same  serotype  B:  2  have 
been  reported  in  Sri  Lanka  (Wijewardana,  1992).  Fatal  septicaemia  in  horses 
and  donkeys  associated  with  HS-causing  B:  2  have  been  reported  in  India 
(Wijewardana,  1992).  There  are  reports  of  serotype  B:  2,3  being  recovered 
from  poultry,  but  these  strains  are  considered  either  weakly  or  non-  pathogenic 
to  poultry  (Wijewardana,  1992). 
HS  occurs  in  South  East  Asia,  Near  and  Middle  East,  Southern  Europe  and 
in  most  part  of  Africa.  Generally,  North  American  cattle  are  regarded  as  free  of 
the  condition  though  it  has  been  recorded  in  bison  in  game  parks.  In  South 
America  it  is  said  to  occur;  however,  it  has  not  been  confirmed  by  laboratory 
procedures.  In  Japan,  the  last  recorded  outbreak  was  in  1954,  while  Australia, 
Ocean,  Canada  and  Western  Europe  have  never  recorded  the  disease  (Carter 
and  De  Alwis.  1989).  It  is  economically  important,  especially  in  the  South  Asia 
region  where  buffaloes  provide  the  power  for  rice  cultivation.  The  study  of  the 
disease  may  provide  parallels  with  human  diseases  characterised  by  a 
septicaemic  endotoxic  phase. 
1.3.5.2.  Epidemiology 
Buffaloes  are  more  prone  to  the  disease.  The  incidence  is  directly  related  to 
animal  husbandry  practices,  the  incidence  being  higher  in  large  nomadic  herds 
compared  to  small  intensively-reared  herds  (Wijewardana,  1992).  In  endemic 
areas  the  outbreaks  are  seasonal  and  the  link  between  successive  outbreaks  is 
believed  to  be  the  carrier  animals.  The  presence  of  the  organism  in  the 
nasopharynx  of  healthy  animals  is  well  established  (Mustafa  et  al.,  1978).  The 
nasopharyngeal  carrier  state  is  followed  by  an  immune  state,  which  persists  for 12 
a  long  period  (Wijewardana,  1992).  The  HS-causing  organism  is  readily 
recovered  from  such  sites  as  tonsils  and  lymph  nodes  associated  with  the  head 
and  neck,  but  it  has  been  observed  that  recovery  of  the  organism  from  the 
nasopharynx  and  other  sites  is  intermittent.  Experimental  infection  tests  have 
also  shown  that  large  numbers  of  organisms  are  required  to  set  up  an  infection 
by  the  intranasal  or  oral  route. 
It  is  generally  believed  that  HS  is  associated  with  wet,  humid  weather  and 
most  outbreaks  occur  during  the  wet  seasons.  In  countries  where  systematic 
epidemiological  studies  have  been  done,  it  has  become  evident  that  outbreaks 
do  occur  at  all  times  of  the  year  but  those  occuring  during  wet  seasons  tend  to 
spread,  presumably  due  to  the  longer  survival  of  the  organism  under  moist 
conditions  (De  Alwis,  1992).  In  the  endemic  areas  outbreaks  usually  coincide 
with  onset  of  rains  (Francis  et  al.,  1980),  which  is  normally  preceded  by  a  long 
dry  period  with  limited  food.  These  adverse  climatic  factors  and  accompanying 
nutritional  deficiencies  may  well  precipitate  the  activation  of  the  carrier  to 
become  a  source  of  infection  for  susceptible  animals.  Maternally-derived 
immunity  wanes  with  age.  Consequently  the  age  group  between  6  months-2 
years  is  most  susceptible,  and  this  is  the  major  group  which  contracts  the 
disease  (De  Alwis,  1992).  The  epidemiological  cycle  is  outlined  in  Figure  1. 
1.3.5.3.  Pathogenesis 
The  successful  transmission  of  disease  by  the  intranasal  and  oral  routes, 
producing  a  syndrome  with  clinical  signs  and  lesions  resembling  natural 
disease  indicates  that  these  may  be  the  natural  routes  of  infection  (De  Alwis, 
1995).  The  organisms  isolated  from  clinically  normal  animals  even  in  the  latent 
carrier  state,  have  been  found  to  be  as  virulent  as  those  from  clinical  cases. 
Also  it  was  established  that  carrier  animals  possessed  high  levels  of  humoral 
immunity  thus  maintaining  a  host-pathogen  balance.  It  appears  that  after  entry 
into  an  unexposed  susceptible  animal,  the  initial  site  of  multiplication  is  the Fig  1:  The  presumptive  epidemiological  cycle  in  haemorrhagic  septicaemia 
(From  De  Alwis,  1995) Fig  1: 
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tonsillar  tissue.  Thus  on  the  one  hand  the  pathogen  will  multiply  in  vivo  and  on 
the  other  the  host  defence  mechanisms  both  specific  and  nonspecific  will 
interact  and,  depending  on  which  process  dominates,  will  lead  either  to  clinical 
disease  or  arrested  infection.  The  dose  of  infecting  organisms,  amongst  other 
factors,  will  be  an  important  determinant  of  outcome.  The  role  of  bacterial 
adherence  in  the  multiplication  of  Pasteurella  in  the  respiratory  tract  in  HS  is  an 
area  that  merits  investigation.  This  phenomenon  could  be  an  important 
determinant  of  the  outcome  of  infection.  Endotoxin  is  likely  to  play  an 
important  role  in  HS,  as  similarities  were  found  in  the  pathological  lesions  in 
natural  HS  and  endotoxic  shock  in  calves  (De  Alwis,  1995). 
1.3.5.4.  Clinical  features 
This  disease  is  usually  manifest  by  a  rapid  course,  sudden  onset  of  fever, 
profuse  salivation,  severe  depression  and  death  in  about  24  hrs.  These  are  the 
usual  symptoms  observed  in  HS.  Oedema  in  the  submandibular  region  and  in 
later  stages  the  affected  animals  may  show  severe  dyspnoea  and  alimentary  tract 
disorders.  In  outbreaks,  sudden  death  without  any  previous  signs  is  usually 
reported.  As  the  disease  progresses,  respiratory  distress  becomes  severe  and 
the  temperature  drops  to  subnormal  levels.  Finally  the  animal  becomes 
recumbent  and  dies. 
1.3.5.5.  Pathology 
At  necropsy  the  gross  findings  are  usually  limited  to  generalised  petechial 
haemorrhages,  particularly  under  the  serosae,  and  oedema  of  the  lungs  and 
lymph  nodes.  Subcutaneous  infiltration  of  gelatinous  fluid  may  be  present  and 
in  some  animals  there  are  lesions  of  early  pneumonia  and  haemorrhagic 
gastroenteritis.  The  spleen  may  show  a  few  haemorrhages  but  is  not  swollen, 
and  this  is  a  means  of  differentiating  it  from  anthrax.  An  experimental  study  in 
Sri  Lanka  showed  that  animals  dying  within  24-36  hrs  of  infection  had 
widespread  petechial  haemorrhages  particularly  on  the  base  of  the  heart, 14 
abdominal  wall  and  to  a  lesser  extent  on  the  intestines,  while  lungs  showed 
only  congestion.  When  the  illness  lasted  over  72  hrs,  there  was  extensive 
consolidation  of  the  lungs,  with  lobulation  due  to  marked  thickening  of  the 
interlobular  septa.  Pleurisy  and  pericarditis  were  the  other  necropsy  lesions 
observed  when  the  disease  ran  through  a  longer  course  (Wijewardana,  1992). 
1.3.5.6.  Diagnosis 
Two  aspects  of  diagnosis,  field  and  laboratory  are  considered  as  important. 
Field  diagnosis  is  important  because  the  immediate  investigation  of  control 
measures  to  prevent  spread  of  disease  is  based  on  a  field  diagnosis.  A  field 
diagnosis  can  be  made  on  the  basis  of  characteristic  clinical  signs,  gross 
pathological  lesions,  herd  history,  morbidity  and  mortality  patterns,  species 
susceptibility,  age  group  affected  etc.  Since  morbidity  and  mortality  are  highly 
variable  and  are  dependent  on  a  number  of  factors  and  their  interactions,  these 
parameters  must  be  viewed  in  the  background  of  surrounding  circumstances. 
Laboratory  confirmation  of  diagnosis  is  by  isolation  and  identification  of  the 
agent.  This  is  done  by  cultural  and  biochemical  as  well  as  serological  methods. 
Direct  microscopic  examination  of  smears  from  material  is  not  conclusive. 
Pasteurellae  are  not  consistently  present  in  nasal  secretions.  Thus,  blood  or 
nasal  secretions  from  animals  during  the  clinical  phase  dose  not  constitute 
reliable  material  and  negative  results  using  these  are  not  conclusive.  From  a 
fresh  carcass,  a  blood  sample  or  swab  collected  within  a  few  hours  of  death 
from  the  heart  or  from  the  jugular  vein  is  satisfactory.  From  older  carcasses,  a 
long  bone  is  the  preferred  specimen.  These  are  transported  to  the  laboratory  in  a 
standard  transport  medium  on  ice  and  well  packed  to  prevent  leakage.  Direct 
culture  yields  results  only  with  fresh  material.  Contaminants  and  post  mortem 
invaders  when  present  overgrow  the  Pasteurellae.  A  small  volume  of  the  eluted 
blood  into  2-3  ml  sterile  physiological  saline,  or  bone  marrow  suspended  in 
saline  is  injected  subcutaneously  or  intramuscularly  into  a  mouse.  If  Pasteurella 15 
are  present,  even  in  small  numbers,  the  mouse  will  die  within  24-36  hrs.  The 
mouse  acts  as  a  biological  screen  and  pure  cultures  of  the  organism  can  be 
obtained  from  the  heart  blood  of  the  mouse.  The  organism  is  identified  by 
morphological  and  cultural  characteristics  and  serological  tests.  A  rapid  slide 
agglutination  test  (Namioka  and  Murata,  1961a)  requiring  a  single  colony  is 
used  initially.  A  single  colony  is  mixed  with  a  drop  of  saline  on  a  slide,  a 
loopful  of  hyperimmune  specific  rabbit  antiserum  is  added  and  the  slide  is 
gently  warmed  while  agitating  with  the  loop.  This  is  followed  by  an  indirect 
haemagglutiation  test  for  capsular  typing  (Carter,  1955;  Sawada  et  al.,  1982) 
and  an  agglutination  test  with  hydrochloric  acid-treated  cells  for  somatic  typing 
(Namioka  and  Bruner,  1963;  Schlink  and  Olson,  1979).  For  routine  diagnosis 
using  material  from  HS  suspected  animals,  the  procedure  used  is  outlined  in 
Figure  2. 
1.3.5.7.  Treatments 
HS  under  field  conditions  is  always  fatal  with  the  majority  of  affected 
animals  dying  without  showing  any  previous  signs.  Therefore  treatment  is  of 
little  value  once  visible  signs  appear  in  the  field;  especially  as  the  sudden  onset 
and  rapid  course  of  the  disease  makes  early  detection  difficult.  The  only 
practical  approach  in  the  face  of  an  outbreak  is  to  check  the  rectal  temperature  of 
all  in-contact  animals  in  diseased  herds  and  carry  out  antibiotic  therapy 
immediately.  Traditionally  intravenous  administration  of  sulphadimedin  or 
sulphamethazine  (33.33%)  solution  has  been  recommended.  Oxytetracycline 
(Francis  et  al.,  1980),  tetracycline,  chloramphenicol  and  penicillin- 
streptomycin  combinations  have  been  found  to  be  useful  (De  Alwis,  1995). 
1.3.5.8.  Control 
Vaccination  is  generally  accepted  as  the  method  of  disease  control.  Several 
types  of  vaccines  have  been  developed.  These  include  plain  bacterins,  alum- 
precipitated  vaccine,  aluminium  hydroxide  gel  vaccine  and  the  oil-adjuvant Fig  2:  Scheme  for  routine  laboratory  diagnosis  of  haemorrhagic 
septicaemia.  (From  De  Alwis,  1995) Fig  2: 
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vaccine.  Most  countries  use  local  strains  as  seed  and  fermentors  for  large-scale 
growth  of  the  cultures.  The  seed  is  periodically  passaged  in  a  natural  host  in 
order  to  retain  its  full  complement  of  antigens.  It  has  been  estimated  that  at  least 
1.5-2.0  mg  of  dry  whole  bacteria  is  required  to  immunise  an  animal.  Thus 
vaccination  needs  the  production  of  dense  cultures,  and  enriched  media  are  now 
used  for  this  purpose.  Growth-promoting  additives  such  as  yeast  extract  are 
incorporated  and  growth  is  enhanced  by  aeration.  Finally,  formalin  at  a  final 
concentration  of  0.3-  0.5  percent  is  used  to  inactivate  the  cultures  (De  Alwis, 
1995). 
Broth  bacterins  confer  only  an  immunity  of  very  short  duration,  and  dense 
bacterin  may  cause  an  endotoxic  shock  and  are  useful  only  in  the  face  of 
outbreaks.  The  alum-precipitated  and  aluminium  hydroxide  gel  vaccines  are 
believed  to  confer  only  4-5  months  of  immunity  and  need  be  given  twice 
yearly.  These  vaccines  are  used  in  the  face  of  outbreaks  in  Sri  Lanka 
(Wijewardana,  1992).  Oil-adjuvant  vaccines  confer  6-9  months  of  immunity. 
This  vaccine  is  traditionally  prepared  by  emulsifying  bacterin  and  mineral  oil 
with  lanolin  to  produce  a  pure  white,  thick  emulsion.  For  prophylactic 
purposes,  the  4-6  months  old  calves  are  vaccinated  with  two  initial  doses 
followed  by  annual  revaccination  to  provide  adequate  immunity. 
Considerable  research  has  been  carried  out  in  order  to  produce  an  improved 
vaccine.  These  range  from  the  low-viscosity  double-emulsion  vaccine  (Verma 
and  Jaiswal  1997)  to  using  immunising  fractions  (Zhang  et  al.,  1994),  purified 
capsular  extract  vaccine  (Boyce  and  Adler,  2000),  a  stable,  avirulent 
streptomycin-  dependent  mutant  (De  Alwis  and  Carter,  1980),  and  a  non-HS 
type  B:  3,4  isolate  from  fallow  deer  (Myint  and  Carter,  1989).  All  these  have 
shown  varying  degrees  of  effectivness.  However,  because  of  certain 
disadvantages,  they  have  failed  to  yield  a  practical  vaccine.  These  types  of 
vaccines  are  discussed  later. 17 
1.3.6.  Vaccination  strategies 
Vaccines  have  been  used  with  varying  degrees  of  success  against  a  number 
of  infectious  diseases.  Vaccination  consists  of  the  administration  of  antigens,  in 
the  form  of  live  attenuated  or  killed  microorganisms  or  as  purified  individual 
components  in  acellular  vaccines  with  the  aim  of  inducing  a  protective  immune 
response  against  the  disease-causing  microorganism.  One  of  the  first  attempts 
to  prevent  disease  in  this  way  came  when  material  from  smallpox  lesions  was 
inoculated  into  non-sufferers.  This  so-called  variolation  was  highly  successful 
in  preventing  subsequent  attacks  of  smallpox,  but  caused  death  from  smallpox 
in  two  percent  of  those  inoculated.  The  technique  was  improved  considerably 
in  1796  when  Jenner  introduced  vaccination,  using  cowpox  rather  than 
smallpox  material.  Vaccination  against  smallpox  has  been  highly  successful 
since  Jenner's  innovation,  so  that  by  1979  smallpox  as  a  disease  was 
considered  to  be  globally  eradicated  (Maskell  and  Dougan,  1988). 
A  modern  vaccine,  for  humans  or  animals,  must  meet  several  requirements 
in  order  to  gain  general  acceptance.  The  task  of  fulfilling  all  these  requirements 
leads  to  major  problems  associated  with  developing  new  vaccines.  A  successful 
vaccine  must  elicit  a  sufficiently  strong  and  long  lasting  response  in  the  arms  of 
the  immune  system  responsible  for  protection.  This  requires  that  protective 
antigens  be  administered  in  a  way  that  will  induce  the  correct  type  of  immunity. 
The  most  effective  immunity  is  often  present  in  individuals  who  have  recovered 
from  a  natural  infection.  In  the  past,  pathogenesis  of  infectious  diseases  has 
had  little  influence  over  vaccine  design.  Many  old  vaccination  schemes 
involved  the  parenteral  administration  of  inactivated  whole  microorganisms  or 
specific  virulence  factors.  With  a  few  notable  exceptions  this  has  proved  to  be 
an  inefficient  approach. 
The  vaccine  should  be  safe.  Even  killed  whole  organisms  are  often  capable, 
following  injection,  of  inducing  serious  side  effects  or  disease.  For  example, 18 
whole-cell  killed  typhoid  vaccine  contains  large  amounts  of  endotoxic 
lipopolysaccharide  which  can  cause  swelling  and  pain  at  the  site  of  injection.  In 
more  serious  cases  typhoid  vaccination  can  lead  to  encephalitis  and  even  death. 
Often  the  risks  of  side  effects  are  considered  worth  taking.  Vaccination  against 
smallpox  carried  a  risk  of  1/1,000,000  of  death.  These  risks  were  worth  taking 
in  an  attempt  to  eradicate  a  disease  prevalent  worldwide  and  with  a  mortality  of 
up  to  45%,  but  would  probably  not  be  acceptable  for  other  milder  infections 
(Maskell  and  Dougan,  1988). 
In  order  to  be  effective,  a  vaccine  must  stimulate  a  protective  immune 
response,  antibody  or  cell-mediated,  against  the  appropriate  antigens  at  the  site 
of  infection  or  microbial  replication.  It  must  protect  against  infection  by 
organisms  following  the  normal  route  of  infection.  Furthermore,  the  ideal 
vaccine  is  one  that  provides  complete  protection  for  the  lifetime  of  the  host  to 
the  largest  realistic  challenge  dose  of  the  most  virulent  strains.  It  must  also  be 
cheap  enough  so  that  all  those  at  risk,  whether  humans  or  animals,  even  in  the 
poorest  countries,  can  be  vaccinated. 
The  vaccination  programme  against  HS  varies.  Some  countries  that  still  use 
the  alum-precipitated  vaccine  administer  it  annually  before  the  rainy  seasons, 
so  that  maximum  protection  is  provided  when  it  is  required  most.  Vaccination 
before  the  onset  of  a  monsoon  or  sometimes  at  the  onset  of  an  outbreak  of  the 
disease  is  practised  in  most  countries.  Verma  and  Jaiswal  (1998)  has  reviewed 
vaccination  programmes  against  HS  with  information  on  the  type  of  vaccines, 
their  dose,  route  and  duration  of  immunity  in  different  countries  (Table  2). 
1.3.7.  Haemorrhagic  septicaemia  vaccines 
1.3.7.1.  Broth  bacterins 
It  has  been  over  100  years  since  the  discovery  of  prophylactic  vaccination  of 
cattle  against  HS  with  killed  vaccines.  In  the  last  century,  different  workers Table  2:  Haemorrhagic  septicaemia  vaccination  practices  in  different  countries 
[Table  based  on  Verma  and  Jaiswal  (1998)  review] 
Country  Type  of  vaccine  Dose  Route  Duration  of  Immunity 
India  Alum-precipitated  vaccine  3  ml  S.  C.  4-  6  months 
Alumnium  hydroxide  gel  3  ml  S.  C.  4-  6  months 
Oil-adjuvant  vaccine  3  ml  i.  m.  1  year  or  more 
Indonesia  Oil-adjuvant  vaccine  3  ml  i.  m.  up  to  1  year 
Animals  older  than  5  months 
vaccinated  every  6  months, 
Thailand  Alumnium  hydroxide  gel,  3  ml  S.  C.  3-4  months 
contains  3x  1010C.  F.  U.  /  Dose 
of  P.  multocida  serotype  B:  2 
Malaysia  Alum-precipitated  vaccine  5  ml  S.  C.  4-6  months 
Oil-adjuvant  vaccine  3  ml  i.  m.  up  to  1  year 
Vietnam  Alum-precipitated  vaccine  2  ml  S.  C.  4-  6  months 
(Two  injections  per  year) 
Oil-adjuvant  vaccine  2  ml  i.  m.  up  to  1  year 
SriLanka  Oil-adjuvant  vaccine.  Cattle  and  3  ml  i.  m.  up  to  1  year 
buffalo  vaccinated  at  4-6  months 
and  given  a  booster  3-6  months  later, 
followed  by  annual  vaccination 
Cambodia  Alum-adjuvant  vaccine  2  ml  S.  C.  3-6  months 
give  twice  a  year 
Myanmar  Live  vaccine  contain  107  C.  F.  UJ  2  ml  i.  n.  1  year 
dose  of  P.  multocida  serotype  B:  3,4 
Phillipines  Killed  alum  adjuvanted  vaccine  5  ml  S.  C.  4-6  months 
booster  every  6  months 
Nepal  Alum-  precipitated  vaccine  5  ml  S.  C.  6  months 
Iran*  Alum-  precipitated  vaccine  2-3  ml  S.  C.  4-6  months 
combined  with  Black  leg  vaccine 
give  twice  a  year 
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inactivated  the  bacteria  by  chemical  or  physical  procedures  and  though  these 
vaccines  can  induce  protection  against  HS  under  field  conditions,  they  only 
promote  short-term  protection.  Chorherr  (Cited  by  Verma  and  Jaiswal,  1998). 
studied  formalin-or  heat-inactivated  P.  multocida  vaccines.  The  index  of 
protection  was  higher  with  the  heat-inactivated  vaccine  than  the  formalinised 
vaccine.  He  did  not  find  any  improvement  in  its  protectivity  by  the  addition  of 
various  adjuvants.  A  vaccine  prepared  from  a  strain  isolated  from  cattle  and 
buffaloes,  and  consisting  of  a  suspension  of  lysed  bacteria  in  5%  (v/v)  saponin 
to  provide  a  continous  antigenic  stimulus,  did  not  find  much  use  due  to 
undesirable  tissue  damaging  effect  at  the  vaccination  site,  (Verma  and  Jaiswal 
1998).  The  main  problem  with  broth  bacterin  is  short-term  immunity  of  about  6 
weeks  (Chandrasekaran,  1994a).  Also,  De  Alwis  (1995)  reported  that  broth 
bacterins  confer  immunity  for  only  a  few  weeks  and  dense  bacterin  may  cause 
shock  reactions. 
1.3.7.2.  Alum-precipitated  and  aluminium  hydroxide  gel  vaccines 
These  vaccines  against  HS  have  been  used  for  over  50  years.  As  described 
by  Edelman  (1980),  two  principal  methods  are  used  to  prepare  vaccines 
containing  aluminium  adjuvant.  In  the  first  method,  a  solution  of  alum  [A] 
(S04)2.12H20]  is  added  into  the  antigen  to  form  a  precipitate  of  protein 
aluminate;  the  product  so  obtained  has  been  termed  alum-precipitated  vaccine. 
In  the  second  method,  antigen  solution  is  added  to  preformed  aluminum 
hydroxide,  aluminium  phosphate,  mixed  aluminium  hydroxide  plus  phosphate 
or  gamma  aluminium  oxide;  the  resulting  preparations  have  been  called 
aluminium-adsorbed  vaccines.  These  vaccines  are  believed  to  confer  immunity 
for  4-5  months  and  need  be  given  twice  yearly  (De  Alwis,  1995).  They  are 
still  used  in  Southern  India,  Central  Africa  and  appear  to  be  the  most  popular 
vaccine  used  in  Asian  countries.  De  Alwis  et  al.  (Cited  by  Verma  and  Jaiswal, 
1998)  reported  a  controlled  trial  in  Sri  Lanka  using  a  standard  vaccine 
containing  2.5  mg  of  bacteria  per  dose  and  this  gave  protection  for  up  to  4 20 
months.  Alum-precipitated  vaccines  in  conjunction  with  levamisole  have  been 
reported  to  increase  antibody  titres  significantly  (Sharma  et  al.,  1980).  The 
efficacy  of  alum-precipitated  vaccine  in  protection  against  challenge  for  HS 
has  been  reported  (Chandrasekaran  et  al.,  1994  a).  They  found  that  all 
buffaloes  vaccinated  with  alum-precipitated  vaccine  were  completely  protected 
for  up  to  6  months  post-immunisation. 
1.3.7.3.  Oil-adjuvanted  vaccines 
Shaking  together  two  immiscible  liquids  can  form  a  simple  emulsion  with 
little  stability,  but  addition  of  an  emulsifying  agent  can  overcome  this  problem. 
This  emulsifying  agent  is  very  important  in  influencing  the  type  of  emulsion 
that  is  produced,  for  example  for  water-in-water  emulsion,  lanolin  has  been 
used  and  Arlacel  A  for  water-in-oil  emulsion.  One  of  most  popular  materials 
used  as  an  adjuvant  is  mineral  oil.  Some  of  these  adjuvants  can  stimulate 
cellular  immunity  and  enhance  protection  in  cattle  against  a  high  challenge  dose 
of  virulent  strains  of  P.  inultocida.  Chandrasekaran  et  al.  (1994  a)  compared 
immunological  and  protective  properties  of  broth  bacterin  and  oil-adjuvant 
vaccines.  The  total  volume  of  the  vaccines  used  was  5.0  ml,  containing  2.25  X 
1010  C.  F.  U.  /  ml  of  P.  multocida  serotype  6:  B  strain.  They  found  that  broth 
bacterin  protected  buffaloes  just  for  a  few  weeks  post-vaccination  against 
experimental  challenge  with  P.  multocida  wild-type  strain,  whereas  the  oil- 
adjuvant  vaccine  protected  the  buffaloes  for  up  to  12  months.  As  was  found  by 
Herbert  (1968),  water-in-oil  emulsion  releases  antigens  over  a  longer  period  of 
time  than  do  aluminum  products  and  they  can  delay  absorption  of  antigen  and 
stimulate  mononuclear  cells  to  produce  antibody  at  local  and  distal  sites.  The 
main  problems  with  adjuvanted  vaccine  seem  to  be  the  extent  of  local  tissue 
inflammatory  responses  (Ahmed  et  al.,  1974). 
Shah  et  al.  (1997)  evaluated  immunisation  against  HS  induced  by 
vaccination  of  buffalo  calves  with  an  improved  oil-adjuvant  vaccine  and  they 21 
found  that  this  new  vaccine  conferred  protection  for  about  one  year  with  a 
single  dose  of  vaccine.  Mineral  oil,  Marco]  52,  was  used  as  adjuvant  together 
with  Span  85  and  Tween  80  as  emulsifiers.  The  vaccine  is  easily  injectable 
intramuscularly  and  did  not  show  any  local  or  systematic  adverse  reaction.  Also 
the  vaccine  appeared  to  be  stable  for  more  than  3  years  at  room  temperature  in 
tropical  areas  of  Pakistan. 
Evaluation  of  various  adjuvants,  like  aluminium  hydroxide,  oil  adjuvant, 
multiple-emulsion  and  sodium  alginate  in  HS  vaccines  in  rabbit  showed  that  the 
oil  adjuvant  and  multiple  emulsion  were  good  adjuvants  for  protection  and 
produced  the  highest  agglutination  titres  for  up  to  91  days  post-vaccination 
(Lalrinliana  et  al.,  1988). 
1.3.7.4.  Multiple  Emulsion  (ME)  vaccine 
Although  the  oil-adjuvant  vaccine  provides  a  higher  degree  of  immunity  in 
cattle  and  buffaloes  than  other  vaccines,  its  main  disadvantage  is  high  viscosity 
that  can  cause  poor  injectability  and  a  local  swelling  at  the  site  of  inoculation 
(Verma  and  Jaiswal,  1997).  For  these  reasons  vaccines  based  on  thinner 
emulsions  preparations  were  evaluated.  Verma  and  Jaiswal  (1997)  showed  that 
the  viscosity  of  oil  adjuvant  vaccines  may  be  reduced  by  re-emulsifying  it  with 
an  equal  volume  of  Tween  80  and  producing  a  ME  vaccine.  For  this  work  a 
formalin-killed,  oil-adjuvant  vaccine  was  prepared  from  P.  multocida  cultured 
on  agar  and  resuspended  the  bacteria  in  saline  to  3.0  x  109  organisms  per  ml. 
The  vaccine  contained  15  parts  of  bacterial  suspension,  10  parts  liquid  paraffin 
plus  one  part  lanoline  as  emulsifying  agent.  Finally  this  oil  adjuvant  vaccine 
was  mixed  with  an  equal  volume  of  2%  (v/v)  Tween  80  in  formol  saline  and 
blended  in  a  mixer.  This  new  ME  vaccine  was  shown  to  be  stable,  of  low 
viscosity  and  easy  to  administer  to  experimental  animals.  It  overcame  the 
problem  of  local  reaction  at  the  site  of  inoculation,  which  sometimes  happens 
with  oil  adjuvant  vaccines.  The  results  of  immunity  trials  in  calves  have  shown 22 
that  ME-HS  vaccine  is  protective  for  up  to  one  year  against  challenge  infection 
with  wild-type  P.  multocida  strains  (Verma  and  Jaiswal,  1997). 
1.3.7.5.  Outer  membrane  protein  (OMP) 
Lu  et  al.  (1988)  showed  that  a  37.5  kDa  outer-membrane  protein  of  P. 
multocida  serotype  A:  3  was  a  promising  vaccine  candidate  in  rabbits  because  it 
was  a  strong  immunogen  and  protective  against  homologous  challenge. 
Protection  in  mice  was  afforded  against  heterologous  challenge  only  if  the 
challenge  strain  possessed  the  37.5  kDa  antigen.  Antibodies  against  P. 
multocida  OMP  in  rabbit  immune  sera  had  an  inhibitory  effect  against  P. 
multocida  proliferation  in  mice  (Lu  et  al.,  1991) 
Abdullahi  et  al.  (1990)  investigated  the  outer-membrane  protein  profile  of 
P.  multocida  serogroup  A:  3  and  they  attempted  to  define  a  protective 
immunogen  by  working  on  immunogenicity  of  outer-membrane  proteins  in  a 
mouse  septicaemia  model.  However,  they  found  that  the  major  outer-membrane 
proteins  were  not  protective  antigens  in  the  mouse  model  of  pasteurellosis. 
Recently,  Pati  et  al.  (1996)  evaluated  immunogenicity  of  outer-membrane 
proteins  of  P.  multocida  serogroup  B:  2  strains  in  buffalo  calves  in  comparison 
with  a  commercial  oil-adjuvant  vaccine.  They  showed  that  calves  vaccinated 
with  either  vaccine  developed  the  highest  mean  log  10  ELISA  titre  at  21  days 
post  vaccination.  Following  subcutaneous  challenge  of  the  vaccinated  animals 
with  virulent  P.  multocida  strain,  all  the  5  buffalo  calves  given  OMP  vaccine 
survived  whereas  only  2  of  three  buffalo  calves  in  the  HS  vaccinated  group 
survived. 
1.3.7.6.  Anti-idiotype  antibodies 
Purified  LPS  from  Gram-negative  organisms  has  generally  been  found  to  be 
poorly  immunogenic  (Sutherland,  et  al.,  1993).  Rebers  et  al.  (1980)  reported 
that  LPS  of  P.  multocida  was  poorly  immunogenic  in  mice  in  its  purified  form, 23 
but  protective  in  chicken.  However,  a  protein-LPS  complex  protected  mice, 
rabbits  and  chicken  (Rebers  and  Heddleston  1974;  Ganfield  et  al.,  1976).  Also 
Philips  and  Rimler  (1984)  and  Rimler  and  Brogden  (1986)  found  that  LPS  has 
been  recognised  as  a  major  immunogen  in  ribosomal  vaccines  against  serotypes 
A  and  D  respectively.  The  poor  immunogenicity  of  purified  LPS  is  probably 
due  to  it  being  a  low  molecular  weight  linear  molecule  which  is  aT  cell 
independent  polyclonal  B  cell  activator  (Sutherland,  et  al.,  1993). 
As  an  alternative  to  using  LPS,  a  strategy  of  using  anti-idiotype  antibodies 
as  vaccine  antigen  (Hiernaux,  1988),  which  mimic  LPS,  was  evaluated  by 
Sutherland  et  al.  (1993).  Idiotypes  are  recognition  sites  located  at  or  near  the 
antigen  binding  site  of  an  antibody  molecule.  Anti-idiotype  antibodies  are 
antibodies  against  an  idiotype  or  another  antibody  molecule.  Manipulation  of 
the  idiotypic  network  also  has  potential  as  an  alternative  means  of  vaccination 
as  shown  in  Figure  3  (Zhang  et  al.,  1994).  Although  anti-idiotypic  vaccines  are 
unlikely  to  replace  a  majority  of  the  conventional  vaccines,  they  have  some 
advantages  such  as  no  antigenic  toxicity  to  the  host,  in  some  cases  less  cost  to 
manipulate,  easily  produced,  no  antigenic  variation  and  the  avoidance  of 
disease  outbreak  resulting  from  reversion  of  attenuated  vaccines.  Also,  anti- 
idiotypic  antibodies  can  mimic  antigens  that  are  difficult  to  synthesise  or  isolate 
in  the  laboratory.  The  induction  of  an  active  immune  response  by  idiotypic 
antibodies  has  been  shown  by  Sutherland  et  al.  (1993)  who  found  that 
polyclonal  anti-idiotype  antibodies  could  be  produced  to  mimic  the  linear  P. 
multocida  lipopolysaccharide  molecule.  The  antibodies,  when  used  as  a  vaccine 
antigen,  induced  antibodies  that  recognised  LPS  and  imparted  acquired 
protection  when  vaccinated  mice  were  challenged  with  homologous  organisms 
of  P.  multocida  capsular  type  A  isolated  from  bovine  pneumonia. Fig  3:  A  simplified  schematic  of  the  idiotypic  network  in  poultry. 
A  chicken  immunised  with  an  antigen  having  a  unique  epitope  produces 
specific  antibodies,  noted  as  AB  1  idiotype  (anti-P.  multocida  antibody).  This 
antibody  can  be  isolated  from  serum  or  eggs.  AB  1  inoculated  into  a  second 
chicken  induces  the  synthesis  of  an  AB2  antibody  (anti-idiotype)  response. 
Isolation  of  AB2  is  also  possible  from  serum  and  eggs.  Immunisation  of  a 
third  chicken  with  affinity  isolated  anti-idiotype  results  in  production  of  AB3 
or anti-anti-idiotype  antibody.  The  anti-anti-  idiotype  antibody  reacts  with  the 
original  antigen  even  though  the  third  chicken  has  never  been  exposed  to  the 
original  antigen.  (From  Zhang  et  al.,  1994) 
(PmAg:  P.  multocida  antigen) Fig  3: 
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1.3.7.7.  Live  attenuated  vaccines 
Currently  available  parenteral  inactivated  vaccines  are  not  very  effective  for 
prevention  of  diseases  caused  by  enteric  or  respiratory  bacteria.  They  do  not 
induce  a  strong  local  immune  response  and,  for  invasive  pathogens  such  as 
Salmonella  typhi,  they  do  not  induce  cell-mediated  immunity.  Thi  led  to  much 
work  on  development  of  live  attenuated  vaccines  for  these  types  of  pathogens. 
Vaccination  with  live  attenuated  organisms  is  important  because  live 
attenuated  vaccines  mimic  natural  infections,  without  causing  disease 
symptoms,  and  can  leave  an  individual  with  strong,  long-lasting  immunity. 
Also,  protection  against  some  infections  needs  mucosal  or  cell-mediated 
immunity  that  live  vaccines  can  induce  better  than  killed  vaccines.  Finally,  live 
vaccines  are  often  cheap  and  easy  to  administer.  One  of  the  main  problems  with 
live  vaccines  in  the  past  was  that  of  reversion  to  virulence. 
Two  main  strategies  have  been  used  in  the  past  to  obtain  attenuated  vaccines. 
A  closely-related  relatively  avirulent  micro-organism  can  be  sought  which 
induces  protection  against  the  pathogen  in  question,  e.  g.  Mycobacterium  bovis 
in  BCG  vaccine  for  tuberculosis  or  Vaccinia  virus  for  smallpox.  Alternatively, 
a  pathogenic  strain  can  be  passaged  many  times  in  vitro  until  it  loses 
pathogenicity,  e.  g.,  Sabin  polio  vaccine  and  the  BCG  vaccine  strain.  The  latter 
type  of  vaccine  can  be  problematic.  The  genetic  lesion  causing  attenuation  is 
often  ill-defined  and  the  strain  could  revert,  causing  vaccine-induced  disease. 
Genetic  manipulation  techniques  have  led  to  the  possibility  of  overcoming  the 
problem  of  reversion,  by  introducing  defined  gene  deletions.  Recombinant 
DNA  techniques,  transposon  mutagenesis  and  other  modern  methods  are  only 
now  having  an  impact  on  the  development  of  new  bacterial  vaccines.  Efficient 
human  and  veterinary  vaccination  with  easily  prepared  and  administered 
vaccine  strains  could  then  ensue,  resulting  in  decreased  incidences  of  these 
insidious  diseases  world-wide.  Experimentally,  using  animal  models,  the  most 25 
successful  vaccines  have  been  those  based  on  live  attenuated  micro-organisms 
which  set  up  a  limited,  clinically  insignificant  infection  in  the  host  that  mimics 
infection  by  the  virulent  pathogen  but  arms  the  immune  system  to  respond  to 
further  infection.  Such  vaccines  include  Salmonella  typhimurium  aro  vaccine  in 
calves  (Ramos  et  al.,  1998),  a  streptomycin-dependent  mutant  of  Salmonella 
typhi  (Curtiss,  1990),  and  aro  or  cya  Salmonella  typhi  strains  in  man  (Tacket 
et  al.,  1992),  and  Pasteurella  multocida  live  streptomycin-dependent  strains  that 
act  as  immunogens  in  turkeys  (Chengappa  et  al.,  1978;  Briggs  and  Skeeles 
1983),  (Table  3). 
Many  vaccines  in  current  use  are  not  very  effective  at  inducing  long-lived 
immunity.  More  effective  vaccines  are  needed  but  the  mechanisms  of 
pathogenecity  and  the  important  virulence  factors  involved  are  ill-defined.  The 
antigens  responsible  for  natural  immunity  are  unknown.  For  this  reason,  there 
has  been  increasing  interest  in  the  use  of  "rational  attenuation"  to  construct  live 
attenuated  bacterial  strains  that  would  not  revert  to  virulence  in  the  host.  This 
has  been  well  established  for  other  bacterial  pathogens  in  animal  models  (Table 
3).  The  introduction  of  certain  auxotrophic  mutations  in  different  genes,  whose 
functions  are  essential  for  bacteria  to  survive  and  grow  in  vivo  and  thus  cause 
disease,  into  the  genome  of  virulent  strains  of  different  bacterial  species, 
renders  them  avirulent  for  experimental  models  or  natural  hosts. 
It  is  generally  accepted  that  live  vaccines  confer  better  immunity  than  killed 
vaccines.  De  Alwis  and  Carter  (1980)  observed  that  susceptible  buffalo  calves 
exposed  to  natural  HS  infection  and  survived,  developed  considerably  higher 
levels  of  antibody  and  immunity  of  longer  duration  than  those  vaccinated  with 
oil-adjuvant  vaccines.  It  was  postulated  that  this  immunity  is  caused  by  natural 
exposure  to  live  virulent  organisms  in  subinfective  numbers. Table  3:  Individual  genes  in  which  mutation  gives  rise  to  attenuation  in  some  pathogen  species 
Strain  Gene  Mutant  phenotype  Reference 
Aeromonas  hydrophila  aroA  Requirement  for  aromatic  A.  A4, 
PABA*  and  DHBAV  28 
Bacillus  subtilis  aroA  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  24 
Bordetella  pertusis  aroA  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  33 
Ervinia  amylovora  galE  Renders  cells  reversibly  rough  27 
Neisseria  gonorrhoeae  aroA  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  3 
Neisseria  meningitidis  galE  Renders  cells  reversibly  rough  22 
Pasteurella  haemolytica  aroA  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  18 
Pasteurella  multocida  A:  3  aroA  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  17 
Pasteurella  multocida  galE  Renders  cells  reversibly  rough  15 
Salmonella  typhi  pab  Requirement  for  PABA  2 
Salmonella  dublin  pur  Requirement  for  purines  26 
Salmonella  typhimurium  aroA  Requirement  for  aromatic  A.  A,  9,16,29 
PABA  and  DHBA  25,34,23 
Salmonella  typhi  aroA,  C,  D  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  4,9,35,21 
Salmonella  typhimurium  dap  Requirement  for  diaminopimelic  acid  5 
Salmonella  typhi  purA  Requirement  for  adenine  2 
Salmonella  typhi  purHD  Requirement  for  hypoxanthine 
and  thiamine  10 
Salmonella  typhimurium  purA  Requirement  for  adenine  31 
Salmonella  typhimurium  aroB  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  14 
Salmonella  typhimurium  galE  Renders  cells  reversibly  rough  12,19,20 
Salmonella  typhi  galE  to  to  of  to  13 
Salmonella  typhimurium  cya,  crp  Inefficient  transport  and  use  of 
carbohydrates  and  AA  and  inability 
to  synthesise  cell  surface  structure  7 
Salmonella  typhimurium  phoP  Regulates  genes  for  acid 
phosphatase  and  virulence  11 
Salmonella  enteritidis  aroA  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  6 
Salmonella  typhimurium  ompR  Outer  membrane  protein, 
modulates  porin  expression  8 
Shigellaflexneri  aroA,  D  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  30,36 
Yersinia  enterocolitica  aroA  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  1 
Yersinia  pestis  aroA  Requirement  for  aromatic  A.  A, 
PABA  and  DHBA  32 
*Amino  acid  vDihydroxybenzoic  acid  *Para  amino  benzoic  acid 
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Prolonged  in  vitro  passage  of  P.  multocida  strains  can  lead  to  considerable 
attenuation,  but  this  has  the  drawback  of  possible  reversion  to  their  original 
virulence  especially  on  animal  passage. 
In  the  last  three  decades,  different  work  has  been  done  on  chemically  or 
physically  altered  live  vaccines.  Wei  and  Carter  (1978)  mutagenised  a  P. 
multocida  type  B  strain  with  N-methyl-N-nitro-N-nitrosoguanidine  (NMG)  to 
obtain  a  genetically  stable  streptomycin-dependent  mutant,  from  which  a  live 
vaccine  was  prepared  that  was  highly  immunogenic  in  mice  and  rabbits.  De 
Alwis  and  Carter  (1980)  successfully  immunised  calves  with  the  live 
streptomycin-dependent  mutant  by  subcutaneous  or  intramuscular  routes  with 
one  or  two  doses  of  vaccine.  Also,  streptomycin-dependent  strains  of  P. 
multocida  serogroups  A:  1  and  A:  3  produced  after  NMG  and  acriflavin 
(diaminoacridine  salts)  treatment  were  reported  to  be  immunogenic  in  cattle, 
swine,  sheep  and  rabbit,  and  protected  against  challenge  with  the  wild-type 
strains  (Chengappa  et  al.,  1979;  Kucera  et  al.,  1981;  Lu  and  Pakes,  1981).  The 
molecular  basis  of  the  mutations  was  unknown. 
A  live  vaccine  of  a  serologically-related  strain  of  P.  multocida  (serotype 
B:  3,4)  to  the  HS-causing  organism  was  isolated  from  deer  and  used  in  calves 
for  protection  against  HS  (Myint  et  al.,  1987).  This  vaccine,  when  inoculated 
subcutaneously  showed  some  toxicity  and  was  lethal  in  a  few  young  buffalo 
calves  but  by  the  intranasal  route  it  was  safe  and  protection  was  reported 
against  subcutaneous  challenge  (Myint  and  Carter  1989;  1990).  It  does  have  the 
advantages  of  apparent  absence  of  anaphylactic  shock,  protection  for  up  to  a 
year,  easy  preparation,  a  relatively  small  dose  and,  when  lyophilised, 
prolonged  viability  (Myint  and  Carter,  1990).  This  vaccine  strain  is  rough  and 
serologically  different  from  typical  HS  strains  that  carry  B:  2  antigens.  The 
difference  in  somatic  antigens  (type  3  and  4  carried  by  the  vaccine  strain  and 
type  2  found  in  HS  cultures)  seems  to  be  responsible  for  the  reduction  in 27 
virulence,  whereas  the  identical  capsular  type  B  helps  in  the  development  of 
protective  immunity  against  HS  (Myint,  1992).  It  has  been  used  extensively  by 
the  intranasal  route  in  several  districts  in  Myanmar,  and  absence  of  outbreaks  in 
these  areas  is  reported,  suggesting  its  efficacy  against  infection  by  natural 
routes  (Carter  et  al.,  1991).  This  vaccine  deserves  a  more  comprehensive  trial. 
When  using  mutants  which  are  not  genetically  defined,  their  stability  is  a 
matter  for  concern.  Homchampa  et  al.  (1992,1994)  constructed  by 
recombinant  DNA  techniques  aroA  mutants  of  P.  multocida  serogroup  A:  1  and 
P.  haemoytica  biotype  A:  1  containing  a  KmR  cassette  inserted  into  the  aroA 
gene.  These  was  done  by  using  a  suicide  vector  approach.  They  found  that  they 
were  attenuated  in  a  mouse  model  and  protected  the  mice  against  wild-type 
challenge.  Interestingly,  the  antibody  levels  in  mice  immunised  with  one  or  two 
doses  of  P.  multocida  aroA  mutant  did  not  show  significant  differentiation, 
suggesting  a  single  dose  may  be  sufficient  for  protection,  but  in  compare,  the 
antibody  levels  in  mice  which  received  two  doses  of  P.  haemolytica  aroA 
mutant  were  approximately  50%  higher  than  those  which  received  single  dose. 
Homchampa  et  al.  (1997)  reported  the  cross  protective  immunity  conferred 
by  a  marker-free  aroA  mutant  of  P.  multocida  serotype  A:  1.  They  found  that 
the  new  marker-free  aroA  mutant  strains  were  highly  attenuated  in  the  mouse 
model.  Also,  they  showed  that  these  mutant  strains  could  confer  protective 
immunity  against  homologous  and  heterologous  (serotype  A:  3  strain)  challenge 
with  one  or  two  doses  of  vaccine,  but  not  against  other  biotypes. 
3.8.  The  approaches  used  for  production  of  attenuated  vaccine  strains 
with  defined  mutations 
Many  genetic  manipulation  experiments  require  the  exchange  of  mutations 
either  between  strains,  from  plasmid  into  the  chromosomal  DNA  or  from  the 
chromosome  onto  plasmids.  Several  widely  used  allelic  exchange  systems  have 
been  developed  to  facilitate  these  tasks. 28 
1.3.8.1.  Use  of  plasmid  incompatibility  in  selectable  marker  exchange 
The  properties  of  plasmid  incompatibility,  particularly  that  of  IncPl  group, 
have  been  widely  used  as  a  means  for  marker  exchange  in  a  variety  of  Gram- 
negative  bacteria  (Ruvkun  and  Ausubel,  1981).  This  method  can  be  used  with 
any  selectable  marker,  the  fragment  to  be  recombined  contains  a  selectable 
marker  such  as  kanamycin  resistance  (KmR)  and  is  cloned  into  a  broad  host 
range  IncPl  plasmid  [such  as  a  tetracycline  resistant  (TcR)  pLAFR  derivative, 
Friedman  et  al.,  1982]  and  maintained  in  an  E.  coli  host.  This  plasmid  is 
introduced  into  the  strain  in  which  the  mutation  is  to  be  recombined  by 
electroporation  or  mating  but,  due  to  the  large  size  of  plasmid,  mating  is 
preferred.  The  pLAFR  plasmids  require  helper  functions  for  their  mobilisation 
as  provided  by  strain  such  as  SMIO  which  contains  a  copy  of  plasmid  RP4 
integrated  into  the  chromosome  (Simon  et  al.,  1983).  Recipients  now  carrying 
the  pLAFR  plasmid  are  then  mated  with  a  strain  carrying  a  second  transmissible 
IncPl  plasmid  with  a  different  selectable  marker.  Plasmid  pPHIJI  is  a  large 
self-transmissible  plasmid  which  confers  gentamycin  resistance  (GmR)  and  is 
often  used  for  this  "kickout"  step.  By  selection  for  GmR  and  KmR  and 
appropriate  counter  selection  against  the  plasmid  pPHIJI  donor  cells, 
exconjugants  arise  that  have  lost  the  original  IncPl  pLAFR  plasmid;  however, 
they  retain  the  KmR  marker  that  is  now  integrated  into  genomic  DNA  via  the 
homology  surrounding  the  insertion  (Fig.  4). 
Generally,  constructs  that  incorporate  the  antibiotic  resistance  marker  within 
the  genomic  fragment  of  interest  are  first  constructed  on  a  small  defined 
plasmid  and  then  cloned  into  pLAFR  for  the  allelic  exchange  into  the 
appropriate  recipient  species. 
1.3.8.2.  Use  of  conditional  replicons  ("suicide  plasmids")  as  a  means  of 
constructing  genetic  duplications  and  null  alleles Fig  4:  Allelic  exchange  of  a  TnphoA  fusion  using  the  IncPl  system. 
The  donor  strain  carries  a  pLAFR  plasmid  containing  gene  X  that  is  disrupted 
with  a  phoA  gene  fusion  marked  by  KmR  (phoAKmR)  as  would  be  the 
situation  for  a  mutation  generated  by  TnphoA  mutagenesis.  The  plasmid  is 
present  in  a  mobiliser  strain  such  as  SM10.  This  donor  is  mated  with  a 
recipient  which  carries  a  marker  that  will  be  used  for  counterselection  against 
the  donor,  in  this  case  SmR  (A).  Transconjugants  from  A  are  mated  with  a 
second  IncPl  plasmid  (e.  g.,  pPH1JI)  that  confers  GmR  (B).  Transconjugants 
from  a  second  mating  are  selected  on  agar  containing  gentamycin  and 
kanamycin  for  acquisition  of  the  plasmid  and  retention  of  KmR  marker  (C). 
TcS  transconjugants  are  grown  under  conditions  that  promote  curing  of  the 
GmR  plasmid.  (From  Maloy,  et  al.,  1996) Fig  4: 
Primary  Donor 
TCR 
r 
IncPl 
X:  -phMAkan'::  X 
::  RP4: 
+ 
Primary  Transconjugant 
TCR 
lncPl 
:  pnoAxan"::  -l 
S,  X+ 
SmR 
r 
Recipient  GmR 
IncPl 
Secondary  Donor 
(B) 
GmR 
IncPl 
R 
X":;  phoAkan'::  X  (C) 
R 
r:;  phoAkanl::  X 
Sm  Sm 
Cured  Transconjugant  Secondary  Transconjugant 29 
Plasmids  that  are  conditional  for  their  replication  can  be  used  to  create 
defined  duplications  within  a  target  genome.  In  this  case,  a  DNA  fragment  is 
cloned  into  a  plasmid  and  then  introduced  into  a  recipient  strain  in  which  the 
plasmid  cannot  replicate.  Thus,  selection  for  an  antibiotic  resistance  marker 
carried  by  the  plasmid,  results  in  isolates  that  have  integrated  the  plasmid  into 
the  genome  via  homology  between  the  cloned  DNA  fragment  and  a 
corresponding  region  of  the  recipient  chromosome. 
Plasmid  vectors  used  for  this  type  of  mutagenesis  must  have  special 
properties  desirable  for  such  insertional  mutagenesis,  such  as  conditional 
replication  to  allow  for  selection  of  chromosomal  integration,  and  must  have  a 
selectable  marker  and  should  be  transferable  to  different  bacterial  species  and 
finally  must  carry  unique  cloning  sites. 
1.3.8.3.  Use  of  suicide  vectors  for  allelic  exchange  of  non-selectable 
mutations 
If  the  mutation  or  construction  is  initially  induced  on  a  plasmid,  allelic 
exchange  can  be  utilised  to  replace  the  wild  type  chromosomal  copy  of  the  gene 
with  the  altered  gene.  Such  replacements  are  usually  easily  achieved  only  if  the 
mutation  is  either  the  result  of,  or  closely  linked  to,  a  selectable  marker  such  as 
antibiotic  resistance  gene.  If  one  of  the  duplicated  sequences  carries  only  a 
mutation,  some  of  the  resolved  products  will  remove  the  wild-type  sequence 
and  leave  the  mutation  in  the  chromosome  (Fig.  5).  The  frequency  with  which 
the  mutation  becomes  incorporated  into  the  chromosome  is  influenced  by  the 
position  of  the  mutation  within  the  region  of  homology.  In  the  absence  of  a 
method  to  select  for  loss  of  the  integrated  plasmid,  a  large  number  of  colonies 
must  be  screened  just  to  find  those  that  had  excised  the  plasmid  sequences. 
One  marker  that  has  been  used  to  select  for  loss  of  an  integrated  plasmid  that 
does  not  carry  a  selectable  marker  is  the  sacB  gene  from  Bacillus  subtilis.  The 
sacB  gene  encodes  the  enzyme  levansucrase,  a  50  kDa  enzyme  secreted  into  the Fig  5:  Use  of  suicide  vectors  for  allelic  exchange  of  nonselectable  mutations 
(A).  Chromosomal  integration  of  a  plasmid  carrying  a  mutation  (*)  on  a  cloned 
fragment  by  homologous  recombination  generates  a  heterodiploid  strain. 
(B).  Two  possible  excision  events  (a  or  b).  Excision  of  the  plasmid  by 
homologous  recombination  on  the  opposite  side  of  the  mutation  from  which 
the  integration  occurred  (excision  b)  results  in  allelic  exchange  of  the  mutation 
from  the  plasmid  to  the  chromosome.  The  excised,  non-replicating  plasmid  is 
lost  upon  cell  division.  (From  Maloy,  et  al.,  1996) Fig  5: 
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culture  medium  by  Bacillus  subtilis  after  induction  by  sucrose.  Expression  of 
this  enzyme  is  toxic  for  Gram-negative  bacteria  such  as  E.  coli,  Agrobacterium 
tumefaciens  and  Rhizobium  meliloti,  (Blomfield  et  al.,  1991;  Gay  et  al.,  1985) 
grown  in  the  presence  of  5%  (w/v)  sucrose,  causing  cell  lysis  within  1h  or 
inhibition  of  growth  because  of  levansucrase  secretion.  Thus,  only  colonies 
that  have  removed  sacB  by  recombining  out  the  integrated  plasmid  sequences 
can  survive  in  the  presence  of  sucrose.  In  practice,  some  sucrose  resistant 
colonies  can  arise  from  alterations  in  either  the  sacB  gene  or  its  expression, 
rather  than  by  deletion  of  vector  from  chromosome.  Thus,  colonies  arising 
from  this  selection  are  subsequently  screened  for  concomitant  loss  of  antibiotic 
resistance  marker  to  ensure  that  the  sucrose  resistant  phenotype  is  due  to  loss  of 
the  integrated  plasmid.  This  approach  has  been  used  in  construction  of  un- 
marked  mutations  in  Helicobacter  pylori  vacA  gene  (Copass  et  al.,  1997)  and 
construction  of  an  eae  deletion  mutant  of  enteropathogenic  E.  coli  (Donnenberg 
and  Kaper,  1991).  Also,  sacB  selection  was  used  successfully  by  Akerley  et  al. 
(1995)  and  Tejada  et  al.  (1996)  in  Bordetella  pertussis  and  Bordetella 
bronchiseptica,  respectively,  for  construction  of  EbvgAS  and  un-marked 
mutation  in  the  fr!  AB  or  fr!  A  (flagellar)  gene. 
Another  strategy  to  select  for  loss  of  the  integrated  plasmid  utilises  the  E. 
coli  rpsL  gene  that  encodes  ribosomal  protein  S  12.  Integration  of  the  plasmid 
carrying  wild  type  rpsL  into  a  streptomycin  resistant  strain  carrying  a 
chromosomal  mutation  in  rpsL  result  is  production  of  a  streptomycin  sensitive 
strain.  This  occurs  because  the  mutation  is  recessive  to  the  wild-type  protein. 
Such  a  plasmid  is  pRTPI  a  suicide  vector  for  allelic  exchange  in  Bordetella 
pertussis  (Stibitz  et  al.,  1986;  Stibitz,  1994). 
The  inability  of  colEl-based  plasmids  to  replicate  in  some  bacterial  species 
has  also  been  exploited  for  allelic  exchange  in  P.  multocida  (Nnalue  and 
Stocker,  1989;  Azad  et  al.,  1994).  The  high  efficiency  of  allelic  exchange, 31 
especially  as  achieved  with  the  selective  marker,  make  it  feasible  to  physically 
screen  chromosomal  integration  of  mutations  for  which  there  is  no  phenotypic 
screen.  Such  approaches  are  also  useful  for  confirming  mutations  for  which 
there  is  no  phenotypic  screen  or  selection.  They  generally  involve  analysis  of 
an  amplified  product  generated  by  polymerase  chain  reaction  (PCR)  using 
primers  that  flank  the  region  of  interest.  The  presence  of  insertion  or  deletion 
mutations.  that  alter  the  size  of  particular  DNA  fragment  can  be  determined 
directly  by  gel  electrophoresis  of  the  amplified  products. 
As  mentioned,  one  approach  to  attenuating  P.  multocida  has  been  to 
develop  nutritional  auxotrophs  by  interrupting  the  pathway  for  biosynthesis  of 
aromatic  metabolites  which  renders  the  strains  dependent  on  p-aminobenzoic 
acid  (PABA)  and  2,3-dihydroxybenzoate,  substrates  not  available  to  bacteria  in 
mammalian  tissues.  Such  mutants  are  unable  to  synthesis  chorismic  acid,  an 
important  precursor  of  aromatic  compounds.  Aromatic  amino  acids  and  other 
compounds  containing  an  aromatic  ring  structure  are  bio-synthesised  in 
bacteria,  fungi  and  plants  via  the  pre-chorismate  or  shikimate  pathway,  utilising 
erythrose-4-phosphate  and  phosphoenolpyrovate  as  precursor  substrates.  In 
bacteria,  the  seven  enzymes  in  the  pathway  ultimately  produce  the  compound 
chorismate  (Fig.  6).  Chorismate  is  the  precursor  of  the  aromatic  amino  acids 
(L-tyrosine,  L-tryptophan  and  L-phenylalanine)  as  well  as  other  aromatic  ring- 
containing  compounds  such  as  quinones  and  folate.  The  five  central  steps  of 
the  pre-chorismate  pathway  are  fused  as  a  single  pentafunctional  enzyme  called 
AROM  in  a  number  of  lower  eukaryotes  (Hawkins  et  al.,  1993).  In  contrast, 
the  corresponding  enzymes  of  the  pathway  in  the  prokaryotes  occur  as 
monofunctional  enzymes  and  their  structural  genes  are  scattered  throughout  the 
genome  (Gunel-Ozcan  et  al.,  1997).  As  a  consequence  of  this  auxotrophy,  the 
mutated  bacteria  should  not  have  sustained  proliferation  within  mammalian 
hosts,  but  they  will  reside  and  grow  for  long  enough  to  stimulate  protective 
immune  responses.  The  introduction  of  certain  auxotrophic  mutations  in  genes Fig  6:  Genes,  enzymes  and  metabolites  comprising  the  shikimate  (pre- 
chorismate)  pathway  in  Salmonella  typhimurium Phosphoenol  pyruvate 
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such  as  the  aroA  gene  that  produces  5-enolpyruvyl-shikimate-3-phosphate 
(EPSP)  synthase  and  catalyses  the  sixth  step  in  shikimate  pathway  into  the 
genomes  of  a  variety  of  prokaryotes  including  Salmonella  spp.  (Hoiseth  and 
Stocker,  1981;  Mukkur  et  al.,  1987),  Bordetella  pertussis  (Roberts  et  al., 
1990),  Bacillus  subtilis  (Yazdi  and  Moir,  1990),  Pasteurella  multocida 
(Homchampa  et  al.,  1992),  Aeromonas  hydrophila  (Moral  et  at.,  1998)  and 
Yersinia  enterocolitica  (Bowe  et  al.,  1989)  (Table  3)  renders  them  avirulent  for 
mice.  Mice  immunised  with  the  appropriate  dose  of  defined  aroA  mutants  are 
generally  well  protected  against  a  subsequent  challenge  with  the  virulent 
parental  strain. 
Mutation  in  the  biosynthesis  of  surface  components  can  create  attenuated 
mutants  of  some  bacterial  species  in  experimental  models.  Dougan  et  al.  (1989) 
reported  that  many  rough  variants  of  virulent  Salmonella  strains  are  less 
virulent  than  smooth  parent  strains.  The  smooth-to-rough  phenotypic  change 
involves  loss  of  the  ability  to  synthesise  or  assemble  the  O-specific  side-chains 
of  the  surface  lipopolysacchride  (LPS)  molecules.  The  LPS  of  Gram-  negative 
bacteria  is  a  major  surface  component  present  only  in  the  outer  leaflet  of  the 
outer  membrane  (Fig.  7).  The  LPS  molecule  consists  of  three  covalently  linked 
regions:  the  lipid  A,  which  anchors  the  molecule  in  the  outer  membrane;  the 
core,  and  the  O-side  chain.  Galactose  may  be  present  in  the  O-antigen,  and  is 
also  a  constituent  of  the  core  portion  of  the  LPS  (Henestrosa  et  al.,  1997). 
Enterobacteria  utilize  galactose  by  the  Leloir  pathway  (Adhya,  1987). 
Metabolism  of  galactose  requires  the  epimerization  of  uridine  diphosphate 
(UDP)-galactose  to  UDP-glucose  (Fig.  8).  The  galE  product,  UDP-Gal-4- 
epimerase,  catalyses  both  this  reaction  and  the  reverse  (Adhya,  1987).  UDP- 
galactose  is  used  as  the  donor  for  both  core  and  O-polysaccharide  biosynthesis. 
Thus  galE  mutants  grown  in  glucose  alone  as  a  carbon  source  are  unable  to 
produce  wild-type  LPS  structures  on  the  cellular  surface  (Robertson  et  al., Fig  7:  The  Gram-negative  bacterial  envelope. 
It  contains  3  different  parts;  plasma  membrane,  periplasmic  space  and 
peptidoglycan  and  outer  membrane.  The  LPS  component  of  the  outer 
membrane  consist  of  three  sections:  lipid  A,  core  and  O-specific  side 
chains.  (From  Prescott  et  al.,  1993) Fig  8:  Schematic  representation  of  the  Leloir  pathway  for  galactose 
metabolism  and  incorporation  of  exogenous  galactose  into  the  LPS  of 
galE  mutants  by  Salmonella  typhi  illustrating  the  stage  sensitive  to 
galactose  (x  x).  Note  that  glucose-  l-phosphate  generated  from 
galactose  after  the  galactose-1-phosphate  uridylyltransfrase  step  is 
recycled  to  UDP-glucose  by  the  uridinediphosphoglucose  synthetase 
reaction.  (Adapted  from  Walker,  1987) b 
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1993)  and  exhibit  a  rough  colonial  morphology  due  to  incomplete  LPS.  If  the 
growth  medium  is  supplemented  with  galactose,  cells  begin  to  synthesise  a 
smooth  LPS  with  complete  O-side  chain,  probably  utilising  galactokinase  and 
galactose-1-phosphate-uridyl  transferase  (Dougan  et  al.,  1989).  However,  galE 
mutants  accumulate  a  toxic  phosphorylated  derivative  of  galactose  and  autolyse. 
In  this  respect,  the  galE  gene  seems  to  play  a  role  in  the  virulence  of  some 
bacteria,  since  it  has  been  shown  that  galE  mutants  of  Salmonella 
typhi,  Salmonella  typhimurium,  Haemophilus  influenzae  and  Erwinia 
amylovora  are  less  virulent  than  their  respective  wild-type  strains  (Hone  et  al., 
1988;  Dougan  et  al.,  1989;  Maskell  et  al.,  1992;  Metzger  et  al.,  1994).  Dougan 
et  al.  (1989)  found  that  a  loss  of  the  O-specific  side  chain  but  maintenance  of  a 
complete  core  in  Salmonella  typhi  resulted  in  a  two-log  increase  in  LD50  after 
intraperitoneial  (i.  p.  )  inoculation  in  BALB/c  mice.  Also,  they  found  that  a 
mutation  in  rfaF  that  affected  core  LPS  structure  increased  the  LD50  an 
additional  two-logs.  Mutations  that  result  in  even  shorter  LPS  structures  are 
quite  fragile,  sensitive  to  detergents  and  have  lost  all  virulence.  Thus,  LPS,  on 
the  basis  of  such  rough  mutants,  has  been  implicated  both  as  a  virulence 
determinant  and  as  a  candidate  protective  antigen.  With  the  exception  of  galE 
mutant,  rough  strains  have  not  found  use  as  Salmonella  vaccines,  although  a 
spontaneously  rough  variant  of  Salmonella  dublin  has  been  sold  for  some  time 
as  a  live  cattle  vaccine. 
Nevertheless,  the  behaviour  of  the  galE  mutants  is  not  the  same  in  all 
bacterial  species,  since  the  pathogenic  potential  of  strains  of  Salmonella  typhi 
defective  for  this  gene  is  not  affected  in  humans  (Hone  et  al.,  1988). 
Henestrosa  et  al.  (1997)  reported  the  importance  of  the  galE  gene  on  the 
virulence  of  P.  multocida  serogroup  D  and  they  showed  that  its  galE  mutant 
was  slightly  attenuated  in  a  mouse  model. 34 
Another  approach  to  attenuating  P.  multocida  used  here  is  by  creating 
mutation  in  the  cya  (adenylate  cyclase)  gene.  As  was  showed  by  Curtiss  and 
Kelly  (1987),  Salmonella  typhimurium  deletion  mutants  lacking  adenylate 
cyclase  (AC)  and  cyclic  AMP  receptor  protein  are  avirulent  and  immunogenic  in 
mice.  Cyclic  AMP  (cAMP)  in  E.  coli  is  known  to  play  a  regulatory  role  in  gene 
transcription  via  its  receptor  protein  and  catabolite  gene  activator  protein.  These 
are  transcription  regulators  of  many  genes  and  operons  concerned  with  the 
transport  and  breakdown  of  catabolites.  Systems  used  for  transporting  carbon 
sources  and  several  amino  acid  permeases  are  all  under  positive  control  by 
cAMP.  Adenylate  cyclase  is  the  enzyme  that  converts  ATP  to  cAMP.  Aiba  et  al. 
(1984)  cloned  and  sequenced  the  adenylate  cyclase  structural  gene  (cya)  of  E. 
coli  and  a  model  for  the  regulation  adenylate  cyclase  activity  has  been 
proposed.  On  the  basis  of  genetic  experiments,  it  was  suggested  that  the 
phosphorylated  form  of  enzyme  III-glucose,  a  component  of 
phosphotransferase  system,  was  an  activator  of  adenylate  cyclase  (Mock  et  al., 
1991).  When  glucose  transport  takes  place,  the  intracellular  concentration  of 
phosphorylated  enzyme  III-glucose  decreases  and  correlates  with  a  decrease  in 
intracellular  cAMP  concentration. 
Mock  et  al.  (1991)  cloned  the  P.  multocida  adenylate  cyclase  gene  and 
expressed  it  in  E.  coli  and  they  found  that  the  P.  multocida  protein  shares 
several  regions  of  identity  with  E.  coli  and  Erwinia  chrysanthemi  adenylate 
cyclases. 
1.3.9.  Immune  and  protective  mechanisms 
1.3.9.1.  Naturally  acquired  immunity 
De  Alwis  and  Carter  (1980)  described  naturally  acquired  immunity  to  HS.  In 
Sri  Lanka,  where  high,  moderate  and  low  HS  incidence  areas  can  be  identified, 
the  naturally  acquired  immunity  comes  from  sub-clinical  infection. 
Occasionally,  cattle  have  been  found  in  Australia  and  USA  with  antibodies  that 35 
will  protect  mice  against  challenge  with  P.  multocida  6:  B  (De  Alwis,  1982). 
Antibodies  against  P.  multocida  capsular  types  B  and  E,  which  cause  HS,  were 
demonstrated  in  a  high  percentage  of  sera  from  domestic  feeder  calves  that  had 
not  been  vaccinated  with  any  Pasteurella  organisms.  These  antibodies  were 
considered  to  be  naturally  acquired  (Sawada  et  al.,  1985).  Naturally  acquired 
antibody  has  been  demonstrated  in  sera  from  buffalo  and  Zebu  cattle  in  HS 
enzootic  areas  of  Asia  and  Africa  (Bain,  1954;  Peereau  et  al.,  Cited  by  Verma 
and  Jaiswal,  1998).  De  Alwis  (1982)  reported  that  when  susceptible  buffalo 
calves  are  exposed  to  natural  infection  with  haemorrhagic  septicaemia  agent, 
some  calves  succumb  to  disease  while  the  others  develop  varying  degrees  of 
immunity  which  is  most  instances  is  considerably  higher  than  that  induced  by 
vaccination.  Immunity  has  been  attributed  to  protective  antibodies  that  develop 
following  non-fatal  exposure  and  can  persist  for  more  than  one  year  in  some 
animals  (Carter  and  De  Alwis,  1989). 
1.3.9.2.  Humoral  and  cell-mediated  immune  responses 
There  has  been  little  work  done  on  the  surface  components  of  P.  inultocida 
that  contribute  to  interference  with  ingestion  by  phagocytosis.  Mahesavaran  and 
Theis  (1979)  studied  phagocytosis  of  a  non-capsulate  P.  multocida  strain  and 
an  encapsulated  type  B  strain  by  qualitatively  measuring  the  uptake  by  bovine 
neutrophils  of  H3-thymidine-labelled  bacteria  in  the  presence  of  heat-stable  and 
heat-labile  opsonins.  The  non-capsulated  strain  was  completely  phagocytosed 
in  the  presence  of  normal  and  heat-inactivated  bovine  serum,  which  indicated 
that  heat-labile  factors  in  serum  (complement)  were  not  involved  in 
opsonization.  Encapsulated  capsular  type  B  strain  was  found  to  interfere  with 
opsonization  with  normal  serum.  While  testing  the  efficacy  of  alum-precipitated 
bacterin  that  provided  protection  to  challenge,  complement-fixation  titres 
against  whole  cell  bacteria,  but  not  titres  against  saline  capsular  extract,  were 
closely  correlated  with  resistance  (Sharma  et  al.,  1980).  Cytophilic  and  opsonin 36 
adhering  antibodies  were  produced  in  rabbits  immunised  with  oil-adjuvant 
vaccine  and  challenge  infected  with  P.  multocida  (Maurya  and  Jaiswal,  1996). 
The  protective  immune  response  to  HS  vaccination  has  long  been  attributed 
to  humoral  responses  and  can  be  transferred  to  native  animals  with  serum  from 
vaccinated  animals  (Maurya  and  Jaiswal,  1996).  Outside  the  passive  protective 
effect,  very  little  is  known  about  the  kinetics  of  antibody  response  following 
oil-adjuvant  vaccine  or  bacterin  adminstration  or  even  what  constitutes  a 
protective  response,  the  functional  classes  of  antibody  involved  in  protection 
and  the  bacterial  antigens  responsible. 
The  majority  of  immune  responses  to  vaccination  in  animals  has  been 
studied  on  the  basis  of  data  on  morbidity/survival  (Collins,  1973).  The  humoral 
response  in  a  mouse  protection  test  has  been  widely  used  as  a  relatively  reliable 
assessment  of  immunity  in  cattle  and  buffalo.  Vaccination  of  animals  elicits  a 
humoral  immune  response,  and  the  presence  of  circulating  antibody  in  cattle 
and  buffalo  correlates  with  immunity  (Carter,  1967).  Dhanda  (Cited  by  Verma 
and  Jaiswal,  1998).  showed  that  levels  of  circulating  antibodies  were 
detectable  from  the  first  week  up  to  18  months  post-vaccination  with  oil- 
adjuvant  vaccine.  It  has  been  difficult  to  determine  whether  these  protective 
antibodies  operate  by  a  bactericidal  or  an  opsonizing  mechanism  (Wijewardana 
et  al.  1990;  Rimler  and  Jaiswal,  1998). 
ELISA  and  immunoblotting  techniques  used  to  examine  the  humoral 
immune  response  to  P.  inultocida  in  bovine  sera  from  Indonesia  and  Malaysia 
showed  elevated  levels  of  antibody  in  vaccinated  animals.  The  serum  antibody 
response  of  buffalo  immunised  with  three  conventional  HS  vaccines,  viz.  broth 
bacterin  (BB),  alum-precipitated  vaccine  (APV)  and  oil  adjuvant  vaccine  (OAV) 
and  one  experimental  double  emulsion  vaccine  (DEV),  was  determined  by 
ELISA.  Antibody  levels  were  significantly  higher  in  buffaloes  immunised  with 
the  adjuvanted  vaccines  (APV,  OAV,  and  DEV)  than  those  immunised  with  BB 37 
alone.  There  also  appeared  to  be  a  relationship  between  ELISA  titters  and  active 
protection  in  buffaloes  (Verma  and  Jaiswal,  1998).  A  preliminary  analysis  of 
the  antibody  isotypes  in  the  sera  of  buffalo  immunised  with  the  oil-adjuvanted 
vaccines  showed  the  anti-Pasteurella  activity  to  be  associated  predominantly 
with  IgGI  or  IgG2  isotypes.  The  principal  response  to  OAV  and  bacterin 
vaccination  was  the  IgG  response  with  only  a  mild  and  transient  IgM  response, 
and  the  major  protective  role  was  due  to  the  IgG  antibody  class.  There  appeared 
to  be  an  association  between  pre-challenge  antibody  titers  and  protection  in 
buffaloes  following  challenge.  Buffaloes  with  initial  high  antibody  levels  were 
protected,  whereas  those  buffaloes  with  low  levels  succumbed  to  challenge.  No 
minimum  antibody  level  necessary  for  protection  has  been  attributed  because  of 
the  difference  in  the  types  of  methods  of  antigen  preparation.  Verma  and 
Jaiswal  (1997)  measured  the  antibody  response  by  indirect  haemagglutination 
assay  (IHA)  and  ELISA  in  cross-bred  male  calves  immunised  with  multiple 
emulsion  (ME)  HS  vaccine.  In  their  study,  an  animal  with  a  minimum  pre- 
challenge  IHA  titre  of  80  withstood  the  challenge  infection  with  virulent  P. 
multocida.  However,  because  of  the  variation  in  the  pre-challenge  titre  among 
the  group  of  animals,  no  minimum  level  of  pre-challenge  antibody  titre  could  be 
proposed. 
There  is  no  evidence  of  a  role  of  a  cell-mediated  immune  (CMI)  response 
in  HS  (Bain  et  al.,  1982).  However,  the  involvement  of  cell-mediated 
immunity  cannot  be  discounted  in  protection  (Wijewardana  et  al.,  1990).  One 
of  the  reasons  for  not  studying  the  role  of  cell-mediated  immune  response  in 
cattle  is  that  P.  multocida  has  not  been  described  as  a  facultative  intracellular 
bacterium.  As  reported  by  Carter  (1967),  Hunter  and  Woebester  (1980), 
Collins  (1973)  and  Snipes  et  al.  (1987)  P.  multocida  appears  to  multiply 
extracellularly  in  the  turkey  and  by  inference,  in  other  animals  as  well.  The 
other  reason  is  largely  a  humoral  response  in  HS.  However,  avian  serotype  A 
strains  of  P.  multocida  have  been  reported  to  invade  cultured  mammalian  cells 38 
(Lee  et  al,  1994;  Adler  et  al,  1996;  Rabier  et  al,  1997),  but  other  serotypes 
have  not  been  examined.  The  leukocyte  migration-inhibition  test  (LMIT)  has 
been  described  as  an  indicator  of  the  cell-mediated  immune  response  (Timms, 
1974).  Verma  and  Jaiswal  (1997)  reported  more  than  20%  leukocyte 
migration-inhibition  in  calves  immunised  with  ME  vaccine  both  at  pre- 
challenge  and  post-challenge  intervals,  thus  indicating  the  involvement  of  cell- 
mediated  immune  mechanisms. 
1.3.10.  Critical  appraisal 
Since  the  discovery  of  the  attenuated  P.  multocida  responsible  for  fowl 
cholera,  and  the  first  use  of  bacterin  to  prevent  HS,  more  than  a  century  has 
passed  in  which  numerous  efforts  have  been  made  to  develop  a  suitable  and 
cost-effective  HS  vaccine.  Most  success  in  HS  vaccinology  has  been  obtained 
with  oil-adjuvant  vaccines  and  recently,  a  live  vaccine  has  been  used  in 
Myanmar  (Table  2).  Both  of  these  vaccine  types  offer  immunity  for  up  to  one 
year.  Because  the  respiratory  tract  is  the  natural  route  of  entry  of  Pasteurella, 
healthy  animals  carry  the  organisms  that  cause  HS  in  their  nasopharynx  ,  and 
such  animals  are  considered  as  seeds  of  an  HS  outbreak.  Local  secretory 
antibodies  (specific  IgA)  are  produced  due  to  intranasal  vaccination  with  live 
HS  vaccine,  which  may  be  an  advantage  in  preventing  natural  infection  of  HS. 
Another  potential  success  in  vaccinology  has  been  the  development  of  a 
multiple  emulsion  vaccine,  which  provided  immunity  for  52  weeks  (Verma  and 
Jaiswal,  1997),  but  this  experimental  vaccine  is  yet  to  go  into  field  use. 
It  has  been  established  from  epidemiological  studies  of  P.  multocida  that  a 
high  level  of  immunity  is  obtained  following  arrested  infection  (De  Alwis, 
1982;  Verma  and  Jaiswal,  1998).  This  observation  indicates  the  need  to 
develop  a  safe,  avirulent,  stable  variant  strain  that  should  produce  the  important 
immunogens  in  vivo  when  administered  as  a  live  vaccine.  Alternatively, 
identification  of  the  important  immunogens  responsible  for  the  high  level  of 39 
immunity  attained  on  natural  exposure  needs  to  be  done  and  development  of 
artificial  media  to  support  in  vitro  expression  of  these  immunogens  or 
expression  of  recombinant  proteins  by  DNA  manipulation.  Adjuvants  have 
played  a  great  role  in  the  development  of  HS  vaccine,  and  the  duration  of 
immunity  depends  on  the  type  of  adjuvant  used.  The  use  of  adjuvants, 
including  the  new  generation  of  adjuvants  (Verma  and  Jaiswal,  1998)  should 
be  evaluated  to  give  an  easily  injectable  vaccine.  But  as  mentioned  in  Table  2, 
the  components  used  in  vaccines,  such  as  aluminium  hydroxide  gel,  alum  and 
mineral  oil,  can  themselves  elicit  a  humoral  immune  response. 
Immune  mechanisms  in  HS  have  been  poorly  understood.  Investigation  into 
the  immune  mechanisms,  virulence  determinants,  comparison  of  live  vaccines, 
killed  vaccines  and  the  carrier  state  are  some  important  areas  that  have  been 
suggested  as  future  lines  of  research  (Verma  and  Jaiswal,  1998). 
1.4.  Objectives  of  research  and  experimental  plan: 
To  construct  defined  attenuated  strains,  and  to  develop  a  general 
methodology  that  could  be  readily  applied  to  a  large  number  of  vaccine  strains 
of  P.  multocida  B:  2.  The  ultimate  goals  were: 
1.  Construction  of  live  defined,  attenuated  (e.  g.  aroA,  cya,  galE)  mutants 
of  P.  multocida  strains  that  cause  haemorrhagic  septicaemia  in  cattle  and 
buffalo 
2.  To  test  these  attenuated  strains  in  a  mouse  experimental  model  for  their 
degree  of  attenuation  and  their  protective  properties. 
3.  Construction  of  marker-free  deletion  of  the  original  mutants  that  showed 
promise  as  potential  vaccine  strains. 
4.  To  do  the  above  work  in  P.  multocida  strains  of  different  geographical 
origin. 2.  MATERIALS  AND  METHODS 
2.1.  General  bacteriological  procedures 
2.1.1.  Sources  of  bacteria 
All  bacterial  strains  used  in  this  study  are  given  in  Table  4.  Strains  were 
available  from  culture  collections  within  the  Division  of  Infection  and 
Immunity,  University  of  Glasgow  or  were  available  commercially. 
2.1.2.  Plasmids 
Plasmids  used  in  this  study  are  given  in  Table  5. 
2.1.3.  Bacterial  growth,  storage  and  media 
The  compositions  of  the  following  media  are  given  in  the  Appendices.  Luria 
Bertani  (LB)  broth,  Luria  Bertani  (LB)  agar,  Brain  Heart  Infusion  (BHI)  broth, 
Cyclodextrin  liquid  (CL)  medium,  BHI  agar,  Blood  Agar  (BA),  Bordet- 
Gengou  (BG)  (Appendix  5.16)  medium,  SOC,  Terrific  broth  and  Pasteurella 
Minimal  Medium  (PMM).  All  media  were  sterilised  by  autoclaving  at  15  p.  s.  i. 
(121  0C)  for  15  min  except  where  stated.  Heat-labile  ingredients  such  as 
antibiotics  were  sterilised  by  filtration  through  a  sterile  0.22  µm  filter  (Gelman 
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Sciences,  USA).  Glassware  was  sterilised  by  heating  to  160  C  for  2  hrs. 
All  strains  were  stored  frozen  in  50%  (v/v)  glycerol  in  BHI  broth  or  LB  at 
-800C.  P.  multocida  strains  from  the  frozen  glycerol  stocks  were  subcultured 
routinely  on  Blood  Agar  (BA)  or  BHI  agar  medium  with  the  supplementation 
of  5%  (v/v)  defibrinated  sheep  blood  (B&  E  laboratories,  Scotland). 
2.1.4.  Growth  of  E.  coli 
E.  coli  strains  were  subcultured  on  LB  agar  medium.  All  plates  were 
incubated  at  370C  overnight.  Liquid  cultures  of  the  strains  were  grown  in  the Table  4:  Bacterial  strains  used  in  this  study 
Strain  Genotype  Source/  Remarks 
E.  coli  supE44  lacU  169  (801acZM  15)  Infection  and  Immunity, 
DH5a  hsd  R17  recAl  endAI  gyrA96  University  of  Glasgow 
thi-1  relAl 
E.  soli  recAI  endAI  gyrA96  thi-1  hsdR 
XL1  Blue  17  supE44relAI  lac[F  proAB  Stratagene 
lacZD  M15  Tn  10  (TcR) 
E.  coli  thi  thrleu  tonA  lacY  supE  Infection  and  Immunity, 
SM10Xpir  recA::  RP4-2-TcR::  Mu,  KmR  University  of  Glasgow 
Bordetella  Wild  type,  standard  strain  for  mouse  Infection  and  Immunity, 
pertussis  18323  protection  test  University  of  Glasgow 
E.  coli  F{  laclq,  Tn10(Tc)  }  mcrA  (mrr- 
TOPIOF  hsdRMS-mcrBC)  801acZM15  lacX74  Invitrogen 
deoR  recAlaraD139  (ara-leu) 
7639  gal  U  galK  rspL(SmR)  endA  1  nupG 
P.  multocida  Isolated  from  a  case  of 
85020  Wild  type  (B:  2)  HS,  Sri  Lanka 
P.  multocida 
Quetta  Vaccine  strain  (B:  2)  Pakistan 
P.  multocida 
JRMT1  P.  in.  85020  aroA::  KmR  This  work 
P.  multocida  P.  m.  Quetta  aroA::  Km  Sm 
JRMT2  (JRMT11  derivative  see  below)  This  work 
P.  multocida 
JRMT3  P.  m.  Quetta  cya::  KmR  This  work 
P.  multocida 
JRMT4  P.  m.  85020  cya::  ApR  This  work 
P.  multocida 
JRMT5  P.  m.  Quetta  cya::  ApR  This  work Table  4:  (continued) 
P.  multocida  P.  m.  85020  cya::  ApR  laroA::  KMR 
JRMT6  (derivative  of  JRMT1)  This  work 
P.  multocida  P.  m.  Quetta  cya::  ApR  /aroA::  Km  SmR 
JRMT1  (derivative  of  JRMT2)  This  work 
P.  multocida 
JRMT8  P.  m.  85020+  pJRMT29  (KmR-sacR  -sacB) 
This  work 
P.  multocida 
JRMT9  P.  m.  Quetta+  pJRMT29  (KmR-sacR-sacB)  This  work 
P.  multocida  Spontaneous  SmR  derivative  of 
JRMT10  P.  multocida  85020  strain  This  work 
P.  multocida  Spontaneous  Sm  derivative  of 
JRMT11  P.  multocida  Quetta  strain  This  work 
P.  multocida 
JRMT12  P.  m.  85020  AaroA  (142  bp)  This  work 
P.  multocida 
JRMT13  P.  m.  Quetta  AaroA  (142  bp)  This  work 
ApR=  Ampicillin  resisrance 
SmR=  Streptomycin  resistance 
KmR=  Kanamycin  resistance Table  5:  The  plasmids  used  in  this  study 
Plasmid  Characteristics  Source/Reference 
pTAg  ApR  KmR  cloning  vector  4.8  kb  R&D  Systems 
pCR-Script  CmR  Cloning  vehicle  3.4  kb  Stratagene 
pCRII-TOPO  ApR  KmR  PCR  cloning  vector  4.0  kb  Invitrogen 
pUC19  ApR  Plasmid  vector  2.7  kb  This  lab 
pACYC184  TcR  ApR  4.24  kb  This  lab 
pUC4K  ApR  KmR  Origin  of  the  KmR  cassette  3.91  kb  Pharmacia 
pAKA16  ApR  cloning  shuttle  vector  5.3  kb  Azad  et  al.  (1994) 
pAKA19  ApR  cloning  suicide  vector  5.0  kb  Azad  et  al.  (1994) 
pEG18.3  KmR-sacR-sacB  11.8  kb  Cotter* 
pJRMT1  ApR  KmR  aroA::  pTAg  (aroA  from  P.  m.  85020)  5.02  kb  This  work 
pJRMT2  ApR  KmR  aroA::  pTAg  (aroA  from  P.  m.  Quetta)  5.02  kb  This  work 
pJRMT3  ApR  aroA::  pAKA19  (aroA  from  pJRMTI)  6.23  kb  This  work 
pJRMT4  ApR  aroA::  pAKA19  (aroA  from  pJRMT2)  6.23  kb  This  work 
pJRMT5  ApR  KmR  Km::  pJRMT3  (KmR  from  pUC4K)  7.47  kb  This  work 
pJRMT6  ApR  KmR  Km::  pJRMT4  (KmR  from  pUC4K)  7.47  kb  This  work 
pJRMT7  CmR  cya::  pCR-Script  (cya  from  P.  m.  85020)  5.9  kb  This  work 
pJRMT8  CmR  cya::  pCR-Script  (cya  from  P.  m.  Quetta)  5.6  kb  This  work 
pJRMT9  CmR  KmR  Km::  pJRMT7  (KmR  from  pUC4K)  5.99  kb  This  work 
pJRMT1O  CmR  KmR  Km::  pJRMT8  (KmR  from  pUC4K)  5.69  kb  This  work 
pJRMT11  ApR  TcR  Ap::  pACYC184  (ApR  from  pAKA16)  4.8  kb  This  work 
pJRMT12  ApR  KmR  cya::  pAKA19  (cya  from  pJRMT9)  8.04  kb  This  work 
pJRMT13  ApR  KmR  galE  ::  pCR-II  Topo  (galE  from  P.  m.  85020)  5.02  kb  This  work 
pJRMT14  ApR  KmR  galE  ::  pCR-1I  Topo  (galE  from  P.  m.  Quetta)  5.02  kb  This  work 
pJRMT15  ApR  galE::  pUC19  (galE  from  pJRMT13)  3.72  kb  This  work 
pJRMT16  ApR  galE::  pUC19  (galE  from  pJRMT14)  3.72  kb  This  work 
pJRMT17  ApR  KmR  Km::  pJRMT15  (KmR  from  pUC4K)  4.96  kb  This  work 
pJRMT18  ApR  KmR  Km::  pJRMT16  (KmR  from  pUC4K)  4.96  kb  This  work Table  5:  (continued) 
pJRMT19  ApR  KmR  galE::  pAKA19  (galE  from  pJRMT15)  7.27  kb  This  work 
pJRMT20  ApR  KmR  galE::  pAKA19  (galE  from  pJRMT16)  7.27  kb  This  work 
pJRMT21  ApR  CmR  Ap::  pJRMT7  (ApR  from  pJRMTI  1)  6.52  kb  This  work 
pJRMT22  ApR  CmR  Ap::  pJTMT8  (ApR  from  pJRMT11)  6.22  kb  This  work 
PJRMT23  ApR  KmR  AaroA::  pTAg  (aroA  from  pJTMT1)  4.4  kb  This  work 
pJRMT24  ApR  KmR  AaroA::  pTAg  (aroA  from  pJTMT2)  4.4  kb  This  work 
pJRMT25  ApR  KmR  AaroA::  pTAg  (aroA  from  pJRMT1)  4.87  kb  This  work 
pJRMT26  ApR  KmR  AaroA::  pTAg  (aroA  from  pJRMT2)  4.87  kb  This  work 
pJRMT27  ApR  Aga/E::  pUC19  (galE  from  pJRMT15)  3.63  kb  This  work 
pJRMT28  ApR  EgalE::  pUC19  (galE  from  pJRMT16)  3.63  kb  This  work 
pJRMT29  ApR  KmR  sacB::  pAKA16  (sacB  from  pEG  18.3)  9.1  kb  This  work 
pJRMT30  ApR  KmR  sacB::  pAKA19  (sacB  from  pEG18.3)  8.8  kb  This  work 
pJRMT31  ApR  AaroA::  pAKA19  (AaroA  from  pJRMT25)  6.15  kb  This  work 
pJRMT32  ApR  AaroA::  pAKA19  (AaroA  from  pJRMT26)  6.15  kb  This  work 
pJRMT33  ApR  KmR  sacB::  pJRMT31  9.95  kb  This  work 
pJRMT34  ApR  KmR  sacB::  pJRMT2  9.95  kb  This  work 
pJRMT35  ApR  KmR  AgalE::  pCR-I1  Topo  (galE  from  pJRMT27)  6.15  kb  This  work 
pJRMT36  ApR  KmR  AgalE::  pCR-II  Topo  (galE  from  pJRMT28)  6.15  kb  This  work 
pJRMT37  ApR  AgalE::  pAKA19  (galE  from  pJRMT35)  5.9  kb  This  work 
pJRMT38  ApR  AgalE::  pAKA19  (galE  from  pJRMT36)  5.9  kb  This  work 
pJRMT39  ApR  KmR  sacB::  pJRMT37  9.7  kb  This  work 
pJRMT40  ApR  KmR  sacB::  pJRMT38  9.7  kb  This  work 
pJRMT41  ApR  AgalE::  pUC19  (galE  from  pJRMT15)  3.47  kb  This  work 
pJRMT42  ApR  AgalE::  pUC19  (galE  from  pJRMT16)  3.47  kb  This  work 
pJRMT43  CmR  Acya::  pCR-Script  (cya  from  P.  m.  85020)  4.74  kb  This  work 
pJRMT44  CmR  Acya::  pCR-Script  (cya  from  P.  m.  Quetta)  4.74  kb  This  work 
pJRMT45  CmR  Acya::  pCR-Script  (cya  from  P.  m.  85020)  5.67  kb  This  work 
pJRMT46  CmR  Acya::  pCR-Script  (cya  from  P.  m.  Quetta)  5.37  kb  This  work 
*Gift  from  Dr.  P.  Cotter,  Department  of  Microbiology,  Immunology  and  Moecular  Genetics,  UCLA 
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corresponding  broth  media  in  a  Universal  containers  or  dimpled  conical  flasks 
with  shaking  overnight  on  an  orbital  shaker  at  150-200  rpm  at  370C.  When 
required,  antibiotic-resistant  strains  were  grown  on  agar  or  in  liquid  media 
containing  the  appropriate  antibiotic  concentration. 
2.1.5.  Growth  of  P.  multocida 
P.  multocida  strains  from  the  frozen  glycerol  stocks  were  subcultured 
routinely  on  BA  or  BHI  agar  medium  with  the  supplementation  of  5%  (v/v) 
defibrinated  sheep  blood.  Liquid  cultures  of  the  strains  were  grown  in  the  BHI 
broth  medium  in  Universal  containers  or  dimpled  conical  flasks  with  shaking 
overnight  on  an  orbital  shaker  at  150-200  rpm  at  37  C.  When  required, 
antibiotic-resistant  strains  were  grown  on  agar  or  in  liquid  media  containing  the 
appropriate  antibiotic  concentration. 
2.1.6.  Isolation  of  spontaneous  streptomycin-resistant  strains 
P.  multocida  85020  and  Quetta  strains  were  grown  overnight  (1012  cells 
ml-1)  in  BHI  broth  with  shaking  at  370C.  A  100  µl  portion  of  each  culture  was 
spread  on  BHI  agar  supplemented  with  5%  (v/v)  sheep  blood  and  streptomycin 
(100  µg  ml-1).  The  seeded  plates  were  allowed  to  dry  and  then  incubated  at 
37"C  for  2-3  days.  Streptomycin  resistant  colonies  were  picked,  and  their 
phenotype  confirmed  by  subculture  on  agar  medium  containing  the  same 
concentration  of  streptomycin.  All  these  strains  were  stored  in  50%  (v/v) 
e 
glycerol  at  -80  C. 
2.2.  Antibiotics 
Antibiotics  used  in  this  study  are:  ampicillin  (Ap),  chloramphenicol  (Cm), 
tetracycline  (Tc),  kanamycin  (Km),  streptomycin  (Sm),  gentamycin  (Gm), 
polymyxin  (Pm)  and  carbenicillin  (Carb).  All  antibiotics  were  obtained  from 
Sigma. 42 
The  sterile  antibiotic  solution  was  added  to  broth  or  agar  media,  after  they 
0  had  been  autoclaved  and  then  cooled  to  =55  C.  The  concentrations  of  the 
antibiotics  used  in  selective  media  were  (µg  ml-1):  Ap  (50),  Cm  (30),  Tc  (15), 
Km  (50),  Sm  (100),  Gm  (350),  Pm  (350)  and  Carb  (60). 
2.3.  DNA  extraction 
2.3.1.  Genomic  DNA  Extraction 
Following  growth  of  the  bacteria  in  appropriate  broth  culture,  the  genomic 
DNA  was  extracted  according  to  the  method  of  Ausubel  et  al.  (1990).  Cells 
from  1.5  ml  of  an  overnight  liquid  culture  of  P.  multocida  in  5  ml  BHI  broth 
were  harvested  by  centrifugation  at  13,000  rpm  for  4  min  in  a  Heraeus 
Medifuge  and  the  bacterial  pellet  resuspended  in  567  µl  of  TE  buffer  (Appendix 
5.5),  by  repeated  pipetting.  30  pl  of  10%  SDS  (w/v)  and  3  pl  of  proteinase  K 
(20  mg  ml-I  in  distilled  water)  were  added  and  mixed  thoroughly  to  give  a  final 
concentration  of  100  µg  ml-1  proteinase  K  in  0.5%  SDS.  The  cell  mixture  was 
incubated  at  370C  for  1h  and  100  µl  of  5M  NaCl  and  80  µl  of  CTAB  [10% 
CTAB  (w/v)  in  0.7  M  NaCI]  were  added,  mixed  thoroughly  and  incubated  at 
65.  C  for  10  min  in  a  water  bath.  After  incubation,  750  pl  of  chloroform: 
isoamyl  alcohol  (24:  1)  (Sigma)  was  added  and  vortexed  for  30  sec.  The 
mixture  was  centrifuged  at  13,000  rpm  for  5  min  and  the  aqueous  phase  was 
transferred  into  a  clean  microfuge  tube  to  which  was  added  750  . tl  of  phenol: 
chloroform:  isoamyl  alcohol  (25:  24:  1)  (Sigma).  This  was  vortexed  and 
centrifuged  as  above  and  the  aqueous  phase  transferred  to  a  clean  tube.  The 
DNA  was  precipitated  by  addition  of  0.6  vol.  of  isopropanol  (Sigma).  The 
precipitated  DNA  was  pelleted  by  centrifugation  at  13,000  rpm  for  5  min  and 
washed  with  1  ml  of  70%  (v/v)  ethanol  and  re-centrifuged  for  5  min  at  13,000 
rpm.  The  supernatant  fluid  was  removed  and  the  pellet  dried  briefly  at  room 
a 
temperature  and  finally  dissolved  in  100  µl  of  TE  buffer  and  stored  at  -20  C. 43 
2.3.2.  Plasmid  DNA  Extraction 
Plasmid  DNA  was  isolated  according  to  the  QlAprep  miniprep  procedure 
(Qiagen),  based  on  alkaline  lysis  of  bacterial  cells  followed  by  selective 
adsorption  of  plasmid  DNA  onto  a  silica  gel  membrane  in  high-salt  buffer  and 
subsequent  elution  in  low-salt  buffer.  This  procedure  is  a  modification  of  the 
alkaline  lysis  method  of  Bimboim  and  Doly  (1979).  Bacteria  are  lysed  under 
alkaline  conditions,  and  the  lysate  is  subsequently  neutralised  and  adjusted  to 
high-salt  binding  conditions  in  one  step,  and  the  lysate  cleared  by 
centrifugation.  The  plasmid  DNA  is  adsorbed  on  to  the  silica-gel  membrane  of 
QlAprep  columns  and  RNA,  cellular  proteins,  and  metabolites  are  not  retained 
on  the  membrane  upon  washing  but  are  found  in  the  flow-through.  Washing 
buffer  and  high-quality  plasmid  DNA  is  then  eluted  from  the  QlAprep  column 
with  distilled  water  to  efficiently  remove  salts.  The  purified  plasmid  DNA  is 
0 
stored  at  -20  C. 
2.4.  Restriction  endonuclease  digestion  of  DNA 
Restriction  endonuclease  enzymes  were  purchased  from  different 
manufacturers  and  used  according  to  the  suppliers'  instructions.  The  suppliers' 
names,  reaction  buffers  and  recognition  sequences  of  restriction  enzymes  used 
in  this  study  are  given  in  Table  6. 
Restriction  enzyme  digestion  was  routinely  performed  in  a  20  tl  volume 
containing  approximately  2  µg  of  DNA,  8  to  20  units  of  enzyme  (2  µl)  and 
reaction  buffer  diluted  to  1  fold.  Sterile  distilled  water,  reaction  buffer  (10x), 
DNA  solution  and  restriction  enzyme  were  sequentially  added  to  a  sterile 
microfuge  tube  placed  on  ice  and  mixed  gently  by  tapping  the  tube.  The 
reaction  mixtures  were  incubated  overnight  at  the  appropriate  temperatures 
(generally  370C,  unless  otherwise  specified)  and  analysed  by  gel 
electrophoresis  in  0.7  to  2%  (w/v)  agarose. Table  6:  The  restriction  endonucleases  used  in  this  study 
Restriction 
enzyme 
Recognition 
sequence 
Reaction 
buffer 
Supplier 
name 
Accl  5' 
... 
GT  LATAC...  3'  NEBuffer  4  Biolab 
Aflll  5'.. 
. 
GTJ  CGAC...  3'  NEBuffer  2+  BSA  Biolab 
5'.. 
. 
C..  TTAAG...  3' 
ApaLI  5'.. 
. 
GITGCAC...  3'  0.5xU.  Buffer  Stratagene 
Aval  5'..  . 
C.  1.  pyCGpuG...  3'  1xU.  Buffer  Stratagene 
Avail  5'.. 
. 
GIGTCC...  3'  1xU.  Buffer  Stratagene 
BamHI  5'.. 
.G 
[-GATCC...  3'  1xU.  Buffer  Stratagene 
BglII  5'. 
.  .A 
LGATCT...  3'  Optimal  buffer  4  Stratagene 
BgII  5'.  GCCNNNNINGGC.  3'  NEBuffer  3  Biolab 
BsmI  5'.. 
. 
GAATGCN  1...  3'  NEBuffer  2  Biolab 
Ear!  5'..  .  CTCTTC(N)  11...  3'  NEBuffer  1  Biolab 
EcoRI  5'...  G.  AATTC...  3'  NEBuffer  EcoRI  Biolab 
EcoRV  5'. 
.. 
GAT  LATC...  3'  React  2  buffer  Gibco  BRL 
HindIII  5'...  AJ.  AGCTT  ...  3'  Buffer  #3  Stratagene 
Hpal  5'...  GTTJ  AAC...  3'  NEBuffer  4  Biolab 
Nsil  5'...  ATGCA  LT...  3'  NEBuffer  NsiI  Biolab 
PstI  5'...  CTGCA.  JG...  3'  NEBuffer  3  Biolab 
PvuII  5'...  CAGICTG...  3'  NEBuffer  2  Biolab 
Sad  5'.. 
. 
GAGCTJ  C...  3'  Optimal  buffer  4  Stratagene 
Sacll  5'...  CCGC-"GG...  3'  Optimal  buffer  4  Stratagene 
Scal  5'...  AGT  LACT...  3'  NEBuffer  ScaI  Biolab 
SmaI  5...  000.  LGGG...  3'  NEBuffer  4  Biolab 
XhoI  5'...  CITCGAG...  3'  React  2  Gibco  BRL 44 
2.5.  Agarose  gel  electrophoresis 
2.5.1.  Sample  preparation 
The  sample  DNA  (5-30  µl)  was  mixed  with  6x  DNA  loading  buffer 
(Appendix  5.9)  in  a  ratio  of  5:  1  prior  to  loading  into  the  wells.  About  4  Al  of 
gel-loading  buffer  was  mixed  with  each  restriction  digest  and  the  mixture  was 
centrifuged  briefly  to  remove  bubbles  before  loading  onto  the  gel.  Different 
types  of  DNA  size  markers  were  used,  depending  on  the  topological  forms  and 
the  fragment  sizes  of  DNA.  For  calculating  the  sizes  of  uncut  plasmids,  a 
supercoiled  DNA  marker  (11  fragments)  (Gibco  BRL,  Paisley,  UK)  was  used. 
For  sizing  the  digested  or  linearised  DNA  fragments,  1  Kb  DNA  marker  (23 
fragments)  (Gibco  BRL)  was  used. 
2.5.2.  Gel  preparation 
Agarose  (type  II-A  medium  EEO,  Sigma)  was  suspended  in  0.5x  Tris- 
borate-EDTA  (TBE)  buffer  (Appendix  5.6)  at  a  suitable  concentration  and 
heated  until  the  agarose  was  completely  dissolved.  The  solution  was  allowed 
to  cool  (hand-hot)  and  ethidium  bromide  (Bio-Rad,  UK)  was  added  to  a  final 
concentration  of  0.5  µg/  ml.  A  gel  tray  was  prepared  by  taping  the  edges  with 
adhesive  tape  and  the  gel  cast  to  the  desired  thickness.  Upon  setting,  the  gel 
was  immersed  in  0.5x  TBE  buffer  in  a  horizontal  submarine  electrophoresis 
tank  (E-C Apparatus  Corporation,  USA). 
2.5.3.  Electrophoresis 
A  powerpack  (model  SL3655,  Scotlab,  UK)  was  used  to  provide  a  constant 
voltage  corresponding  to  1-5  volts/  cm2.  Electrophoresis  was  carried  out  until 
the  marker  dyes  migrated  an  appropriate  distance. 
2.5.4.  Visualisation  of  DNA 
An  UV  transilluminator  (model  TM-40,  UVP  Inc.,  California,  USA)  was 
used  to  visualise  the  ethidium  bromide-stained  DNA.  Images  were  stored 45 
electronically  as  appropriate  using  the  Ultra  Violet  Products  Gel  Documentation 
System-Image  Store  5000,  version  7.2  (Ultra  Violet  Products,  Cambridge, 
UK).  Images  were  printed  using  a  video  graphic  printer  (model  UP-860, 
Sony).  Where  appropriate,  photographs  were  captured  with  Fotolook  (version 
2.07.2  Agfa,  UK)  using  a  flatbed  scanner  (model  Studioscan  Ilsi,  Agfa). 
Electronic  images  were  edited  using  Adobe  Photoshop  3.0  and  images  labelled 
with  Microsoft  Powerpoint  4.0. 
2.5.5.  Elution  and  purification  of  DNA  from  agarose  gel 
Before  proceeding  to  the  cloning  protocol,  DNA  fragments  were  eluted  and 
purified  from  agarose  gel  by  the  GenEluteTM  Agarose  spin  column 
(SUPELCO)  or  QIAEXII  Gel  Extraction  kit  (QIAGEN). 
The  DNA  band  of  interest  was  excised  from  an  ethidium  bromide-stained 
agarose  gel  with  a  sharp  scalpel  under  long  wave  UV  light.  For  the  GenElute 
agarose  column  procedure,  100  µl  of  TE  buffer  (Appendix  5.5)  were  added  to 
the  column  which  was  positioned  in  the  top  of  a  microfuge  tube,  centrifuged 
for  5  sec  at  maximum  speed  (13,000  rpm)  in  a  Heraeus  microcentrifuge.  The 
agarose  gel  slice  containing  DNA  was  then  placed  in  the  washed  spin  column, 
which  was  put  on  top  of  a  clean  tube  and  centrifuged  for  10  min  at  maximum 
speed  (13,000  rpm)  in  the  microcentrifuge.  The  DNA  was  collected  in  a 
volume  of  approximately  30-50  tl  TE  buffer. 
For  QIAEXII  Gel  Extraction  kit,  the  gel  slice  was  put  in  a  pre-weighed 
microfuge  tube.  About  3  volumes  of  buffer  QX1  and  Qiaex  resin  (10-15  µl) 
were  added  and  incubated  at  550C  in  a  water  bath  for  10  min  with  shaking 
every  2  min  until  the  agarose  was  dissolved.  Following  centrifugation  for  1 
min  at  13,000  rpm  the  supernate  was  removed.  The  pellet  was  then  washed 
once  with  500  µl  of  Buffer  QXI  and  twice  with  500  tl  of  buffer  PE,  with 
centrifugation  as  before.  The  resin/  DNA  pellet  was  air-dried,  10-25  µl  of 
0  sterile  distilled  water  was  added  and,  after  incubation  for  5  min  at  50  C,  the 46 
resin  was  removed  by  centrifugation  as  before  and  the  eluted  DNA  in  a  volume 
of  approximately  20  µl  distilled  water  and  retained  for  immediate  use  or  stored 
0 
at  -20  C. 
2.6.  Estimation  of  DNA  concentration 
The  concentration  of  DNA  was  estimated  by  measuring  the  absorbance  at 
260nm  in  a1  cm  quartz  cuvette  in  a  spectrophotometer  (Shimadzu  recording 
spectrophotometer  UV-240)  and  by  applying  the  equation: 
Concentration  of  DNA  (ng/  µl)=  AB  260nmx  50  x  dilution  factor 
Alternatively,  the  approximate  concentration  of  DNA  fragments  was 
determined  visually  on  agarose  gel,  by  comparison  of  their  staining  intensities 
with  those  of  known  quantities  of  marker  DNA  of  a  similar  size. 
2.7.  Concentration  of  DNA 
To  precipitate  and  concentrate  the  DNA,  3  volumes  of  ethanol  95%  (v/v) 
and  0.1  volume  of  3M  sodium  acetate  (pH  5.3)  was  added  to  the  sample, 
mixed  and  the  resultant  mixture  stored  at  either  -20*C  overnight  or at  -800C  for 
30  min  depending  on  the  time  available.  The  sample  was  then  centrifuged  at 
15,000  rpm  (Biofuge,  Rotor:  HFA  14.2)  for  15  min  and  the  supernate 
discarded.  The  DNA  pellet  was  washed  with  cold  ethanol  70%  (v/v)  and  dried 
at  room  temperature  for  10-15  min.  The  DNA  was  resuspended  in  an 
appropriate  volume  of  sterile  distilled  water  and  if  necessary  heated  to  65ýC  for 
30  min  to  aid  dissolving. 
2.8.  Polymerase  chain  reaction  (PCR) 
2.8.1.  PCR  primers 
During  primer  design,  care  was  taken  to  avoid  potential  internal  secondary 
structure  and  where  possible  a  GC  clamp  was  engineered  at  the  3'  end  of  the 
primer.  Additionally,  for  PCR,  primers  were  checked  for  overlap,  potential  for 47 
secondary  structure  and  for  compatible  Tm  values.  Tm  values  were  calculated 
according  to  the  equation: 
Tm("C)  =4  (G+C)  +2  (A+T)-SSC 
Primers  (50  nmol,  desalted  and  deprotected)  were  obtained  from  Gibco 
BRL  (Paisley,  UK)  and  resuspended  in  sterile  distilled  water  to  give  final 
concentrations  of  50  pmol/  µ1  for  PCR.  Table  7  shows  the  primers  used  in  this 
study. 
2.8.2.  Components  of  PCR 
Except  where  otherwise  stated,  the  reaction  mixture  (25  µl)  contained  (final 
concentration)  10  mM  Tris-HCI  (pH  8.4),  50  mM  KCI,  3.0  MM  M902,0.2 
mM  of  each  deoxynucleoside  triphosphate  (dNTPs)  (Life  Technologies 
Paisley,  Ltd.  UK),  100  pmol  each  primer,  1.0  U  of  Taq  DNA  polymerase  (Life 
Technologies  Ltd,  Paisley,  UK)  and  2.5  µl  of  template  DNA  preparation.  The 
PCR  assays  were  performed  in  0.5  ml  microfuge  tubes  (Sarsted  Ltd., 
Leicester,  UK). 
2.8.3.  Conditions  for  PCR 
Amplification  was  done  in  a  Hybaid  thermal  cycler  (model:  Touchdown, 
0 
Hybaid  Ltd,  Middlesex,  UK)  using  35  cycles  of  denaturation  at  94  C  for  1 
min,  annealing  at  55*C  for  30  sec,  extension  at  72"C  for  6  min  with  a  final 
extension  at  72ýC  for  6  min.  The  products  of  the  PCR  were  stored  at  -20ýC  or 
used  immediately. 
2.8.4.  Analysis  of  amplicons 
The  amplified  products  (8-10  µl)  were  mixed  with  2  µl  of  6-fold  loading 
buffer  (Appendix  5.9)  and  electrophoresed  in  a  1%  (w/v)  agarose  gel.  The 
1  Kb  DNA  ladder  was  used  as  DNA  molecular  weight  markers. b 
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2.9.  CLONING 
2.9.1.  PCR  product  cloning 
2.9.1.1.  Cloning  into  pCR-ScriptTM 
Cloning  was  performed  using  the  pCR-ScriptTM  cloning  kit  (Stratagene, 
Cambridge,  UK)  according  to  manufacturer's  instructions.  This  procedure 
involves  blunt  cloning  of  the  "polished"  PCR  product  into  a  pre-digested  SrfI 
vector  site.  The  ligation  occurs  in  the  presence  of  Srfl,  which  reduces  the 
frequency  of  vector  self-ligations.  PCR  products  were  electrophoresed  in 
agarose  gel,  purified  by  gel  extraction  kit  (Qiaexll)  and  then  "polished"  to 
generate  blunt  ends  (section  2.9.4).  The  polished  PCR  product  was  then 
added  to  the  ligation  reaction  containing  the  following: 
pCR-ScriptTM  Cm  SK(+)  cloning  vector  (10  ng/  µl)  1.0  µl 
pCR-Script  10  reaction  buffer  1.0  Al 
ATP(10mM)  0.5  µl 
Polished  PCR  product  2-4  µl 
Sr.  f  1(5  U/  µ1)  1.0  Al 
T4  DNA  ligase  (4  U/  µl)  1.0  Al 
The  ligation  mixture  was  mixed  gently  and  incubated  at  room  temperature 
for  1  h,  then  incubated  at  65"C  for  10  min,  transformed  into  E.  coli  (section  2. 
10.2)  and  a  blue-white  screen  was  performed  (section  2.10.3). 
2.9.1.2.  Cloning  into  pCR®2.1-TOPO  cloning  vector 
PCR  products  were  routinely  cloned  using  the  pCR®2.1-TOPO  vector 
included  in  the  TOPO-TA  cloning  kit  (Invitrogen,  The  Netherlands). 
Amplicons  of  interest  were  excised  following  agarose  gel  analysis  and  DNA 
extracted  using  the  Qiaexll  kit.  The  DNA  was  resuspended  to  a  concentration 
of  approximately  50  ng/  µl.  Ligation  of  the  PCR  product  into  pCR®2.1-TOPO 
was  performed  according  to  manufacturer's  instructions.  Briefly,  4  t1  of 49 
cleaned  PCR  product  was  mixed  gently  with  1  µl  of  TOPO  mix  (containing 
topoisomerase,  prepared  pCR®2.1-TOPO  and  ligation  buffer).  After 
incubation  for  5  min  at  room  temperature,  the  mixture  was  put  onto  ice. 
Immediately,  one  vial  of  TOP1OF  One  Shot  competent  cells  were  thawed 
gently  on  ice  and  2  µl  mercaptoethanol  (0.5  M)  was  added.  To  the  cells,  2  µ1  of 
the  ligation  mix  was  added  with  gentle  mixing.  After  incubation  on  ice  for  30 
min,  the  cells  were  then  heat-shocked  at  42"C  for  30  sec  in  a  water  bath  and 
returned  to  ice  for  2  min.  SOC  medium  (Appendix  5.7)  250  µl  was  added  to 
the  vial  and  the  cells  shaken  at  370C  for  2  hrs  before  100  µl  aliquots  were 
spread  on  selective  agar  medium. 
2.9.2.  Standard  cloning  protocol 
2.9.2.1.  DNA  preparation 
Vector  and  insert  DNA  were  subjected  to  restriction  enzyme  digestion  to 
obtain  complementary  cohesive  overhangs  and  the  resultant  fragments  were 
gel-purified.  DNA  concentrations  were  estimated  according  to  section  2.6  and 
ratios  determined  as  follows: 
100  ng  vector  x?  kb  insert=?  ng  insert  DNA  to  every  100  ng  vector  for  a  1:  1  ratio 
?  kb  vector 
Insert:  Vector  ratios  of  1:  1  and  3:  1  were  commonly  used. 
2.9.2.2.  Ligation  strategies 
Ligation  reactions  were  performed  in  a  total  volume  of  10  µl  using  3  units  of 
DNA  ligase  (Promega,  USA)  and  Promega  ligase  buffer.  After  incubation  at 
16"C  for  18  h  the  reactions  were  transferred  to  4"C  for  2  hrs.  The  ligase  was 
inactivated  by  heating  to  70*C  for  10  min  and  the  products  stored  at  -20 
*C  until 
use. 50 
2.9.2.3.  Ligation  Express  Kit 
The  ligation  was  performed  according  to  the  manufacturer's  instructions 
(Clontech).  Compatible  vector  and  insert  termini  were  prepared  and  ratios 
calculated  as  described  previously  (section  2.9.2.1).  Approximately  300  ng 
of  total  DNA  was  used  per  reaction  (maximum  volume  of  DNA  solution  was  7 
t1).  To  the  DNA  was  added  1.5  µl  of  plasmid  ligation  buffer,  1.2  Al  of  ATP 
(10  mM)  and  1.0  µl  of  T4  DNA  ligase  (100  U).  After  thorough  mixing  the 
reaction  was  incubated  for  30  min  at  16  C.  To  this,  1  µl  of  glycogen  (20  µg), 
85  µl  of  distilled  water  and  250  µl  of  ethanol  100%  was  added.  The  DNA  was 
precipitated  using  a  dry  ice/  ethanol  bath  for  30-60  min  and  the  DNA  recovered 
by  centrifuging  at  15,000  rpm  in  a  Biofuge  (Rotor  HFA  14.2).  After  careful 
removal  of  the  supernate,  the  pellet  was  briefly  air-dried  and  a  wash  in  ethanol 
70%  (v/v)  was  performed  to  remove  salts.  The  DNA  was  resuspended  in  5  µl 
0  of  distilled  water  and  stored  at  -20  C. 
2.9.3.  Dephosphorylation  of  linearized  DNA 
In  order  to  prevent  linearized  vectors  from  self-ligation  or  recircularization 
during  cloning,  the  5'-phosphate  groups  of  double-stranded  DNA  fragments 
were  removed  by  treatment  with  calf  intestinal  phosphatase  (CIP)  (Promega), 
according  to  the  protocol  of  Sambrook  et  al.  (1989). 
Plasmid  DNA  (2-4  µg)  was  digested  to  completion  with  the  appropriate 
restriction  enzyme  in  a  40  µl  volume.  Then  2.5  µl  (1  U/  µl)  of  CIP  and  4.5  µl 
CIP  buffer  were  added  to  the  digestion  mix  and  incubated  at  37*C  for  30-60 
min.  The  CIP  was  heat  inactivated  at  750C  for  15  min  and  the 
dephosphorylated  DNA  fragments  were  purified  by  agarose  gel  electrophoresis 
in  TBE  buffer  (Appendia  5.6),  followed  by  GenElute  agarose  Spin  Column 
preparation  (Suppelco,  UK)  (section  2.5.5). 51 
2.9.4.  "Filling  in"  or  "Trimming"  reaction  for  blunt  end  ligation 
For  ease  of  cloning,  incompatible  DNA  ends  were  converted  into  blunt 
ends.  This  was  carried  out  by  "filling  in"  of  3'  recessed  ends  (e.  g.  produced  by 
BamHI)  or  "trimming"  of  3'  protruding  ends  of  DNA  (e.  g.  produced  by  Pstl). 
Plasmid  DNA  was  digested  to  completion  with  the  appropriate  restriction 
enzyme  in  a  40  µl  volume  and  fragments  were  separated  by  agarose  gel 
electrophoresis.  DNA  fragments  of  interest  were  purified  by  the  GenElute 
agarose  spin  column  (Suppelco,  UK)  (section  2.5.5)  and  taken  up  in  30-50  µl 
distilled  water  in  a  fresh  microfuge  tube  to  which  REact  4  was  added  as  a 
substitute  for  DNA  polymerase  buffer.  dNTPs  mix  (a  mixture  of  25  mM 
dATP,  dCTP,  dGTP  and  dTTP;  obtained  from  Life  Technologies  Ltd.  UK) 
was  added  to  the  tube  at  a  final  concentration  of  1mM  (filling  reaction)  or  2  mM 
(trimming  reaction).  To  this  was  added  1-2  µl  of  Klenow  fragment  of  E.  coli 
DNA  polymerase  I  (Biolab  UK)  for  the  "filling  in"  reaction  or  bacteriophage  T4 
DNA  polymerase  (Biolab  UK)  for  the  "trimming"  reaction.  The  reactions  were 
incubated  for  15  min  at  room  temperature  (filling  in)  or  for  the  same  period  at 
12*C  (trimming).  DNA  polymerase  enzymes  were  inactivated  by  heating  the 
reaction  mixture  to  75.  C  for  10  min  before  proceeding  with  the  ligation  or 
cloning  protocols. 
2.10.  DNA  transformation 
In  order  to  study  the  molecular  basis  of  pathogenesis,  an  efficient  means  of 
transforming  bacteria  is  necesseary.  The  efficient  introduction  of  DNA  into  the 
bacteria  is  a  phenomenon  of  great  practical  importance  in  molecular  biology. 
Methods  of  chemical  treatment  yielding  high  efficiency  transformation  with 
some  strains  of  E.  coli  have  been  described;  but  the  preparation  of  such  highly 
competent  cells  is  affected  by  many  factors  and  the  level  of  competence 
obtained  can  vary  considerably  from  batch  to  batch  (Hanahan,  1983). 52 
Rendering  prokaryotic  and  eukaryotic  cells  permeable  to  nucleic  acid  by 
exposure  to  electrical  fields  is  now  a  commonly  used  technique  and  is  referred 
to  as  electroporation  (Dower  et  al.,  1988).  A  possible  mechanism  suggested  to 
explain  this  technique  is  the  opening  of  a  new  compartment  to  the  interior  of  the 
cell  to  passive  diffusion  of  DNA  and  the  bulk  of  flow  of  medium,  containing 
the  DNA,  into  the  cells.  Both  E.  coli  and  P.  multocida  strains  have  been 
transformed  to  reasonable  efficiencies  with  this  technique  (Dower  et  al.,  1988; 
Jablonski  et  al.,  1992a) 
2.10.1.  Preparation  of  electroporation-competent  cells 
An  overnight  culture  of  E.  coli  or  P.  multocida  was  diluted  1  in  100  in  pre- 
warmed  500  ml  of  LB  or  BHI  broth  respectively  in  a2  litre  dimpled  flask.  The 
flask  was  shaken  vigorously  at  37ýC  until  an  OD540nm  of  0.5-0.7  was 
obtained.  The  flask  was  then  chilled  on  ice  for  20  min  and  cells  harvested  at 
0  10,000  rpm  for  15  min  in  a  Sorvall  Superspeed  (rotor  GS-3)  at  4  C.  The 
resultant  bacterial  pellet  was  resuspended  in  500  ml  of  cold  sterile  distilled 
water  and  centrifuged  as  described  previously.  The  cell  pellet  was  then 
resuspended  in  250  ml  of  cold  sterile  distilled  water,  centrifuged  as  before  and 
resuspended  in  100  ml  of  cold  sterile  10%  (v/v)  glycerol,  centrifuged  as  before 
and  the  cell  pellet  was  resuspended  in  10  ml  of  cold  sterile  10%  (v/v)  glycerol. 
Following  a  final  centrifugation,  the  cells  were  resuspended  in  1.5  ml  of  cold 
sterile  10%  (v/v)  glycerol  and  100  µl  aliquots  were  snap  frozen  in  liquid 
nitrogen.  Cells  remained  cold  (on  ice)  at  all  times  during  the  procedure  and 
0 
were  stored  at  -80  C. 
2.10.2.  Electroporation  procedure 
The  E.  coli  and  P.  multocida  strains  were  transformed  by  electroporation 
procedures  described  by  Dower  et  al.  (1988)  and  Jablonski  et  al.  (1992a).  Prior 
to  electroporation,  a2  mm  electroporation  cuvette  (Flowgen,  UK)  and  the 
safety  chamber  were  chilled  at  -20"C.  To  the  cold  cuvette,  1-5  µl  of  DNA 53 
(ligation  mixture  or  plasmid  preparation)  and  40  tl  of  competent  cells  (cells 
from  -800C  were  thawed  on  ice)  were  added.  The  mixture  was  shaken  to  the 
bottom  of  the  cuvette  and  a  Bio-Rad  Gene  Pulser  (model  1652078,  Bio-Rad 
laboratories,  UK)  set  at  2.0  KV  (field  strength  10  KV/  cm2)  for  E.  coli  and  2.5 
KV  (field  strength  12.5  KV/  cm2)  for  P.  multocida  strains  and  25  pFD  was 
connected  to  a  Bio-Rad  pulse  controller  (model  1652098)  set  to  200  S2 
resistance  for  E.  coli  and  400  SZ  resistance  for  P.  multocida  strains.  The  cells 
were  pulsed  once  to  give  a  time  constant  of  4-5  msec  for  E.  coli  and  9-10  msec 
for  P.  multocida  strains.  Immediately  following  electroporation,  one  nil  of  pre- 
warmed  SOC  medium  for  E.  coli  or  BHI  broth  for  P.  multocida  strains  was 
added  and  the  cells  incubated  at  370C,  E.  coli  cells  for  one  h  and  P.  multocida 
cells  for  3-4  hrs,  without  shaking,  to  allow  expression  of  plasmid-encoded 
antibiotic  resistance.  Aliquots  of  100  tI  transformed  cells  were  then  spread 
onto  selective  plates  containing  appropriate  antibiotic(s)  and  the  plates  were 
incubated  at  37C  to  obtain  transformant  colonies.  0 
2.10.3.  Blue-white  screening  of  recombinants 
Following  incubation  of  the  transformed  cells  in  SOC  medium,  100  µl 
aliquots  were  spread  onto  pre-warmed  LB  agar  plates  containing  appropriate 
antibiotics,  2  mg/ml  of  isopropyl-D-thiogalactopyranoside  (IPTG)  (Sigma)  and 
40  mg/ml  of  5-bromo-4-chloro-3-indolyl-D-galactoside  (X-GAL)  (Sigma).  The 
remainder  of  the  SOC  suspension  was  centrifuged  and  the  cell  pellet 
resuspended  in  150  tl  of  SOC  and  spread  onto  other  plates  to  increase  the  cell 
concentration.  The  plates  were  then  incubated  at  370C  overnight.  Resultant 
white  colonies  (potentially  containing  insert)  were  cultured  and  plasmid  DNA 
prepared  according  to  section  2.3.2.  The  plasmids  were  analysed  by 
restriction  enzyme  digestion  (section  2.4)  for  the  presence  of  an  insert. 54 
2.11.  Conjugation  (plate  mating) 
This  was  carried  out  by  the  method  of  Bradley  et  al.  (1980).  Each  strain  was 
grown  overnight  at  370C  on  a  shaker  in  5  ml  BHI  for  P.  multocida  recipient 
strain  or  LB  broth  for  E.  coli  donor  strain  containing  the  appropriate  antibiotic. 
An  aliquot  (0.5  ml)  of  overnight  culture  was  inoculated  into  10  ml  pre-warmed 
BHI  or  LB  broth  and  incubation  continued  at  37eC  with  shaking,  E.  coli  for  2 
hrs  and  P.  multocida  for  4  hrs,  until  the  culture  reached  an  optical  density 
OD540nm  of  =0.5-0.6  (=5  x  107  cells  ml-1).  The  cells  were  harvested  by 
centrifugation  at  5000  rpm  for  5  min  and  washed  with  the  same  media  and 
resuspended  in  200  Itl  of  media.  Equal  volumes  (50-100  µl)  of  the  cultures  of 
donor  and  recipient  strains  were  mixed  gently  in  a  microfuge  tube  by  repeating 
pipetting  and  put  on  top  of  a  sterile  filter  paper  (cellulose  nitrate  membrane 
filters,  Whatman)  on  BA  plates  which  were  allowed  to  dry  at  room 
temperature,  then  incubated  at  370C  face  up  overnight.  Growth  from  the  mating 
on  top  of  the  filter  paper  was  resuspended  in  5  ml  of  BHI  broth,  and  100  µl 
aliquots  of  neat  sample  and  lOx  dilutions  were  spread  onto  BHI  agar 
transconjugant-  selection  plates  containing  the  required  selective  antibiotics  and 
0  were  incubated  at  37  C  for  48  hrs. 
2.12.  Southern  blot  hybridisation 
In  this  study,  PCR  amplimers  of  the  P.  multocida  aroA  gene,  cya  gene  and 
galE  gene,  plasmid  pAKA  19,  a  KmR  cassette  and  an  ApR  cassette  were  used 
as  probes  for  hybridisation  to  digested  genomic  DNA  of  P.  multocida  strains  or 
PCR  products.  The  transfer  and  hybridisation  of  DNA  fragments  were 
essentially  carried  out  according  to  Southern  (1975),  as  described  by  Sambrook 
et  al.  (1989)  or  by  Ausubel  et  al.  (1990). 
2.12.1.  Assembly  of  the  blot 
DNA  fragments  generated  by  restriction  enzyme  digestion  were  separated  by 
gel  electrophoresis,  stained  with  0.5  µg  ml-1  ethidium  bromide,  and 55 
photographed  under  UV  light.  One  corner  of  the  gel  was  cut  off  for  orientation 
and  the  DNA  denatured  in  the  gel  by  soaking  the  gel  twice  for  15  min  in 
denaturation  solution  (Appendix  5.12)  with  constant,  gentle  agitation.  After 
that  the  gel  was  rinsed  twice  in  distilled  water  and  placed  twice  for  15  min  in 
neutralisation  solution  (Appendix  5.13)  with  gentle  agitation. 
A  DNA  transfer  pyramid  was  assembled  (Fig.  9)  by  filling  a  reservoir  with 
transfer  solution  (20x  SSC)  (Appendix  5.11)  and  the  gel  support  was  put  in 
place.  A  wick,  made  from  Whatman  3  MM  paper,  was  prepared  so  that  each 
end  dipped  into  the  transfer  solution  and  the  middle  lay  flat  on  the  support.  Air 
bubbles  between  the  wick  and  support  were  removed  by  rolling  a  pipette  over 
the  surface  of  the  paper.  The  gel  was  removed  from  the  neutralisation  solution 
and  placed  over  the  Whatman  3  MM  wick,  with  sample  wells  face  down  and 
any  air  bubbles  between  the  wick  and  the  gel  were  smoothed  away  as  before.  A 
sheet  of  nylon  membrane  (Hybond  N+,  Amersham  Pharmacia  Biotech,  UK) 
was  cut  to  the  exact  size  of  the  gel,  placed  on  top  of  gel,  again  avoiding  trapped 
air  bubbles  beneath  the  membrane,  and  with  scissors  the  corner  of  the 
membrane  that  corresponded  to  the  cut  corner  of  the  gel  was  snipped  off,  the 
edges  of  the  membrane  surrounded  with  Nesco  film  membrane,  to  stop  "short 
circuits"  (in  which  transfer  solution  flows  directly  from  the  reservoir  to  the  dry 
paper  towels  above  the  membrane,  rather  than  passing  through  the  gel)  and 
then,  three  pieces  of  pre-wetted  3  MM  filter  paper,  cut  to  exactly  the  same  size 
as  the  nylon  membrane,  were  placed  on  top  of  the  membrane  and  air  bubbles 
were  smoothed  out.  Finally,  a  pile  of  paper  towels  (5-8  cm  high)  was  placed 
on  top.  A  glass  plate  was  put  on  top  of  the  pile  and  the  layers  weighed  down 
with  a  weight  (0.7-1  kg  e.  g.  a  bottle).  For  convenience,  the  assembled  blot  was 
usually  left  undisturbed  overnight.  After  blotting  overnight,  the  nylon 
membrane  was  wrapped  between  two  sheets  of  plastic  and  both  sides  of  the 
wet  membrane,  without  prior  washing,  exposed  to  a  source  of  UV  radiation 
and  the  DNA  crosslinked  to  the  membrane  using  a  UV  crosslinker Fig  9:  Uni-directional  capillary  Southern  blotting 
(From  Darling  and  Brickell,  1994) Fig  9: 
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(Spectrolinker  XL-1000,  Spectroline,  New  York,  USA).  A  proportion  of  the 
thymine  residues  in  the  DNA  will  cross-link  to  amine  groups  on  the  surface  of 
the  membrane  (Darling  and  Brickell,  1994)  and  fix  the  DNA  to  the  membrane. 
The  membrane  was  then  prehybridised  for  a  minimum  of  4  hrs  in  a  rolling 
hybridisation  oven  (model  HB-1D,  Techne,  Cambridge,  UK)  with  at  least  20 
ml  of  prehydridising  solution  (Appendix  5.11).  The  temperature  of  the  oven 
was  set  within  the  range  500C  and  680C  depending  on  the  desired  hybridisation 
stringency.  This  temperature  was  maintained  for  the  subsequent  hybridisation 
and  washing  steps  (see  below). 
2.12.2.  Preparation  of  digoxigenin-labelled  probes 
Template  DNA  was  excised  from  an  agarose  gel  with  a  sterile  scalpel. 
Extraction  was  done  by  the  method  that  explained  in  section  2.3  and  the 
concentration  of  DNA  estimated  as  described  in  Section  2.6.  The  random 
priming  method  was  utilised  as  described  in  The  DIG  System  User's  Guide  for 
Filter  Hybridisation  (Boehringer  Mannheim,  Germany).  The  nonradioactive 
DIG  system  uses  digoxigenin  (DIG),  a  steroid  hapten,  to  label  DNA,  RNA  or 
oligonucleotides  for  hybridisation  and  subsequent  colour  or  luminescence 
detection.  For  DNA  labelling,  digoxigenin  is  coupled  to  dUTP  via  an  alkaline- 
labile  ester-bond.  The  use  of  the  alkaline-labile  form  of  DIG-  11-dUTP  enables 
easier  and  more  efficient  stripping  of  blots  for  rehybridisation  experiments  with 
a  second  DIG-labelled  probe  (Fig.  10).  Briefly,  approximately  1  µg  of  template 
DNA  was  diluted  in  distilled  water  to  a  total  volume  of  15  µl.  The  DNA  was 
denatured  in  a  boiling  water  bath  for  10  min  followed  by  immediate  chilling  on 
ice.  Hexanucleotide  mixture  (10x)  (Boehringer  Mannheim,  Germany)  and 
dNTP  labelling  mixture  (10x),  2  tl  of  each,  were  added  to  the  tube  on  ice.  To 
the  reaction,  1  pl  of  labelling-grade  Klenow  DNA  polymerase  enzyme  was 
added  to  a  final  concentration  of  100  U/ml.  After  brief  centrifugation,  the 
reaction  was  incubated  overnight  at  370C,  then  terminated  by  adding  2.  tl  of 
EDTA  (200  mM,  pH  8).  The  contents  of  the  labelling  tube  were  then  stored  at Fig  10:  The  labelling  and  detection  alternatives  offered  by  the  DIG  system 
(Boehringer  Mannheim) Fig  10: 
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-20  C.  Denaturation  of  the  probe  was  performed  for  10  min  in  a  boiling  water 
bath  followed  by  immediate  chilling  on  ice.  The  denatured  probe  was  diluted 
into  10  ml  of  pre-hybridisation  solution. 
2.12.3.  Probe  hybridisation 
The  prehybridising  solution  was  discarded  and  the  denatured  probe 
immediately  added  to  the  roller  tube.  Hybridisation  was  performed  for  a 
minimum  of  8  hrs  at  68*C.  The  membrane  was  washed  at  the  hybridisation 
temperature  for  2x  15  min  in  100  ml  of  2x  washing  solution  (Appendix  5.11) 
followed  by  2x  15  min  washes  in  100  ml  0.5x  washing  solution  (Appendix  5. 
a  11)  at  68  C. 
2.12.4.  Chemiluminescent  detection 
Detection  was  performed  according  to  the  protocol  described  in  The  DIG 
System  User's  Guide  for  Filter  Hybridisation  (Boehringer  Mannheim, 
Germany).  The  washed  membrane  was  equilibrated  for  1-3  min  in  washing 
buffer  (Appendix  5.11).  Antibody  blocking  solution  was  then  incubated  with 
the  membrane  for  30-60  min.  The  antibody  (anti-DIG  conjugated  to  alkaline 
phosphatase)  was  diluted  to  1  in  10,000  in  the  blocking  solution  and  the 
membrane  was  incubated  for  30  min  in  at  least  20  ml  of  antibody  solution.  The 
membrane  was  washed  for  2x  15  min  in  washing  buffer  and  then  equilibrated 
in  detection  buffer  (Appendix  5.11)  for  3  min.  The  alkaline  phosphatase 
substrate  used  (CSPD)  was  diluted  to  1  in  100  in  detection  buffer  and  this  was 
dripped  onto  the  membrane  prior  to  sealing  within  a  plastic  sheet.  After  5  min, 
the  excess  substrate  was  removed  using  a  damp  paper  towel  on  the  top  plastic 
0  surface.  The  plastic  was  heat  sealed  and  then  incubated  at  37  C  for  15  min,  to 
allow  the  alkaline  phosphatase  chemiluminescent  reaction  to  occur  at  a  steady 
rate.  The  membrane  was  then  exposed  in  the  sealed  plastic  to  photosensitive 
film  (Kodak,  X-ray  film,  UK)  for  up  to  24  hrs,  although  15-30  min  was 
usually  sufficient.  After  exposure,  the  autoradiograph  was  immersed  in 58 
developing  solution  (LX24,  Kodak,  UK)  with  agitation  for  2-3  min.  The  film 
was  then  rinsed  in  water  and  fixed,  with  agitation,  in  Unifix  solution  (Kodak, 
UK)  for  15  min.  Finally  the  film  was  washed  with  tap  water  for  3-5  min  and 
air  dried. 
For  re-probing  the  blot,  the  membrane  was  thoroughly  rinsed  in  distilled 
water,  incubated  twice  for  20  min  in  0.2  M  NaOH,  0.1%  (w/v)  SDS  at  37oC 
with  gently  agitation,  rinsed  in  2x  SSC  and  then  re-hybridized  overnight  with 
another  DNA  probe. 
2.13.  Virulence  and  protection  tests 
2.13.1.  Inoculum  preparation 
A  stock  culture  of  P.  multocida  maintained  at  -80ýC  in  50%  glycerol  was 
plated  onto  BA  plates  and  incubated  overnight  at  379C,  then  a  single  colony 
was  inoculated  into  5  ml  BHI  broth  and  incubated  overnight  at  37"C  with 
shaking.  One  ml  of  the  culture  was  inoculated  into  20  ml  of  pre-warmed  BHI 
broth  and  the  OD  at  540nm  measured  at  intervals  of  2  hrs  for  12  hrs  to  obtain 
the  growth  curves  for  each  strain  (Fig.  11). 
Generally  at  OD540nm  =1  (late  exponential  phase,  Fig.  11),  lOx  serial 
dilutions  of  cells  in  phosphate-buffered  saline  (PBS)  as  a  suspension  medium 
were  prepared  and  1,2  and  3  hrs  after  dilution  a  100  pl  portion  of  diluted 
culture  in  PBS  was  plated  onto  BA  for  checking  the  survival  time  of  bacteria  in 
PBS. 
For  animal  inoculation,  when  the  OD540nm  of  cultures  reached  =1.0  (109 
C.  F.  U.  /  ml),  lOx  serial  dilutions  in  PBS  were  prepared  and  from  dilution 
10-5,10-6,10-7  and  10-8  and  100  µl  aliquots  were  spread  onto  BA  plates  for 
viable  counting. Fig  11:  Growth  curve  of  4  different  strains  of  P.  multocida  in  BHI  broth 
10  ml-volumes  of  BHI  broth  were  inoculated  with  overnight  cultures  of 
the  different  bacterial  strains  and  incubated  at  370C  with  shaking.  The 
OD540  nm  was  measured  at  intervals 
1:  P.  multocida  85020  (wild  type) 
2:  P.  multocida  JRMT1  (aroA-) 
3:  P.  multocida  Quetta  (wild  type) 
4:  P.  multocida  JRMT2  (aroA-) Fig  11: 
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2.13.2.  Selection  of  animal  models 
Animals  vary  in  their  susceptibility  to  P.  multocida  infection  and  this  may  in 
turn  be  influenced  by  different  factors;  such  as  the  number  of  organisms  and 
route  of  the  inoculation.  Although  virulence  of  P.  multocida  may  vary 
considerably  for  different  animal  species,  the  mouse  appears  to  be  the  animal 
most  susceptible  to  lethal  infection.  Virulence  of  different  serogroups  is 
roughly  comparable  in  mice  (Rimler  and  Rhoades,  1989).  HS  working  parties 
set  up  by  the  UN  Food  and  Agricultural  Organisation  have  recommended  the 
use  of  the  mouse  for  testing  HS  vaccines.  The  mouse  provides  a  good  model  of 
infection  as  it  manifests  a  septicaemia  similar  to  HS  in  natural  hosts  (Bain  et  al., 
1982;  De  Alwis  et  al.  1990). 
Groups  of  3-6  female  4-6  week  old  BALB/c  (inbred)  mice  (Harlan  Olac, 
Shaws  farm,  Black-thorn,  Bicester,  UK)  were  used  in  this  study.  The  mice 
were  injected  intraperitoneally  (i.  p.  )  with  0.5  ml  of  lOx  serial  dilutions  in  PBS 
of  exponential  phase  cultures  (OD540nm  =1)  in  BHI  broth. 
For  intranasal  (i.  n.  )  inoculation  the  method  described  by  Rushton  (1978) 
was  used.  Mice  responded  satisfactorily  to  halothane  adminstered  in  the  same 
way  and  there  was  time  for  handling  of  mice  before  they  made  a  rapid 
recovery.  When  the  level  of  narcosis  with  halothane  was  correct,  mice  were 
recumbent,  insensitive  and  breathing  evenly  and  shallowly.  First  the  mice  were 
anaesthetised  with  halothane,  and  then  in  deep  narcosis,  50  µl  of  appropriate 
bacterial  dilution  was  applied  to  the  nares  and  allowed  to  be  inhaled. 
Subcutaneous  (s.  c.  )  vaccination  consisted  of  injecting  200  Al  of  appropriate 
bacterial  dilutions  into  the  nape  of  the  neck  of  the  mouse.  Mice  vaccinated  s.  c. 
were  also  anaesthetised  with  halothane.  Before  and  after  injection,  the  mice 
were  weighed  and  checked  daily.  For  collecting  blood  samples  and  taking  the 
internal  organs,  the  mice  were  sacrificed  in  the  C02  cabinet  and  then 
disinfected  with  chlorhexidine  skin  disinfectant  (Adams  Health  Care,  UK).  The 60 
appropriate  samples  were  prepared  aseptically  and  collected  in  pre-weighed 
Universal  bottles  and  the  weight  of  each  organ  was  calculated.  The  organs  were 
then  homogenised  in  10  ml-volumes  of  sterile  PBS  using  a  sterile  homogeniser 
(Silverson  machines,  UK).  The  samples,  0.1  ml  of  neat  and  lOx  serial 
dilutions  for  each  organ  were  plated  onto  BA  and  incubated  overnight  at  370C. 
It  should  be  noted  that  no  statistical  analysis  was  performed  with  these  tests. 
This  was  because  only  small  numbers  of  mice  were  used  as  clear  differences 
were  apparent  between  parent  and  mutant  strains. 
2.14.  Adenylate  cyclase  assay 
2.14.1.  Preparation  of  cell  free  extract 
P.  multocida  strains  were  grown  in  BHI  broth  to  late  exponential  phase 
(OD540nm  =  1.5)  and  Bordetella  pertussis  was  grown  in  CL  (Imaizumi  et  al., 
1983)  (Appendix  5.17)  medium  and  served  as  a  positive  control.  The  cultures 
were  centrifuged  at  10,000  rpm  for  15  min  at  40C  and  the  cell  pellet 
resuspended  in  10  ml  25  mM  HEPES  (pH  7.5)  (Sigma).  The  cells  were 
sonicated  3  times  for  20  seconds  with  40  seconds  cooling  intervals.  The 
ruptured  cells  were  centrifuged  at  33,000  rpm  for  90  min  at  4C  (Sorvall, 
Combi)  and  the  supernate  stored  in  0.5  ml  aliquots  at  -70  C. 
2.14.2.  Quantification  of  proteins  using  the  Lowry  procedure 
This  assay  relies  on  the  formation  of  a  protein-copper  complex  (Biuret 
reaction)  and  the  reduction  of  the  phosphomolybdate-phosphotungstate  reagent 
(Folin-ciocalteu  phenol  reagent,  Sigma)  by  the  tyrosine  and  tryptophan  residues 
of  the  protein.  This  method  is  applicable  when  the  protein  concentration  per 
assay  ranges  between  20  and  200  µg.  The  method  also  needs  a  standard  curve 
(Fig.  12),  which  is  generally  established  with  bovine  serum  albumin  (BSA) 
(Sigma). Fig  12:  Protein  estimation  standard  curve  developed  by  the  Lowry  method 
(Section  2.14.2) Fig  12: 
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Protein  standards  containing  25  to  100  µg  protein  per  ml  were  used. 
Dilutions  of  the  sample  of  unknown  protein  concentrations  were  prepared  in 
triplicate,  in  a  total  volumes  of  200  µl.  A  blank  tube  with  no  protein  sample 
was  also  prepared.  One  ml  of  reagent  C  (Appendix  5.14)  was  added  to  each 
tube  and  the  contents  vortexed  and  allowed  to  stand  at  room  temperature  for  10 
min.  Solution  D  (Appendix  5.14)  (100  µl)  was  added  rapidly  to  each  tube, 
with  immediate  mixing.  All  solutions  was  allowed  to  stand  for  30  min  at  room 
temperature  before  their  absorbance  at  660  nm  was  recorded. 
2.14.3.  Adenylate  cyclase  assay 
The  enzyme  activity  of  adenylate  cyclase  was  measured  in  an  assay  which 
involved  two  steps,  incubation  of  the  sample  with  ATP,  the  substrate  from 
which  the  adenylate  cyclase  generates  cyclic  3',  5'  adenosine  mono  phosphate 
(cAMP),  and  then  measurement  of  the  cAMP  generated  by  a  competitive 
binding  assay.  This  was  based  on  the  method  described  by  Hewlett  and  Wolff 
(1976).  Test  tubes  containing  80  gi  of  180  mM  Tricine  [N-tris- 
(hydroxymethyl)-methyl  glycine]  pH  8.0  and  40  µl  of  unknown  sample  were 
incubated  for  4  min  in  a  300C  water  bath.  The  reaction  was  started  by  addition 
of  120  p12  mM  ATP  in  20  mM  MgCl2.  The  reaction  was  terminated  after  120 
min  by  addition  of  200  pl  cAMP  assay  buffer  (Appendix  5.14)  and  immersion 
0 
in  a  boiling  water  bath  for  10  min.  Samples  were  stored  sealed  at  -20  C  and 
assayed  for  cAMP  in  triplicate  at  a  later  date. 
2.14.4.  cAMP  enzyme  immunoassay  (EIA)  kit  (Amersham  Life  Science) 
This  procedure  combines  the  use  of  a  peroxidase-labelled  cAMP  conjugate, 
a  specific  antiserum  which  can  be  immobilised  on  to  pre-coated  microtitre 
plates,  and  a  stabilised  substrate  solution.  The  assay  is  based  on  the 
competition  between  unlabelled  cAMP  and  a  fixed  quantity  of  peroxidase- 
labelled  cAMP  for  a  limited  number  of  binding  sites  on  a  cAMP-specific 
antibody.  With  fixed  amount  of  antibody  and  peroxidase-labelled  cAMP,  the 62 
amount  of  peroxidase-labelled  ligand  bound  by  the  antibody  will  be  inversely 
proportional  to  the  concentration  of  added  unlabelled  ligand.  The  peroxidase 
ligand  that  is  bound  to  the  antibody  is  immobilised  on  to  polystyrene  microtitre 
wells  pre-coated  with  second  antibody,  as  demonstrated  in  Figure  13.  Thus  any 
unbound  ligand  can  be  removed  from  the  wells  by  a  simple  washing  procedure. 
The  amount  of  peroxidase-labelled  cAMP  bound  to  the  antibody  is 
determined  by  addition  of  a  tetramethylbenzidine  (TMB)/  hydrogen  peroxidase 
substrate.  The  reaction  is  stopped  by  addition  of  an  acid  solution,  and  the 
resultant  colour  read  at  450nm  in  a  microtitre  plate  spectrophotometer 
(Dynatech  Laboratories). 
cAMP  may  be  measured  in  the  range  12.5-3200  fmol  per  well  (4-1052 
pg/well).  According  to  the  manufacture  instructions,  a  working  standard  curve 
was  prepared  (Fig.  14)  and  samples  assayed  by  non-acetylation  procedure 
(Table  8). 
2.15.5-enolpyruvylshikimate  3-phosphate  (EPSP)  synthase 
assay  procedure: 
5-enolpyruvylshikimate  3-phosphate  (EPSP)  synthase  is  assayed  in  either 
the  forward  or  reverse  direction  by  using  appropriate  coupling  enzymes.  For 
the  forward  assay,  formation  of  EPSP  is  coupled  to  the  chorismate  synthase 
reaction  while  for  the  reverse  reaction  the  release  of  phosphoenolpyruvate  is 
coupled  to  the  pyruvate  kinase  and  lactate  dehydrogenase  reactions. 
EPSP  synthase  was  assayed  by  method  of  Lewendon  and  Coggins  (1987). 
EPSP  is  prepared  enzymatically  from  shikimate  3-phosphate  and  phosphoenol- 
pyruvate  using  purified  E.  coli  EPSP  synthase.  Shikimate  3-phosphate  is 
isolated  from  an  aroA-  strain  of  Klebsiella  pneumoniae  (ATCC  25597)  as 
described  by  Coggins  et  al.  (1987).  Chorismate  synthase,  for  use  as  a  coupling 
enzyme,  is  partially  purified  from  Neurospora  crassa  (Coggins  et  al.,  1987) Fig  13:  The  simplified  cAMP  assay  by  competition  between  unlabelled 
cAMP  and  fixed  quantity  of  peroxidase-labelled  cAMP  for  a  limited 
number  of  binding  sites  on  a  cAMP-specific  antibody  (Amersham) ý  CL 
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(Non-acetylation  protocol) 
Points  represent  the  log10  cAMP  concentration  against  (B/B0)  for  each  set 
of  replicated  wells.  For  calculation  of  standard  curve  data,  the  average 
absorbance  (AB)  at  450nm  was  calculated  for  each  set  of  replicate  wells. 
The  percent  bound  for  each  standard  or  test  sample  was  calculated  from 
the  following  relationship: 
B:  AB450nm  of  standard  or  test  sample 
BO:  Zero  standard  (no-enzyme  blank) 
NSP:  Non-spesific  binding  (no-antiserum  blank) 
%BBO  =  Standard  or sample  AB  -  NSB  AB  x  100 
Bp  AB  -  NSBAB Fig  14: 
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10  100  1000 Table  8:  Enzyme  immunoassay  protocol  for  cAMP;  non-acetylation  assay 
(all  volumes  are  in  microlitres) 
NSB 
Zero  standard 
blank  (Be)  Standards 
Test 
samples 
Assay  buffer  200  100  ----  ---- 
Standard  ----  ----  100  ---- 
Test  sample  ----  ----  ----  100 
Antiserum  ----  100  100  100 
Covered  plate,  incubated  at  3-5  °C  for  2  hrs 
Peroxidase 
conjugate 
50  50  50  50 
Covered  plate,  incubated  at  3-5  C  for  60  min 
Aspirated,  washed  all  wells  four  times  with  400  µl  washing  buffer 
Substrate  150  150  150  150 
Covered  plate,  incubated  at  room  temperature  for  exactly  60  min  w  hile  shaking 
1.0  M  sulphuric 
acid*  100  100  100  100 
*=  Reaction  can  be  read  at  630  nm  before  acidification  but  halting  the 
reaction  prior  to  end  point  determination  is  recommended. 63 
and  the  coupling  enzymes  pyruvate  kinase  and  lactate  dehydrogenase  are 
obtained  from  Boehringer  (Mannheim,  Germany).  (EPSP,  shikimate  3- 
phosphate  and  chorismate  synthase  were  kindly  supplied  by  Professor  J.  R. 
Coggins,  Glasgow  University). 
For  routine  purposes  and  in  particular  for  monitoring  the  enzyme 
purification,  EPSP  synthase  is  assayed  in  the  reverse  direction.  In  this 
procedure  the  following  reagents  were  mixed  together  and  NADH  oxidation  is 
monitored  continuously  at  340nm  in  a1  ml  cuvette  at  250C:  cell  free  extract  395 
µl,  EPSP  synthase  assay  buffer  (Appendix  5.14)  500  p1,2  mM  NADH  50  µl, 
pyruvate  kinase/lactate  dehydrogenase  5  pl,  EPSP  (0.7  mg/  ml)  50  µl. 
(Change  in  AB  /  min/  ml)  =  U/  ml 
6.2 
2.16.  Phagocytosis  assay 
The  murine  macrophage-like  cell  line  RAW267.7  was  maintained  in  RPMI 
0  1640  medium  (containing  calf  serum  [10%  v/v]  and  10  mM  glutamine)  at  37  C 
in  the  absence  of  antibiotics.  Approximately  105  cells  ml-  I  were  seeded  in 
tissue  culture  plates  or  flasks  and  incubated  for  48  to  72  hrs  until  cell  numbers 
had  increased  to  5x  105  cells  ml-1.  Cell  numbers  and  viability  were  confirmed 
by  trypan  blue  exclusion  counts.  Infections  were  carried  out  with  suspensions 
of  P.  multocida  strains  at  concentrations  of  2-3  x  108  C.  F.  U.  ml-1  which  were 
prepared  in  RPMI  by  resuspension  of  exponential  cultures  grown  in  BHI  broth 
for  4  hrs.  After  incubation  for  2  hrs  at  370C,  the  cells  were  washed  twice  with 
PBS,  and  extracellular  bacteria  were  killed  by  addition  of  RPMI  supplemented 
with  polymyxin  B  sulphate  (Sigma  U.  K)  and  gentamycin  to  a  final 
concentration  of  350  µg/  ml  of  each  and  incubation  continued  for  2  hrs.  This 
concentration  of  polymyxin  and  gentamycin  killed  >99.99%  of  5x  109  C.  F.  U. 
P.  multocida  organisms  over  the  2  hrs  period,  as  confirmed  by  plate  counting. 64 
The  cells  were  then  washed  three  times  with  PBS  and  resuspended  in  RPMI 
and,  at  chosen  intervals,  digitonin  (Sigma,  UK)  was  added  to  final 
concentration  of  100  µg/  ml  and  left  for  30  min  at  370C  to  lyse  the  eukaryotic 
cells.  Surviving  bacteria  were  estimated  by  plating  aliquots  on  BA. 65 
3.  RESULTS 
3.1.  Construction  of  defined  mutations  in  P.  multocida  strains 
3.1.1.  Cloning  of  the  aroA  gene 
Forward  and  reverse  primers  were  designed  according  to  the  aroA  sequence 
of  P.  multocida  strain  PBA100  serotype  A:  1  a  chicken  isolate,  published  by 
Homchampa  et  al.  (1992)  (Genbank  accession  number  Z14100).  The  aroA 
genes  of  P.  multocida  85020  and  Quetta  strains  were  amplified  by  PCR  using 
primers  AroAl  and  AroA2  (Table  7)  as  1.2  kb  amplimer  (nt.  315-1514).  The 
PCR  products  were  electrophoresed  in  a  0.8%  (w/v)  agarose  gel  and  the  DNA 
bands  cut  out  from  the  gel  and  purified  by  Agarose  Spin  Columns. 
A  ligation  mixture  containing  the  aroA  gene  fragment  and  the  pTAg  cloning 
vector  was  incubated  at  160C  overnight.  The  ligation  mixture  was  heat 
inactivated  and  used  to  transform  E.  coli  XL1  Blue  competent  cells.  Then  the 
bacteria  were  spread  onto  LB-X-Gal-IPTG  agar  containing  Ap,  Km  (vector 
antibiotic  markers)  and  Tc  (competent  cells  are  resistant  to  Tc)  and  incubated 
overnight  at  37"C.  White  colonies  were  picked  and  inoculated  into  5  ml  of  LB 
broth  containing  appropriate  antibiotics.  Recombinant  plasmids  were  analysed 
and  confirmed  by  restriction  digestion  and  PCR.  Digestion  with  BamHI  and 
Xhol  which  cut  in  the  MCS  of  pTAg  produced  fragments  of  =1.2  kb  and  =4.0 
kb  equivalent  to  the  aroA  insert  and  cut  vector  respectively  (Fig.  15A,  lanes  1 
and  2).  PCR  analysis  using  AroA  primers  1  and  2  (Table  7)  produced  a  =1.2 
kb  fragment  from  both  genomic  and  plasmid  DNA  (Fig.  15  B).  The  =4.0  kb 
band  in  lanes  2  and  4  are  probably  plasmid  DNA  and  the  very  low  molecular 
weight  band  is  probably  primer  dimers.  The  plasmids  were  designated Fig  15:  Analysis  of  plasmids  pJRMTland  pJRMT2  (size  as  kb) 
A:  Restriction  analysis 
Lane  M:  1  kb  DNA  marker 
Lane  1:  plasmid  pJRMT1  digested  with  BamHUXhoI 
Lane  2:  plasmid  pJRMT2  digested  with  BamHUXhoI 
Lane  3:  plasmid  pJRMT1  undigested 
Lane  4:  plasmid  pJRMT2  undigested 
Lane  M:  supercoiled  DNA  marker 
B:  PCR  analysis  of  plasmid  pJRMT1  and  pJRMT2  with  primers  AroAl  and 
ATOA2 
Lane  1:  P.  multocida  85020  genomic  DNA 
Lane  2:  plasmid  pJRMT1  DNA 
Lane  3:  P.  multocida  Quetta  genornic  DNA 
Lane  4:  plasmid  pJRMT2 
Lane  M:  1  kb  DNA  marker Fig  15: 
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pJRMT1  (aroA  insert  from  85020)  and  pJRMT2  (aroA  insert  from  Quetta) 
(Fig.  16). 
3.1.2.  Subcloning  of  aroA  gene  into  suicide  vector  pAKA19 
Plasmid  pAKA19  is  a  suicide  derivative  of  pAKA16  which  was  developed 
for  gene  transfer  to  P.  multocida  and  P.  (Mannheimia)  haemolytica.  pAKA  16 
was  obtained  by  insertion  of  the  lacZ  peptide-encoding  region  and  a  multiple 
cloning  site  from  pIC20H  into  a  plasmid  which  was  originaly  isolated  from  P. 
haemolytica  serotype  Al  (Azad  et  al.,  1994).  The  vector  encodes  ampicillin 
resistance,  and  contains  14  unique  restriction  sites  and  the  property  of 
phenotypic  identification  of  recombinant  clones  in  E.  coli  by  insertional 
inactivation  of  ß-galactosidase  activity.  It  can  be  transferred  by  conjugation  to 
P.  multocida  and  P.  haemolytica.  pAKA19  was  constructed  by  replacment  of 
the  origin  of  DNA  replication  (ori  p)  of  pAKA  16  with  a  ColE  I  type  on  from 
plasmid  pBR322.  This  derivative  will  replicate  in  E.  coli,  but  not  in  either  P. 
multocida  or  P.  haemolytica,  and  is  suitable  for  use  as  a  suicide  vector  for  these 
Pasteurella  species  (Azad  et  al.,  1994).  For  E.  coli  hosts  containing  low  copy 
number  plasmids  like  pAKA16,  pAKA19  and  pEG18.3,  Terrific  broth  (Tartof 
and  Hobbs,  Cited  by  Azad,  et  al.,  1992)  containing  I%  (w/v)  yeast  nitrogen 
base  (Difco)  was  used.  Cells  were  inoculated  into  5  ml  of  volumes  Terrific 
broth  and  incubated  at  37*C  for  2-3  hrs  until  the  OD540nm  reached  =0.3-0.4, 
then  chloramphenicol  30  or  170  µg/  ml  was  added  and  incubation  at  37  C 
continued  for  another  16-18  hrs 
. 
The  amplification  of  ColE1-type  plasmids  in 
E.  coli  by  inhibition  of  protein  synthesis  with  Cm  (Clewell,  1972)  or  amino 
acid  starvation  (Schroeter  et  al.,  1988)  is  well  established.  In  our  work, 
pAKA16  was  amplified  very  well  in  presence  of  170  µg/  ml  Cm,  whereas 
plasmids  pAKA19  and  pEG18.3  amplified  better  in  Teriffic  broth  plus  1% 
(w/v)  YNB  without  Cm  (Fig.  17). Fig  16:  The  map  of  plasmids  pJRMT1  and  pJRMT2 
The  aroA  genes  of  P.  multocida  strains  85020  and  Quetta  were  amplified 
by  PCR  and  cloned  into  the  pTAg  cloning  vector. Fig  16: 
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Avail  Avail  App Fig  17:  Plasmid  DNA  concentration  from  E.  coli  DH5a  containing  low 
copy  number  plasmids  in  different  culture  media  (size  as  kb). 
A:  Plasmid  pAKA16  from  E.  coli  DH5a  grown  in: 
Lane  1:  LB  broth 
Lane  2:  Terrific  broth 
Lane  3:  Terrific  broth+1%  yeast  nitrogen  base 
Lane  4:  Terrific  broth+1  %  yeast  nitrogen  base+170  µg/ml  chloramphenicol 
Lane  5:  Terrific  broth+l  %  yeast  nitrogen  base+30  µg/ml  chloramphenicol 
Plasmid  pAKA19  from  E.  coli  DH5a  grown  in: 
Lane  6:  LB  broth 
Lane  7:  Terrific  broth 
Lane  8:  Terrific  broth+l  %  (w/v)  yeast  nitrogen  base 
Lane  9:  Terrific  broth+1%  (w/v)  yeast  nitrogen  base+170  µg/  ml 
chloramphenicol 
Lane  10:  Terrific  broth+1%  (w/v)yeast  nitrogen  base+30  µg/  ml 
chloramphenicol 
Lane  M:  supercoiled  DNA  marker 
B:  Plasmid  pEG18.3  from  E.  coli  DH5a  grown  in: 
Lane  1:  LB  broth 
Lane  2:  Terrific  broth 
Lane  3:  Terrific  broth+l  %  (w/v)  yeast  nitrogen  base 
Lane  4:  Terrific  broth+1  %  (w/v)  yeast  nitrogen  base+170  µg/  ml 
chloramphenicol 
Lane  5:  Terrific  broth+1  %  (w/v)  yeast  nitrogen  base+30  tg  /ml 
chloramphenicol 
Lane  M:  supercoiled  DNA  marker Fig  17: 
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The  aroA  fragments  were  cut  out  from  plasmids  pJRMTI  and  pJRMT2  with 
BamHI  and  XhoI  and  plasmid  pAKA19  was  digested  with  BamHI  and  XhoI 
and  dephosphorylated.  The  fragments  were  ligated  and  transformed  into  E.  coli 
DH5a.  White  colonies  were  selected  from  LB-X-Gal-IPTG  plates  containing 
ampicillin.  Recombinant  plasmids  were  confirmed  by  restriction  analysis  and 
termed  pJRMT3  and  pJRMT4  respectively  (Fig.  20  A).  BamHUXhoI  digests 
of  these  plasmids  produced  the  expected  =  1.2  kb  aroA  insert  and  =5.0  kb 
pAKA  19  vector  (Fig.  18). 
3.1.3.  Insertion  of  a  kanamycin  resistance  cassette  into  the  aroA  gene 
The  KmR  cassette  was  cut  out  as  a  1.24  kb  fragment  (from  nt.  421-1661) 
from  plasmid  pUC4K  with  PstI  and  plasmids  pJRMT3  and  pJRMT4  were 
digested  with  Nsil  (at  nt.  718)  (Fig.  20A)  and  dephosphorylated.  Digested 
material  was  run  in  a  0.8%  (w/v)  agarose  gel  and  the  relevant  fragments 
purified  and  ligated.  The  ligation  mixture  was  transformed  into  E.  coli  DH5ct 
competent  cells  by  electroporation  and  colonies  resistant  to  both  Ap  and  Km 
were  selected  on  LB  agar  containing  these  antibiotics.  Recombinant  plasmids 
were  confirmed  by  restriction  analysis  and  designated  as  pJRMT5  and  pJRMT6 
respectively  (Fig.  20B).  BamHUXhoI  digestion  showed  a  =2.4  kb  aroA::  KmR 
insert  and  the  -5.0  kb  pAKA19  vector  (Fig.  19). 
3.1.4.  Allelic  exchange 
The  suicide  plasmids  pJRMT5  and  pJRMT6  were  used  with  P.  rnultocida 
strains  for  allelic  exchange,  and  introduced  into  strain  85020  by  electroporation 
and  into  the  SmR  Quetta  strain  JRMTI  1  (Table  4)  by  conjugation.  For  the  latter 
procedure,  the  plasmids  were  transformed  to  E.  coli  SM  10A,  pir  by 
electroporation.  100  tl  aliquots  of  bacteria  were  spread  onto  BHI  agar 
supplemented  with  5%  (v/v)  sheep  blood  containing  kanamycin  only  for  strain 
85020  and  kanamycin  with  streptomycin  for  strain  Quetta  SmR  in  order  to 
select  KmR  and  KmR-SmR  colonies  respectively.  For  each  strain  picked  up  50 Fig  18:  Restriction  analysis  of  plasmids  pJRMT3  and  pJRMT4  (the  aroA 
genes  cloned  into  pAKA19  vector,  size  as  kb) 
Left: 
Lane  1:  plasmid  pJRMT3  digested  with  BamHIJXhoI  (bands  of  =1.2  and 
=5.0  kb) 
Lane  2:  plasmid  pJRMT4  digested  with  BamHIJXhol  (bands  of  =1.2  and 
=5.0  kb) 
Lane  M:  1  kb  marker 
Right: 
Lane  M:  supercoiled  DNA  marker 
Lane  1:  plasmid  pJRMT3  undigested 
Lane  2:  plasmid  pJRMT4  undigested 
Fig  19:  Restriction  analysis  of  plasmids  pJRMT5  and  pJRMT6  (size  as  kb) 
Left: 
Lane  1:  plasmid  pJRMT5  digested  with  BamHUXhoI  (bands  of  =2.4  and 
=5.0  kb) 
Lane  2:  plasmid  pJRMT6  digested  with  BamHI/XhoI  (bands  of  =2.4  and 
=5.0  kb) 
Lane  3:  1  kb  DNA  marker 
Right: 
Lane  1:  plasmid  pJRMT5  undigested 
Lane  2:  plasmid  pJRMT6  undigested 
Lane  M:  supercoiled  DNA  marker Fig  19 
Fig  18: Fig  20: 
A:  The  map  of  plasmids  pJRMT3  and  pJRMT4 
The  aroA  gene  was  inserted  as  a  BamHUXhoI  fragment  into  pAKA19  which 
had  been  digested  with  BamHIIXhoI  and  dephosphorylated. 
B:  The  map  of  plasmids  pJRMT5  and  pJRMT6 
The  kanamycin  resistance  cassette  from  plasmid  pUC4K  was  inserted  into 
plasmids  pJRMT3  and  pJRMT4. Fig  21 
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single  colonies  from  different  selective  plates  and  subcultured  on  BHI  agar 
supplemented  with  5%  (v/v)  sheep  blood  containing  appropriate  antibiotics  for 
five  days.  then  20  single  clones  of  each  strain  checked  by  PCR.  From  these 
clones  just  8  or  9  clones  were  showed  correct  predicted  patern  that  selected  and 
one  of  them  for  each  P.  multocida  strains  have  been  choosen  as  aroA  mutant 
strain  for  further  works. 
3.1.5.  Confirmation  of  the  P.  multocida  aroA  mutant  strains 
Potential  mutant  derivatives  were  tested  by  PCR,  growth  in  Pasteurella 
Minimal  Medium  (Jabloneski  et  al.,  1992b),  assay  for  the  enzyme  EPSP 
synthase  and  Southern  blot  hybridisation. 
3.1.5.1.  PCR 
The  aroA  primers  AroAl  and  AroA2  amplified  a  larger  =2.4  kb 
amplimer(aroA  gene+  kanamycin  resistance  cassette)  from  P.  multocida 
JRMT1,  derived  from  P.  multocida  85020,  and  JRMT2,  derived  from  P. 
multocida  Quetta  SmR,  than  from  the  parent  strains  which  produced  the 
expected  =  1.2  kb  amplimer  (Fig.  21). 
3.1.5.2.  Growth  in  Pasteurella  Minimal  Medium  (PMM) 
Bacteria  were  grown  on  BHI  agar  supplemented  with  5%  (v/v)  sheep  blood 
at  370  C  overnight.  Several  colonies  were  inoculated  into  PMM  with  and 
without  aromix  supplementation  and  incubated  at  37OC  with  shaking  (250 
rpm).  The  OD540nm  values  were  measured  after  24  and  48  hrs  (Fig.  22).  Both 
mutant  strains  failed  to  grow  in  PMM  unless  supplemented  with  aromix. 
3.1.5.3.  Southern  blot  hybridisation 
The  PCR  products  and  genomic  DNA,  digested  with  EcoRV,  of  the  wild 
type  and  the  mutant  strains  were  electrophoresed  in  a  0.7%  (w/v)  agarose  gel 
and  a  blot  processed  for  hybridisation  with  the  aroA  probe  (aroA  gene  of  P. 
multocida  85020  amplified  by  PCR  and  dig-labelled)  and  with  the  kanamycin Fig  21:  PCR  analysis  of  aroA  in  wild-type  and  mutated  P.  multocida  strains 
(size  as  kb) 
The  AroA  primers  were  used  with  genomic  DNA  preparations  as  template 
Lane  1:  P.  multocida  85020 
Lane  2:  P.  multocida  JRMT1 
Lane  3:  P.  multocida  Quetta 
Lane  4:  P.  multocida  JRMT2 
Lane  M:  1  kb  DNA  marker Fig  21: Fig  22:  Growth  of  P.  multocida  strains  in  Pasteurella  Minimal  Medium 
P.  multocida  strains  85020,  JRMTI,  Quetta  and  JRMT2  were  inoculated  into 
PMM  with  (indicated  by  +)  or  without  aromix  supplementation  and  the 
OD540nm  was  measured  after  shaking  for  24  and  48  hrs  at  37'C. Fig  22: 
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resistance  cassette  (PstI  fragment  of  plasmid  pUC4K).  With  the  PCR  products, 
the  aroA  probe  hybridised  to  =1.2  kb  band  for  the  wild  type  and  the  =2.4  kb 
band  for  the  mutant  strains  as  expected  (Fig.  23A,  left).  The  KmR  probe 
hybridised  to  only  the  =2.4  kb  band  obtained  from  PCR  of  the  mutant  strains 
(Fig.  23A,  right).  In  genomic  DNA  digested  with  EcoRV,  the  wild-type  strains 
showed  two  bands  of  =1.8  and  =1.6  kb.  This  would  confirm  the  presence  of 
an  EcoRV  site  in  the  aroA  gene  (nt.  931).  No  hybridisation  was  detected  with 
the  KmR  probe.  For  the  mutant  strains,  two  bands  of  =1.8  and  =2.8  kb  were 
visible  with  the  aroA  probe  (Fig.  23B,  left)  and  the  KmR  probe  hybridised 
only  with  the  bigger  band  (Fig.  23B,  right).  This  confirmed  insertion  of  the 
KmR  cassette  into  the  section  of  aroA  represented  by  the  1.6  kb  EcoRV 
fragment. 
3.1.5.4.  EPSP  synthase  assay 
For  the  EPSP  synthase  assay,  a  cell  free  extract  was  prepared  and  the 
protein  concentration  measured  by  Lowry  procedure.  Total  protein 
concentrations  for  P.  multocida  85020  and  Quetta  wild-type  strains  was  12.8 
and  14.7  mg/  ml  respectively  and  for  aroA  mutant  JRMTI  and  JRMT2  strains 
was  9.6  and  9.9  mg/  ml  respectively.  The  values  for  EPSP  synthase  enzyme 
activity  obtained  for  P.  multocida  85020  and  Quetta  wild-type  strains  was 
0.024  and  0.021  U/  ml  respectively,  whereas  no  activity  was  detected  for  aroA 
mutant  JRMT  1  and  JRMT2  strains. 
3.1.6.  Cloning  of  cya  gene 
Primers  were  designed  according  to  the  sequence  of  the  cYa  gene  of  P. 
multocida  CNPI  (NCTC  10332)  (Mock  et  al.,  1991;  Genbank  accession 
number  M68901).  The  cya  gene  amplified  from  P.  multocida  strain  85020  was 
2503  bp  (from  nt.  171-2674)  using  the  primers  Cya4  and  Cya5  (Table  7). 
Primer  Cya4  was  not  used  successfully  with  strain  Quetta  and  a  supplementary 
primer  Cya6  had  to  be  designed  (Table  7).  The  cya  gene  amplified  from  P. Fig  23:  Southern  blot  hybridisation  P.  multocida  stains  85020,  Quetta  and  their 
aroA  mutants,  JRMT1  and  JRMT2  (size  as  kb) 
A:  PCR  products  obtained  with  AroA  primers  from  genomic  DNA  of  P. 
multocida  strains 
Left:  Hybridisation  with  aroA  probe 
Right:  Hybridisation  with  KmR  probe 
Lane  1:  P.  multocida  85020  (wild-type) 
Lane  2:  P.  multocida  JRMTI  (aroA  mutant) 
Lane  3:  P.  multocida  Quetta  (wild-type) 
Lane  4:  P.  multocida  JRMT2  (aroA  mutant) 
B:  The  genomic  DNA  of  P.  multocida  strains,  digested  with  EcoRV 
Left:  Hybridisation  with  aroA  probe 
Right:  Hybridisation  with  KmR  probe 
Lane  1:  P.  multocida  JRMT1  (aroA  mutant) 
Lane  2:  P.  multocida  85020  (wild-type) 
Lane  3:  P.  multocida  JRMT2  (aroA  mutant) 
Lane  4:  P.  multocida  Quetta  (wild-type) Fig  23: 
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multocida  strain  Quetta  was  2203  bp  (from  nt.  171-2372)  using  primers  Cya5 
and  Cya6  (Table  7). 
The  above  PCR  products  were  electrophoresed  on  a  0.8%  (w/v)  agarose 
gel,  and  the  relevant  fragments  purified,  using  Gen  Elute  Agarose  Spin 
Columns.  The  purified  PCR  products  from  the  agarose  gels  were  cloned  into 
pCR-Script  Cam  SK  (+)  cloning  vector  (Table  5)  and  the  ligation  mixture  was 
transformed  into  E.  coli  XL1Blue  competent  cells.  Bacteria  were  spread  onto 
LB-X-Gal-IPTG  agar  containing  chloramphenicol  and  incubated  overnight  at 
a  37  C.  Recombinants  were  checked  by  picking  white  colonies  and  performing 
PCR  and  restriction  enzyme  analysis.  HpaI  cut  at  nucleotides  690  and  1857 
within  the  cya  gene  and  would  be  expected  to  produce  fragments  of  =1.17  kb 
(internal  cya  gene  fragment)  plus  =4.7  kb  for  the  cya  gene  from  strain  85020 
and  =4.4  kb  for  the  Quetta  cya  gene  (vector  =3.4  kb  +  =0.5  kb  and  =0.8  kb  of 
the  remaining  cya  gene  for  strain  85020  and  =0.5  kb  and  X0.5  kb  for  strain 
Quetta).  The  new  plasmids  were  designated  pJRMT7  for  P.  multocida  85020 
and  pJRMT8  for  P.  multocida  Quetta  (Fig.  24  &  25). 
3.1.7.  Insertion  of  the  kanamycin  resistance  cassette  into  the  cya  genes 
The  plasmids  pJRMT7  and  pJRMT8  were  digested  with  Hpal  to  remove  the 
1168  bp  middle  fragment  (from  nt.  690-1857)  of  the  cya  genes, 
electrophoresed  in  0.7%  (w/v)  agarose  gel  and  the  larger  fragments  purified  as 
vector.  These  fragments  were  dephosphorylated  by  CIP.  The  kanamycin 
resistance  cassette  was  removed  as  a  1252  bp  fragment  from  Hincll-digested 
plasmid  pUC4K  (nt.  413-1665)  and  ligated  with  the  Hpal  fragments  of 
plasmids  pJRMT7  and  pJRMT8.  E.  coli  XL1  Blue  competent  cells  were 
transformed  by  electroporation  and  the  bacteria  spread  onto  LB  agar  containing 
chloramphenicol  and  kanamycin.  The  recombinant  plasmids  were  confirmed  by 
restriction  analysis  and  were  named  as  pJTMT9  and  pJRMT  10  for  P.  inultocida 
85020  and  Quetta  strains  respectively  (Fig.  27).  As  expected,  Hpal  did  not  cut Fig  24: 
A:  Restriction  analysis  of  plasmids  pJRMT7  and  pJRMT8  (cya  genes  cloned 
into  pCR-Script,  size  as  kb) 
Lanes  1-4:  plasmid  pJRMT7  digested  with  HpaI  (different  clones) 
Lanes  5-7:  plasmid  pJRMT8  digested  with  Hpal  (different  clones) 
Lane  M:  1  kb  marker 
B:  PCR  analysis  of  plasmids  pJRMT7  and  pJRMT8  with  Cya  primers 
Lane  M:  1  kb  DNA  marker 
Lane  1:  plasmid  pJRMT7  (plasmid  DNA  as  template)  with  primers  Cya4 
and  Cya5 
Lane  2:  plasmid  pJRMT8  with  primers  Cya5  and  Cya6 
Lane  3:  P.  multocida  85020  genomic  DNA  with  primers  Cya4  and  Cya5 
Lane  4:  P.  multocida  Quetta  genomic  DNA  with  primers  Cya5  and  Cya6 Fig  24: 
A. 
B. Fig  25:  Map  of  plasmids  pJRMT7  and  pJRMT8 
The  cya  genes  of  P.  multocida  strains  were  amplified  by  PCR  (as  2.5  and  2.2 
kb  fragments  for  85020  and  Quetta  strains  respectively)  and  cloned  into  pCR- 
Script  cloning  vector Fig  25: 
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Lane  1:  plasmid  pJRMT9  digested  with  Hpal  (un-affected) 
Lane  2:  plasmid  pJRMT10  digested  with  Hpal  (un-affected) 
Lane  3:  plasmid  pJRMT7  digested  with  Hpal 
Lane  4:  plasmid  pJRMT8  digested  with  Hpal 
Lane  5:  plasmid  pJRMT9  digested  with  BamHlJSacII 
Lane  6:  plasmid  pJRMT10  digested  with  BamHUSacII 
Lane  M:  1  kb  DNA  marker Fig  26: Fig  27:  Map  of  plasmids  pJRMT9  and  pJRMT10 
Plasmids  pJRMT7  and  pJRMT8  were  digested  with  Hpal,  to  remove  middle 
part  of  the  cya  gene  which  was  replaced  with  the  kanamycin  resistance  cassette 
(Km). Fig  27: 
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plasmid  pJRMT9  and  pJRMT  10  whereas  it  produced  two  fragments  of  =1.17 
and  =4.7  kb  for  plasmid  pJRMT7  and  two  fragments  of  =1.17  and  -4.4  kb  for 
plasmid  pJRMT8  (Fig.  26).  Also  digestion  with  BamHI1SacII  produced  two 
fragments  of  =3.4  and  =2.55  kb  for  plasmid  pJRMT9  and  two  fragments  of 
=3.4  and  =2.25  kb  for  plasmid  pJRMT10  (Fig.  26).  This  was  expected  as 
these  enzymes  would  remove  the  complete  insert,  leaving  the  plasmid  vector 
(3.4  kb). 
3.1.8.  Allelic  exchange 
As  the  backbone  of  pCR-Script  vector  of  plasmid  pJRMT9  and  pJRMT10  is 
a  ColE1-based  replication,  it  should  not  replicate  in  Pasteurella  and  so  should 
act  as  a  suicide  vector.  The  plasmids  pJRMT9  and  pJRMT  10  were  introduced 
into  P.  multocida  strains  for  allelic  exchange  by  electroporation  and  bacteria 
spread  onto  BHI  agar  supplemented  with  5%  (v/v)  sheep  blood  containing 
kanamycin.  Some  KmR  colonies  were  patched  onto  BHI  agar  containing 
kanamycin  and  then  further  subcultured  onto  BHI  agar  plates  without 
kanamycin.  After  10-100  subcultures  on  BHI  agar  without  antibiotic,  some 
clones  from  both  85020  and  Quetta  strains  were  inoculated  into  BHI  broth  and 
genomic  DNA  prepared.  The  genomic  DNA  was  digested  with  Accl  restriction 
enzyme  (the  unique  AccI  site  at  nt.  1459  in  the  cya  gene  sequence  was 
removed  by  digestion  with  HpaI).  The  digested  materials  were  run  in  0.6% 
(w/v)  agarose  gel  and  examined  by  Southern  blot  hybridisation.  All  samples 
when  hybridised  with  cya  probe  (PCR  amplimer  from  P.  multocida  strain 
85020  using  primers  Cya4  and  Cya5)  showed  four  bands  of  =2.3,  =3.4,  -5.0 
and  =7.0  kb  except  the  wild-type  that  just  showed  hybridisation  to  two  bands 
of  =2.3  and  =5.0  kb  (Fig.  28A).  No  hybridisation  was  detected  with  DNA 
from  parent  strains  with  KmR  probe  (Fig.  28B),  but  the  other  samples 
showed  two  bands  of  =3.4  and  =7.0  kb  (Fig.  28B).  Also  as  controls  the 
plasmids  pJRMT9  and  pJRMTIO  were  digested  with  Accl  and  run  in  an Fig  28:  Southern  blot  hybridisation  of  P.  multocida  cya::  KmR  clones 
digested  with  Accl  (size  as  kb) 
A:  Hybridisation  with  cya  probe 
B:  Hybridisation  with  KrR  probe 
Lanes  1-4:  P.  multocida  Quetta  cya::  Km'  clones 
Lane  5:  P.  multocida  Quetta  wild  type  strain Fig  28: 
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agarose  gel  for  Southern  blotting.  When  hybridised  with  the  c_ya  or  KmR 
probes,  they  showed  two  bands  of  =3.4  and  =7.0  kb. 
From  more  than  3000  single  KmR  clones  obtained  in  repeat  experiments, 
about  300  were  checked  by  Southern  blot  hybridisation  and  just  one  of  them, 
derived  from  the  P.  multocida  strain  Quetta,  showed  the  predicted  size  band 
(=7.0  kb)  that  could  be  designated  as  a  mutated  cya  gene.  The  mutant  strain 
was  confirmed  by  Southern  blot  hybridization  and  designated  as  P.  multocida 
JRMT3  (Fig.  29  lane  1).  The  cya  probe  hybridised  to  two  bands  of  =  2.2  and 
-5.0  kb  for  the  P.  multocida  Quetta  parent  strain  and  one  band  of  =7.0  kb  for 
P.  multocida  JRMT3  (Fig.  29  lane  1).  In  addition,  the  PCR  products  obtained 
with  Cya5  and  Cya6  primers  for  wild-type  and  JRMT3  strains  were 
hybridised  with  cya  and  KmR  probes.  Each  probe  hybridised  to  a  =7.0  kb  for 
JRMT3  and  two  bands  of  =2.2  and  =5.0  kb  were  obtained  with  the  Quetta 
parent  strain  and  the  cya  probe  (Fig.  30).  The  predicted  hybridisation  pattern 
was  also  obtained  for  genomic  DNA;  a  =2.2  kb  fragment  for  theQuetta  parent 
strain  and  a  similar  sized  fragment  from  JRMT3  as  the  =1.25  kb  KmR  cassette 
replaced  a=1.17  kb  internal  Hpal  fragment. 
Plasmids  pJRMT9  and  pJRMT10  were  electroporated  into  P.  inultocida 
strain  85020  and  60  KmR  clones  were  examined  by  Southern  blotting.  In  all 
cases,  the  cya  probe  hybridised  to  four  bands  as  =2.4,  =3.6,  =5.0  and  =7.0 
kb  for  pJRMT9  and  five  bands  of  =1.6,  =2.4,  =5.0,  =6.0  and  =7.0  kb  for 
pJRMT10,  and  the  KmR  probe  hybridised  one  band  of  =6.0  kb  for  pJRMT9 
and  two  bands  as  =6.0  and  =7.0  kb  for  pJRMTIO  plasmids  (Fig.  31). 
Therefore,  in  the  case  of  P.  multocida  85020,  no  strain  demonstrated  the 
correct  gene  type  expected  for  allelic  exchange  of  the  cya  allele.  Also  some  of 
these  KmR  clones  were  checked  for  plasmid  replication  with  the  Miniprep  kit 
(QIAgen)  but  they  did  not  show  any  specific  plasmid  band. Fig  29:  Southern  blot  hybridisation  of  P.  multocida  Quetta  cya::  KmR  clones 
digested  with  AccI  (size  as  kb) 
A:  Hybridisation  with  cya  probe 
B:  Hybridisation  with  KmR  probe 
Lanes  1-5:  P.  multocida  Quetta  cya::  KmR  clones  after  transformation  Witt 
plasmid  pJRMT9 
Lane  6:  P.  multocida  Quetta  wild-type  strain 
Only  the  digest  in  lane  1  shows  the  expected  pattern.  This  strain  was 
designated  as  P.  multocida  JRMT  3. Fig  29: 
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JRMT  3  (size  as  kb) 
A:  Hybridisation  with  cya  probe 
B:  Hybridisation  with  KmR  probe 
Lane  1:  PCR  product  with  Cya  primers  (CyaS  and  Cya6)  from  P.  multocida 
Quetta  strain 
Lane  2:  PCR  product  with  CyaS  and  Cya6  from  P.  multocida  JRMT3 
Lane  3:  P.  multocida  strain  Quetta  genomic  DNA  digested  with  AccI 
Lane  4:  P.  multocida  strain  JRMT3  genomic  DNA  digested  with  Accl Fig  30: 
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transformed  with  plasmids  pJRMT9  and  pJRMT10  and  DNA 
digested  with  AccI  (size  as  kb) 
A:  Hybridisation  with  cya  probe 
B:  Hybridisation  with  KMR  probe 
Lanes  1-7:  P.  multocida  85020  cya::  KmR  clones  transformed  with  plasmid 
pJRMT9 
Lanes  8-12:  P.  multocida  85020  cya::  KmR  clones  transformed  with  plasmid 
pJRMT10 
Lane  13:  P.  multocida  strain  85020  wild-type Fig  31: 
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3.1.9.  Subcloning  of  interrupted  cya  gene  into  the  vector  pAKA19  for 
conjugative  transfer  to  P.  multocida 
Success  at  creating  a  defined  P.  multocida  cya  mutant  was  apparently  only 
achieved  with  the  Quetta  strain  (JRMT3).  In  order  to  derive  a  similar  derivative 
of  strain  85020,  an  alternative  approach  was  attempted.  The  interrupted  cya 
gene  with  the  kanamycin  resistance  cassette  was  removed  from  plasmid 
pJRMT9  with  PvuII  as  a  =3.0  kb  fragment  and  cloned  into  pAKA19  digested 
withHincIUEcoRI  and  dephosphorylated  and  treated  with  Klenow  enzyme  to 
produce  blunt  ends.  Plasmid  DNA  was  transformed  into  E.  coli  DH5a  and 
bacteria  were  spread  onto  LB-X-Gal-IPTG  agar  containing  ampicillin  and 
kanamycin.  The  seeded  plates  were  incubated  at  37°C  overnight  and  white 
colonies  were  examined  by  restriction  analysis.  A  chosen  clone  was  named  as 
plasmid  pJRMT12  for  P.  multocida  strain  85020  (Fig.  33B).  Digestion  with 
HindIlIIEcoRV  just  linearised  plasmid  pAKA19,  whereas  it  produced  two 
fragments  of  =3.0  and  =5.0  kb  for  plasmid  pJRMT12  (Fig.  32).  Then  this 
plasmid  was  transformed  into  E.  coli  SM10Xpir  by  electroporation.  Ten  single 
colonies  were  picked  from  LB  agar  containing  ampicillin  and  kanamycin  and 
the  plasmid  construct  confirmed  by  restriction  analysis. 
3.1.10.  Allelic  exchange 
The  plasmid  pJRMT12  was  transformed  to  both  P.  multocida  parent  strains 
by  transconjugation  and  electroporation.  The  treated  cells  were  plated  onto  BHI 
agar  supplemented  with  5%  (v/v)  sheep  blood  containing  streptomycin  and 
kanamycin  and  also  onto  plates  containing  kanamycin  alone.  Single  SmR-KmR 
or  KmR  colonies  were  picked,  genomic  DNA  was  prepared  and  digested  with 
Accl  and  checked  by  Southern  blot  hybridisation  (Fig.  34).  With  P.  multocida 
85020  the  cya  probe  hybridised  to  three  bands  of  =1.7,  =2.3  and  =4.0  kb,  but 
for  the  Quetta  strain  it  hybridised  to  three  bands  of  =1.3,  =3.0  and  =4.0  kb. 
The  kanamycin  resistance  probe  hybridised  to  two  or  three  bands  of  =1.7,  =3.0 
and  =4.0  kb  with  P.  multocida  85020  and  to  one  band  of  =3.0  kb  with  the Fig  32: Fig  32:  Restriction  analysis  of  plasmid  pJRMT12  (size  as  kb) 
Lane  1:  plasmid  pJRMT12  undigested 
Lane  2:  plasmid  pAKA19  undigested 
Lane  M:  supercoiled  DNA  marker 
Lane  3:  plasmid  pJRMT12  digested  with  HindIl  JEcoRV 
Lane  4:  plasmid  pAKA19  digested  with  HindIII/EcoRV 
Lane  M:  1  kb  DNA  marker Fig  33:  Map  of  plasmids  pJRMTI  1  and  pJRMT12 
A:  The  ampicillin  resistance  cassette  (ApR)  removed  from  plasmid  pAKA16 
and  cloned  into  plasmid  pACYC  184  to  create  plasmid  pJRMT  11. 
B:  The  KmR-interrupted  cya  gene  was  removed  from  plasmid  pJRMT9  and 
cloned  into  plasmid  pAKA19  to  create  plasmid  pJRMT12. A. 
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1141  uI  Eagi  nlli.  u1 Fig  34:  Southern  blot  hybridisation  of  P.  multocida  cya::  KmR  clones 
transformed  with  plasmid  pJRMT12  by  transconjugation  and 
genomic  DNA  digested  with  Accl  (size  as  kb) 
A:  Hybridisation  with  cya  probe 
B:  Hybridisation  with  KmR  probe 
Lanes  1-6:  P.  multocida  strain  85020  clones 
Lanes  7-11:  P.  multocida  strain  Quetta  clones 
Lane  12:  P.  multocida  strain  85020  wild-type Fig  34: 
A1234  5"  6/89  10  11  12 
t 
5.0 
4.0  ago  40  "., 
a  to  40  '*  ,  -ow  460  4.0 
3.0 
13 
1.7 
"r"r1.3 
B123456y,  7  89  10  11  12 
t 
f 
-1.0  40 
I  3.0 
.ý 74 
Quetta  strain.  Therefore,  again,  no  colonies  were  found  where  DNA 
hybridisation  with  the  cya  and  KmR  probes  gave  the  expected  pattern  for  allelic 
exchange  at  the  cya  locus. 
3.1.11.  Cyclic  AMP  assay 
This  was  a  functional  approach  for  confirmation  of  cya  gene  inactivation, 
by  showing  that  the  cells  cannot  produce  cAMP.  After  preparation  of  cell-free 
extracts  of  the  wild-type  and  cya  mutants,  and  Bordetella  pertussis  as  control, 
the  protein  concentration  were  measured  by  the  Lowry  procedure.  The  values 
for  P.  multocida  85020  and  Quetta  wild-type  strains  were  9.8  and  9.1  mg/  ml 
respectively,  for  the  cya  mutant  JRMT3  strain  it  was  8.3  mg/  ml  and  for  B. 
pertussis  it  was  8.2  mg/  ml.  When  cAMP  was  measured  by  EIA  (Amersham 
Kit)  on  three  different  occasions,  consistent  results  would  not  be  obtained. 
Each  time,  different  low  values  except  for  the  B.  pertussis  samples  that  did 
show  consistent  evidence  of  activity  (Table  9  and  10). 
3.1.12.  Cloning  of  galE  gene 
Forward  and  reverse  primers  were  designed  according  to  the  galE  sequence 
of  P.  multocida  strain  PM25  serotype  D:  12  (Henestrosa  et  al,  1997;  Genbank 
Accession  No.  U76617).  The  galE  genes  of  P.  multocida  85020  and  Quetta 
strains  were  amplified  by  PCR  as  1017  bp  fragments  (from  nt.  379-1396).  The 
PCR  products  were  electrophoresed  in  1.0%  (w/v)  agarose  gel  and  DNA  bands 
were  cut  out  from  gel  and  purified  by  the  Agarose  Gel  Spin  Columns  method. 
The  ligation  mixture  containing  the  galE  gene  fragment  and  pCR®2.1-TOPO 
cloning  vector,  was  transformed  into  E.  coli  TOP1OF  one  shot  competent 
cells.  Recombinant  plasmids  were  analysed  by  PCR  and  restriction  analysis 
and  were  named  as  plasmid  pJRMT13  for  P.  multocida  85020  and  pJRMT14 
for  P.  multocida  Quetta  strains  (Fig.  36).  Digestion  with  EcoRI  which  cuts  on 
each  side  of  the  cloned  insert  produced  a  1.0  kb  fragment  (galE  gene)  and  a 
vector  fragment  of  =2.5  kb  as  predicted  (Fig.  35A).  PCR  analysis  with  galE Table  9:  Adenylate  cyclase  assay  by  enzyme  immunoassay  kit 
P.  m.  85020  cell  extract  B.  pertu  ssis  cell  extract 
Incubation  untreated  boiled*  untre  ated  boiled* 
time  (min)  %B/BO  activi  t  %B/BO  activity  %B/BO  activity  %B/BO  activity 
0  88.4  40  90.0  33  75.8  180  85.0  60 
30  63.3  65  89.1  38  58.2  500  83.2  65 
60  62.5  180  87.9  45  45.6  750  80.4  80 
120  58.9  480  87.0  47  37.1  1000  78.2  85 
*  Cell  free  extract  were  heated  at  100  *C  in  water  bath  for  10  min  to  destroy  adenylate 
cyclase  activity  then  used  in  cAMP  assay  reaction  as  controls 
The  adenylate  cyclase  activity  as  fmol/well  of  samples  can  be  read  from  graph  (Fig.  14). Table  10:  Adenylate  cyclase  assay  of  P.  multocida  strains  85020,  Quetta, 
their  aroA  mutants  and  cya  mutants  by  enzyme  immunoassay  kit 
Strains  Experiment  1  Experiment  2  Experiment  3 
%B/BO  Activi  *  %B/BO  Activity  %B/BO  Activity 
P.  m.  85020  (W.  T.  )  68.9  280  66.1  380  58.3  550 
of  "  cya::  KmR  79.5  90  68.1  320  64.2  400 
c  a::  KmR  72.1  210  74.3  180  70.3  280 
of  c  a::  A  R  73.0  200  74.8  175  71.8  210 
P.  m.  JRMT1  aroA-  74.2  180  68.4  320  69.4  290 
cya::  ApR  76.1  160  71.5  210  78.0  105 
of  c  a::  A  R  73.4  200  76.0  160  69.5  290 
P.  m.  Quetta  (W.  T.  )  61.4  470  68.2  320  67.1  350 
of  "ca::  KmR  72.1  210  69.8  300  74.5  175 
to  JRMT3  (cya::  KmR)  68.6  320  73.7  200  81.0  90 
P.  m.  Quetta  c  a::  A  R  71.6  210  71.4  210  76.4  160 
P.  m.  JRMTI  aroA' 
82.1  70  69.4  290  67.8  340 
of  "ca::  A  R  78.3  105  73.1  200  70.2  280 
to  "ca::  A  R  74.8  175  74.3  175  72.5  200 
ATP+  cell  exttract 
no  incubation 
88.1  43  80.4  90  82.3  70 
ATP  +  Boiled  extract  74.2  180  75.2  170  88.5  40 
*  The  adenylate  cyclase  activity  as  fmol/well  of  samples  can  be  read  from  graph  (Fig.  14). Fig  35:  Analysis  of  plasmids  pJRMT13  and  pJRMT14  (size  as  kb) 
A:  Restriction  analysis: 
Lane  M:  1  kb  DNA  marker 
Lane  1:  plasmid  pJRMT13  digested  with  EcoRl 
Lane  2:  plasmid  pJRMT13  undigested 
Lane  3:  plasmid  pJRMT14  digested  with  EcoRl 
Lane  4:  plasmid  pJRMT14  undigested 
B:  PCR  analysis  with  GaIE  primers  (GalEI  and  GaIE2): 
Lane  1:  plasmid  pJRMT13  PCR  product 
Lane  2:  plasmid  pJRMT14  PCR  product 
Lane  3:  plasmid  pJRMT15  PCR  product 
Lane  4:  plasmid  pJRMT16  PCR  product 
Lane  5:  P.  multocida  85020 
Lane  6:  P.  multocida  Quetta 
Lane  M:  1  kb  DNA  marker Fig  35: 
A. 
B Fig  36:  Map  of  plasmids  pJRMT13  and  pJRMT14 
The  amplified  galE  genes  of  the  P.  multocida  strains  were  cloned  into 
pCR®2.1-TOPO  vector. Fig  36: 
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primers  produced  the  expected  =1.0  kb  amplimer  (galE  gene)  (Fig.  35B,  lane  1 
and  2).  Larger  bands  visible  on  the  gel  may  represent  plasmid  template  DNA. 
3.1.13.  Cloning  of  galE  gene  into  plasmid  pUC  19 
Plasmid  pUC19  has  a  ColE1  origin  of  replication  and  so  should  act  as  a 
suicide  vector  when  transformed  to  Pasteurella  strains.  The  galE  genes  were 
removed  from  plasmids  pJRMT13  and  pJRMT14  with  EcoRI  and  plasmid 
pUC19  was  digested  with  EcoRI  and  dephosphorylated.  Gel-purified  material 
was  ligated  and  transformed  into  E.  coli  DHSa  competent  cells  by 
electroporation  and  the  bacteria  plated  onto  LB-X-Gal-IPTG  agar  containing 
ampicillin.  After  incubation  for  24  hrs  at  370C,  white  colonies  were  picked  and 
recombinant  plasmids  were  confirmed  by  restriction  analysis  and  were  named 
as  plasmids  pJRMT15  and  pJRMT16  for  P.  multocida  85020  and  Quetta 
strains,  respectively  (Fig.  38A).  PvuII-digestion  of  plasmid  pUC19  produced 
two  fragments  of  =0.32  and  =2.37  kb,  but  for  plasmids  pJRMT15  and 
pJRMT16  two  fragments  of  =1.34  and  =2.37  kb  were  produced  as  predicted 
(Fig.  38A).  Digestion  with  Earl  produced  three  fragments  of  =0.39,  =0.49  and 
=1.8  kb  for  pJRMT15  and  for  pJRMT16  four  fragments  of  =0.48,  =0.49, 
=0.93  and  =1.8  kb  were  produced  (Fig.  37B,  the  two  fragments  of  =0.48  and 
=0.49  overlapped).  PCR  analysis  with  GaIE  primers  (Table  7)  amplified  the 
expected  1.0  kb  band  for  plasmid  pJRMT15  and  pJRMT16  (Fig.  35B,  lanes  3 
and  4). 
3.1.14.  Insertion  of  the  KmR  cassette  into  the  galE  gene 
The  plasmids  pJRMT15  and  pJRMT16  were  digested  with  NsiI  (at  nt.  615 
Fig.  38A)  and  dephosphorylated.  The  kanamycin  resistance  cassette  was  cut 
out  from  plasmid  pUC4K  with  Pal  (nt.  417-1657).  Digested  material  was  run 
in  a  0.8%  (w/v)  agarose  gel  and  DNA  bands  purified,  ligated  and  transformed 
into  E.  coli  DH5a  competent  cells  by  electroporation.  Recombinant  plasmids 
were  confirmed  by  restriction  analysis  and  designated  as  pJRMT17  and Fig  37:  Restriction  analysis  of  plasmids  pJRMT15  and  pJRMT16  (size  as  kb) 
A: 
Lane  M:  supercoiled  DNA  marker 
Lana  1:  plasmid  pUC  19  undigested 
Lane  2:  plasmid  pJRMT15  undigested 
Lane  3:  plasmid  pJRMT16  undigested 
Lane  M:  supercoiled  DNA  marker 
B: 
Lane  M:  1  kb  DNA  marker 
Lane  1:  plasmid  pUC  19  digested  with  PvuI1(=0.32  and  =2.37  kb  fragments) 
Lane  2:  plasmid  pUC19  digested  with  Earl  (=0.39,  =0.49  and  =1.8  kb 
fragments) 
Lane  3:  plasmid  pJRMT15  digested  with  PvuII  (=1.34  and  =2.37  kb 
fragments) 
Lane  4:  plasmid  pJRMT15  digested  with  Earl  (=0.48,  =0.49,  =0.93  and  =1.8 
kb  fragments)  (two  fragments  of  =0.48  and  =0.49  overlapped) 
Lane  5:  plasmid  pJRMT16  digested  with  PvuII  (=1.34  and  =2.37  kb 
fragments) 
Lane  6:  plasmid  pJRMT16  digested  with  Earl  (=0.48,  =0.49,  =0.93  and  =1.8 
kb  fragments) Fig  37: 
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B. Fig  38: 
A:  Map  of  plasmids  pJRMT15  and  pJRMT16 
The  galE  gene  was  removed  from  plasmid  pJRMT13  and  pJRMT14  with 
EcoRI  and  cloned  into  pUC19. 
B:  Plasmid  map  of  plasmids  pJRMT17  and  pJRMT18 
The  plasmids  pJRMT15  and  pJRMT16  were  digested  with  Nsil  and  ligated 
with  the  kanamycin  resistance  fragment  (KmR)  from  pUC4K. Fig  38: 
A. 
C 
B. 
Eca 
MM  Earl  rvuli 
Sad  EcoRI 
Xhol 76 
pJRMT18,  for  P.  multocida  85020  and  Quetta  strains  respectively  (Fig.  38B). 
As  expected  XhoI  digestion  of  plasmid  pJRMT15  and  pJRMT16  just  linearised 
them  (=3.72  kb  fragment)  but  for  pJRMT17  and  pJRMT18  two  fragments  of 
=1.3  and  =3.66  kb  were  produced  (Fig.  39B  lanes  5  and  6).  Digestion  of 
plasmids  pJRMT15  and  pJRMT16  with  Earl  produced  four  fragments  of 
=0.48,  =0.49,  =0.95  and  =1.8  kb  but  for  pJRMT17  and  pJRMT18  five 
fragments  of  X0.48,  X0.49,  =0.95,  =1.2  and  =1.8  kb  were  produced  as 
predicted  (Fig  39B;  the  two  fragments  of  =0.48  and  =0.49  overlapped). 
3.1.15.  Allelic  exchange 
The  plasmids  pJRMT17  and  pJRMT18  were  transformed  to  the  P. 
multocida  strains  for  allelic  exchange  by  electroporation  and  were  plated  onto 
BHI  agar  supplemented  with  5%  (v/v)  sheep  blood  containing  kanamycin. 
After  incubation  for  48  hrs  at  370C,  KmR  colonies  were  picked  and  patched 
onto  BHI  agar  containing  kanamycin.  After  ten  subcultures,  however,  all  the 
KmR  clones  examined  contained  plasmid  of  the  size  of  plasmid  pJRMT17 
(=4.9  kb).  PCR  analysis  of  the  KmR  clones  with  galE  primers  showed  two  or 
three  bands  as  =1.0  kb  (wild-type  galE  gene)  and  a  second  band  as  =2.2  kb 
(interrupted  galE  gene  with  KmR  cassette)  (Fig.  40). 
3.1.16.  Cloning  of  interrupted  galE  gene  into  the  vector  pAKA19 
Because  of  the  apparent  replication  of  plasmids  pJRMT17  and  pJRMT18 
(ColEl  origin)  in  P.  multocida  strains,  it  was  decided  to  use  pAKA19  as  a 
suicide  vector  because  although  it  also  had  a  ColE1-based  origin,  it  was  used 
successfully  before.  The  plasmids  pJRMT17  and  pJRMT18  were  digested  with 
EcoRI  and  the  KmR-interrupted  galE  gene  ligated  into  pAKA19  which  had 
been  digested  with  EcoRI  and  dephosphorylated.  The  ligation  mixture  was 
transformed  into  E.  coli  DH5a  competent  cells  by  electroporation  and  plated 
out  onto  LB-X-Gal-IPTG  agar  containing  ampicillin  and  also  LB  agar 
containing  ampicillin  and  kanamycin.  White  colonies  from  LB-X-Gal-IPTG Fig  39:  Analysis  of  plasmids  pJRMT17  and  pJRMT18  (size  as  kb) 
A:  Undigested  plasmid  DNA 
Lane  M:  supercoiled  DNA  marker 
Lane  1:  plasmid  pJRMT15 
Lane  2:  plasmid  pJRMT17 
Lane  3:  plasmid  pJRMT16 
Lane  4:  plasmid  pJRMT18 
Lane  M:  supercoiled  DNA  marker 
B:  Restriction  analysis 
LaneM:  1  kb  DNA  marker 
Lane  1:  plasmid  pJRMT15  digested  with  Earl  (4  fragments,  3  bands) 
Lane  2:  plasmid  pJRMT15  digested  with  XhoI  (linearised) 
Lane  3:  plasmid  pJRMT15  digested  with  BamHIIXhoI  (linearised) 
Lane  4:  plasmid  pJRMT17  digested  with  Earl  (5  fragments,  4  bands) 
Lane  5:  plasmid  pJRMT17  digested  with  Xhol  (2  fragments) 
Lane  6:  plasmid  pJRMT17  digested  with  BamHUXhoI  (2  fragments) 
Lane  7:  plasmid  pJRMT16  digested  with  Earl  (4  fragments,  3  bands) 
Lane  8:  plasmid  pJRMT16  digested  with  XhoI  (linearised) 
Lane  9:  plasmid  pJRMT16  digested  with  BamHUXhoI  (linearised) 
Lane  10:  plasmid  pJRMT18  digested  with  Earl  (5  fragments,  4  bands) 
Lane  11:  plasmid  pJRMT18  digested  with  XhoI  (2  fragments) 
Lane  12:  plasmid  pJRMT18  digested  with  BamHUXhoI  (2  fragments) 
LaneM:  1  kb  DNA  marker Fig  39: 
A. 
B. Fig  40:  PCR  analysis  of  P.  multocida  galE::  KmR  clones  transformed  with 
plasmids  pJRMT17  and  pJRMT18  (size  as  kb) 
A: 
Lanes  1-7:  transformed  clones 
Lane  8:  P.  multocida  85020 
Lane  M:  1  kb  DNA  marker 
For  all  clones  the  GalE  primers  amplified  two  bands,  of  =1.0  kb  representing 
the  wild-type  gene  and  =2.2  kb  as  the  mutated  gene. 
B: 
Lanes  1-11:  transformed  clones 
Lane  12:  P.  multocida  Quetta 
Lane  M:  1  kb  DNA  marker 
For  all  clones  the  GalE  primers  amplified  two  bands,  of  =1.0  kb  representing 
the  wild-type  gene  and  =2.2  kb  as  the  mutated  gene. Fig  40: 
A. 
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agar  or single  colonies  from  LB  agar  containing  ampicillin  and  kanamycin  were 
examined  by  restriction  analysis  and  designated  as  pJRMT19  and  pJRMT20  for 
P.  multocida  85020  and  Quetta  strains  respectivly  (Fig.  42A).  Digestion  with 
EcoRI  just  linearised  plasmid  pAKA19  whereas  it  produced  two  bands,  of  2.2 
kb  (galE  gene  interrupted  with  KmR  cassette)  and  5.0  kb  for  the  vector  for 
plasmids  pJRMT19  and  pJRMT20  (Fig.  41). 
3.1.17.  Allelic  exchange 
The  plasmids  pJRMT19  and  pJRMT20  were  transferred  to  the  P.  multocida 
strains  for  allelic  exchange  by  electroporation  and  conjugation  and  plated  onto 
BHI  agar  supplemented  with  5%  (v/v)  sheep  blood  containing  appropriate 
antibiotics.  Single  colonies  were  picked  and  patched  onto  kanamycin  plates. 
After  three  subcultures  in  the  presence  of  Km,  the  KmR  clones  were  checked 
by  PCR  but  most  of  them  showed  two  bands  representing  the  wild-type  galE 
gene  and  the  mutated  gene  with  KmR  cassette  insertion.  When  some  of  them 
were  checked  for  plasmid  replication,  as  was  found  for  the  previous  ColEl- 
based  vector,  the  plasmids  pJRMT19  and  pJRMT20  did  not  appear  to  act  as 
suicide  vectors  in  P.  multocida  strains  and  were  maintained  in  the  presence  of 
kanamycin. 
The  possibility  was  considered  that  galactose  present  in  BHI  agar 
supplemented  with  sheep  blood  could  produce  problems  for  growth  of  galE 
mutants  (see  section  1.4.6.8).  Thus  a  minimal  medium  was  prepared,  as 
Mohammad  Tabatabaei  (MT)  minimal  medium  (Appendix  5.15).  This  was  a 
modification  of  the  PMM  medium  (Appendix  5.10).  After  electroporation,  0.5 
ml  of  MT  minimal  medium  was  added  and  the  transformed  cells  incubated  for 
recovery.  After  4  hrs  100  µl  aliquots  were  spread  on  MT  minimal  agar 
containing  kanamycin  and  incubated  at  37"C  for  48  hrs.  Some  single  colonies 
were  grown,  but  when  checked  by  PCR  they  showed  the  same  pattern  as 
above. Fig  41:  Restriction  analysis  of  plasmids  pJRMT19  and  pJRMT20  (size  as  kb) 
A: 
Lanes  1-2:  plasmid  pJRMT19  digested  with  EcoRI  (=2.2  and  =5.0  kb 
fragments) 
Lanes  3-4:  plasmid  pJRMT20  digested  with  EcoRI  (=2.2  and  =5.0  kb 
fragments) 
Lane  5:  plasmid  pAKA19  digested  with  EcoRI  (linearised 
plasmid  DNA) 
Lane  M:  1  kb  DNA  marker 
B:  Undigested  plasmid  DNA 
Lanes  1-2:  plasmid  pJRMT19 
Lanes  3-4:  plasmid  pJRMT20 
Lane  5:  plasmid  pPAKA19 
Lane  M:  supercoiled  DNA  marker Fig  41: 
A. 
B. Fig  42: 
A:  Map  of  plasmids  pJRMT19  and  pJRMT20 
The  KmR-interrupted  galE  genes  were  cut  out  from  plasmid  pJRMT17  and 
pJRMT18  with  EcoRI  and  cloned  into  pAKA19  which  had  been  digested  with 
EcoRI  and  dephosphorylated 
. 
B:  Map  of  plasmids  pJRMT21  and  pJRMT22 
The  ampicillin  resistance  cassette  was  cut  out  with  ScaUSacII  from  plasmid 
pJRMT11  and  cloned  into  pJRMT7  and  pJRMT8  which  had  been  digested 
with  Hpal  and  dephosphorylated 
. Fig  42: 
A. 
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3.2.  Construction  of  double  mutants  (aroA::  kmRandcya::  ApR) 
The  data  of  Homchampa  et  al.  (1992)  indicated  that  strains  with  a  single 
attenuating  mutation  may  be  too  virulent  at  high  doses  to  confer  protection  in  a 
single  dose,  but  they  suggested  that  introduction  of  a  second  attenuating 
mutation  may  overcome  this  problem.  This  assumption  was  examined  in  mouse 
experiments  reported  later  (Section  3.5). 
Double  mutants  were  constructed  by  using  the  aroA::  KmR  (or  aroA 
deletion)  (Section  3.3.1)  strain  as  recipient  and  plasmid  containing  cya::  ApR 
(or  cya  deletion)  (Section  3.3.3).  Selection  of  inheritance  of  ApR  by  the 
recipient  will  indicate  exchange  of  the  cya::  ApR  sequence  with  the  cya  sequence 
in  chromosome.  For  the  deletion  derivatives,  initial  selection  used  the  resistance 
marker  encoded  by  the  plasmid. 
3.2.1.  Mutation  of  cya  gene  by  insertion  of  an  ApR  cassette 
For  construction  of  a  double  mutant  derived  from  aroA::  KmR  strain,  it  was 
necessary  to  use  the  cya  gene  interrupted  by  a  sequence  encoding  resistance  to 
an  antibiotic  other  than  kanamycin. 
3.2.1.1.  Cloning  of  ampicillin  resistance  cassette 
The  ampicillin  resistance  cassette  was  cut  out  with  Apall/Scal  from  plasmid 
pAKA16  as  a  1416  bp  (from  nt.  1865-3330)  fragment,  blunted  by  Klenow 
enzyme  and  cloned  into  PvuIIJScaI  digested  and  dephosphorylated  pACYC  184 
(919  bp  removed  from  nt.  3850-515)  (Table  4).  This  recombinant  plasmid  was 
confirmed  by  restriction  analysis  and  named  as  plasmid  pJRMT11  (Fig.  33A). 
Digestion  of  plasmid  pACYC  184  with  Scal/Sacl1  produced  two  fragments  of 
=0.9  and  =3.0  kb  as  predicted  whereas  plasmid  pJRMT11  produced  two 
fragments  of  =1.7  and  =3.0  kb  (Fig.  43). Fig  43:  Restriction  analysis  of  plasmid  pJRMT11  (size  as  kb) 
Lane  M:  1kb  DNA  marker 
Lane  1:  plasmid  pJRMT11  digested  with  ScaUSacH 
Lane  2:  plasmid  pACYC  184  digested  with  ScaUSacII 
Lane  3:  plasmid  pJRMT11  undigested 
Lane  4:  plasmid  pACYC  184  undigested 
Lane  M:  supercoiled  DNA  marker Fig  43 79 
3.2.1.2.  Insertion  of  ApR  cassette  into  the  cya  gene 
The  plasmids  pJRMT7  and  pJRMT8  were  digested  with  Hpal  and  the  1168 
bp  middle  fragment  (from  nt.  690-1857)  of  the  cya  gene  removed,  run  in  a 
0.7%  (w/v)  agarose  gel  and  the  larger  fragments  purified  as  vector.  The 
ampicillin  resistance  cassette  was  removed  as  a  1734  bp  fragment  with 
ScaI/SacII  from  plasmid  pJRMT1  1,  treated  with  Klenow  enzyme  and  ligated 
with  HpaI  vector  fragments  of  pJRMT7  and  pJRMT8.  The  E.  coli  XL1  Blue 
competent  cells  were  transformed  by  electroporation  and  the  bacteria  spread 
onto  LB  agar  containing  chloramphenicol  and  ampicillin.  The  recombinant 
plasmids  were  confirmed  by  restriction  analysis  and  were  named  plasmid 
pJRMT21  and  pJRMT22  for  P.  multocida  85020  and  Quetta  strains 
respectively.  Treatment  of  plasmids  pJRMT21  and  pJRMT22  with  HpaI  had  no 
effect  (not  shown)  whereas  for  plasmids  pJRMT7  and  pJRMT8,  two  fragments 
of  =1.17  and  =4.7  or  =1.17  and  =4.4  kb  respectively,  were  produced  (Fig. 
44).  The  sequence  of  the  ApR  cassette  was  unknown,  thus  plasmids  pJRMT21 
and  pJRMT22  were  not  digested  with  BamHUSacII. 
3.2.1.3.  Allelic  exchange 
The  plasmids  pJRMT21  and  pJRMT22  were  transformed  to  parent  P. 
multocida  strains  85020  and  Quetta  and  aroA  mutant  strains  JRMT1  and 
JRMT2  for  allelic  exchange  by  electroporation  and  plated  onto  BHI  agar 
supplemented  with  5%  (v/v)  sheep  blood  containing  appropriate  antibiotics. 
Selection  was  made  for  ApR  for  P.  multocida  85020  and  Quetta  strains  and 
ApR-KmR  for  P.  multocida  JRMT1  and  JRMT2  strains.  Potential  mutants 
were  checked  by  Southern  blot  hybridisation  and  designated  as  P.  multocida 
JRMT4  and  JRMT5  from  P.  multocida  strains  85020  and  Quetta,  respectively, 
and  P.  multocida  JRMT6  and  JRMT7  from  P.  multocida  JRMT1  and  JRMT2 
strains,  respectively.  The  genomic  DNA  of  P.  multocida  double  mutants  and 
single  ApR  mutants  were  digested  with  AccI  and  hybridised  with  cya  and Fig  44:  Restriction  analysis  of  plasmids  pJRMT21  and  pJRMT22  (size  as  kb) 
Lane  1:  plasmid  pJRMT9  digested  with  Hpal 
Lane  2:  plasmid  pJRMT10  digested  with  HpaI 
Lane  3:  plasmid  pJRMT7  digested  with  HpaI 
Lane  4:  plasmid  pJRMT8  digested  with  HpaI 
Lane  5:  plasmid  pJRMT9  digested  with  BamHI/SacII 
Lane  6:  plasmid  pJRMT10  digested  with  BamHUSacII 
Lane  M:  1  kb  DNA  marker Fig  44: 80 
ampicillin  resistance  (ApR)  probes.  The  cya  probe  hybridised  to  two  bands  of 
=2.6  and  =6.0  for  the  parent  strains  JRMT1  and  JRMT2  and  most  of  the 
putative  double  mutants  (e.  g.  JRMT6  and  JRMT7),  except  for  one  clone  which 
showed  hybridisation  to  three  bands  of  =2.6,  =6.0  and  =8.0  kb  (Fig.  45).  The 
ApR  probe  did  not  hybridise  to  any  band  for  the  parent  JRMT1  and  JRMT2 
strains,  but  for  the  double  mutants  of  JRMT1  (e.  g.  JRMT6)  it  hybridised  to 
two  bands  as  with  the  cya  probe.  Two  bands  were  also  obtained  for  the  double 
mutants  of  JRMT2  (e.  g.  JRMT7)  at  =6.5  and  =8.0  or  =2.6  kb  (Fig.  45).  The 
cya  probe  with  Quetta  ApR  (JRMT5  strains)  hybridised  to  3-4  bands  of  =2.6, 
=3.0,  =6.0  and  =7.0  kb  (Fig.  46,  lanes  1-5)  and  two  bands  of  =2.6  and  =6.0 
kb  for  the  Quetta  parent  strain  (Fig.  46,  lane  6).  It  hybridised  to  three  bands  for 
strain  85020  ApR  (JRMT4)  (Fig.  46,  lane  7).  The  ApR  probe  did  not  hybridise 
to  any  bands  for  the  parent  strains  and  hybridised  to  two  or  three  bands  of 
=2.6,  =5.5  and  =7.0  kb  for  the  ApR  mutants  (e.  g.  JRMT4  and  JRMT5).  When 
plasmids  pJRMT21  and  pJRMT22  were  digested  with  Accl,  they  hybridised  to 
two  fragments  (data  not  shown),  and  this  indicated  that  at  least  one  Accl  site  is 
present  in  the  ApR  cassette.  Thus  the  ApR  probe  for  transformed  cells  should 
have  hybridised  to  two  band,  but  at  different  sizes  to  those  in  the  wild-type. 
However,  in  these  cells  they  hybridised  to  more  than  two  bands  with  ApR  or 
cya  probes. 
3.3.  Construction  of  marker-free  mutants 
For  use  as  vaccine  strains,  attenuated  mutants  should  not  carry  antibiotic 
resistance  markers.  To  select  such  mutants,  the  first  step  (first  crossing-over) 
involved  selection  for  the  antibiotic  resistance  marker  that  was  carried  by  the 
vector  and  then,  in  the  second  step,  either  selection  can  be  made  against  the 
vector  (second  crossing-over)  or  loss  of  the  vector  may  be  anticipated  on 
repeated  subculture. Fig  45:  Southern  blot  hybridisation  of  P.  multocida  double  mutant  strains 
(size  as  kb) 
A:  Hybridisation  with  cya  probe 
B:  Hybridisation  with  ApR  probe 
Lanes  1-7:  P.  multocida  JRMT6  aroA::  KmR,  cya::  ApR 
Lane  8:  P.  multocida  JRMT1  aroA::  KmR 
Lanes  9-11:  P.  multocida  JRMT7  aroA::  KmR,  cya::  ApR 
Lane  12:  P.  multocida  JRMT2  aroA::  KmR Fig  45: 
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P`  yý  1ý Fig  46:  Southern  blot  hybridisation  of  P.  multocida  cya::  ApR  mutant  strains 
transformed  with  plasmids  pJRMT21  and  pJRMT22  (size  as  kb) 
A:  Hybridisation  with  cya  probe 
B:  Hybridisation  with  ampicillin  probe 
Lanes  1-5:  P.  multocida  JRMT5  (Quetta)  cya::  ApR 
Lane  6:  P.  multocida  Quetta 
Lane  7:  P.  multocida  JRMT4  (85020)  cya::  ApR 
Lane  8:  p.  multocida  85020 Fig  46: 
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3.3.1.  Construction  of  marker-free  aroA  mutants 
3.3.1.1.  Construction  of  deleted  aroA  gene  (621  bp  deletion) 
The  plasmids  pJRMT1  and  pJRMT2  were  digested  with  NdeIJSacII  (See 
Fig.  17)  and  a  621  bp  middle  section  of  the  aroA  gene  (from  nt.  459-1080) 
removed.  The  remaining  portion  was  "polished"  by  T4  DNA  polymerase,  run 
in  a  0.7%  (w/v)  agarose  gel  and  the  fragments  (=4.4  kb)  purified  from  the  gel, 
self  ligated  and  transformed  into  E.  coli  DH5ct  competent  cells  by 
electroporation.  ApR-KmR  clones  were  selected  on  LB  agar  containing 
ampicillin  and  kanamycin.  Recombinant  plasmids  were  named  pJRMT23  for  P. 
multocida  85020  and  pJRMT24  for  P.  multocida  Quetta  strains  respectively 
(Fig.  48A)  and  confirmed  by  PCR  and  restriction  analysis  (Fig.  47).  As 
expected,  BgII  digestion  of  plasmids  pJRMT1  and  pJRMT2  produced  three 
fragments  of  z0.8,  =1.3  and  =3.0  kb  (Fig.  17)  while  for  plasmids  pJRMT23 
and  pJRMT24  it  produced  two  fragments  of  =1.3  and  =3.0  kb  (Fig.  47A). 
Digestion  of  plasmids  pJRMT1  and  pJRMT2  with  EcoRV  produced  linearised 
DNA  of  =5.1  kb  (see  Fig.  17)  whereas  it  had  no  affect  on  plasmids  pJRMT23 
and  pJRMT24  (Fig.  47A),  because  the  EcoRV  site  had  been  removed.  Also, 
Ndel/SacII  digestion  of  plasmids  pJRMT1  and  pJRMT2  produced  two 
fragments  of  =0.63  and  =4.4  kb  (see  Fig.  17)  but  had  no  affect  on  plasmids 
pJRMT23  and  pJRMT24  (Fig.  47A)  because  these  sites  had  also  been 
removed.  PCR  analysis  of  plasmids  pJRMTI  and  pJRMT2  with  AroA  primers 
amplified  a  =1.2  kb  fragment  from  the  native  aroA  gene  whereas  only  a  =0.6 
kb  fragment  was  amplified  for  plasmids  pJRMT23  and  pJRMT24,  as  predicted 
(Fig.  47B).  The  larger  sized  bands  in  Fig.  47B  are  probably  plasmid  template 
DNA. 
3.3.1.2.  Allelic  exchange 
The  plasmids  pJRMT23  and  pJRMT24  were  transformed  into  P.  multocida 
strains  by  electroporation  and  plated  out  onto  BHI  agar  supplemented  with  5% Fig  47:  Analysis  of  plasmids  pJRMT23  and  pJRMT24  (size  as  kb) 
A:  Restriction  analysis: 
Lane  1:  1  kb  DNA  marker 
Lane  2:  plasmid  pJRMT23  digested  with  Bg1I  (1.3  and  3.0  kb) 
Lane  3:  plasmid  pJRMT23  digested  with  EcoRV  (non-affected) 
Lane  4:  plasmid  pJRMT23  digested  with  NdeI/SacII  (non-affected) 
Lane  5:  plasmid  pJRMT23  undigested 
Lane  6:  plasmid  pJRMT24  digested  with  Bg1I  (1.3  and  3.0  kb) 
Lane  7:  plasmid  pJRMT24  digested  with  EcoRV  (non-affected) 
Lane  8:  plasmid  pJRMT24  digested  with  NdeI/SacII  (non-affected) 
Lane  9:  plasmid  pJRMT24  undigested 
Lane  10:  1  kb  DNA  marker 
Lane  11:  plasmid  pJRMTI  digested  with  Bg1I  (0.8,1.3  and  3.0  kb) 
Lane  12:  plasmid  pJRMT1  digested  with  EcoRV  (linearised) 
Lane  13:  plasmid  pJRMTI  digested  with  NdeIJSacII  (0.6  and  4.3  kb) 
Lane  14:  plasmid  pJRMTI  undigested 
Lane  15:  supercoiled  DNA  marker 
B:  PCR  analysis  with  AroA  primers  (AroAI  and  AroA2) 
Lane  M:  1  kb  DNA  marker 
Lane  1:  plasmid  pJRMT1 
Lanes  2-8:  plasmid  pJRMT23  (different  clones) 
Lane  9:  plasmid  pJRMT2 
Lanes  10-12:  plasmid  pJRMT24  (different  clones) Fig  47 
A. 
B. Fig  48: 
A:  Maps  of  plasmids  pJRMT23  and  pJRMT24 
The  plasmids  pJRMT1  and  pJRMT2  were  digested  with  NdeUSacII  to  remove 
a  621  bp  section  of  the  aroA  gene  and  the  plasmid  DNA  self-ligated  as 
plasmids  pJRMT23  and  pJRMT24. 
B:  Maps  of  plasmids  pJRMT25  and  pJRMT26 
The  plasmid  pJRMT1  and  pJRMT2  were  digested  with  AflIIUNsiI  to  remove  a 
142  bp  section  of  the  aroA  gene  and  the  plasmids  DNA  self  ligated. Fig  48: 
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(v/v)  sheep  blood  containing  kanamycin.  After  incubation  for  48  hrs  at  37  C, 
single  KmR  colonies  were  patched  onto  BHI  agar  supplemented  with  5%  (v/v) 
sheep  blood  without  any  antibiotic.  After  incubation,  this  procedure  was 
repeated  until  some  KmS  clones  were  found.  Some  KmS  clones  were 
inoculated  into  BHI  broth  and  genomic  DNA  prepared  for  PCR  with  aroA 
primers.  Some  clones  showed  two  bands,  one  of  wild-type  gene  size  and  the 
other  the  size  of  the  mutated  gene  (Fig.  49  &  50). 
In  another  experiment,  the  procedure  outlined  by  Homchampa  et  al.  (1997) 
consisting  of  a  combination  of  repeated  subculturing  and  auxotrophic 
enrichment  was  evaluated.  However,  after  passage  in  this  way,  when  selected 
clones  were  checked  by  PCR,  all  of  them  showed  the  wild-type  pattern. 
3.3.1.3.  Construction  of  an  alternative  deleted  aroA  gene  (142  bp  deletion) 
It  was  not  clear  why  the  KmS  clones  above  showed  both  native  and  deleted 
aroA  amplimers.  For  this  reason  a  smaller  deletion  was  engineered  which 
would  leave  longer  flanking  regions  of  the  aroA  gene  for  recombination  with 
the  native  gene.  For  this  purpose,  plasmids  pJRMT1  and  pJRMT2  were 
digested  with  Af1II  (at  nt.  938)  and  SacII  (at  nt.  1080)  and  a  142  bp  middle 
fragment  of  the  aroA  gene  removed  (Fig.  17).  The  digested  material  was  made 
blunt  ended,  religated  and  transformed  into  E.  coli  DH5a.  Recombinant 
plasmids  were  analysed  by  PCR  and  restriction  analysis  and  they  were 
designated  pJRMT25  for  P.  multocida  85020  and  pJRMT26  for  P.  multocida 
Quetta  strains  respectively  (Fig.  48B).  As  expected  Earl  digestion  of  plasmid 
pJRMTI  and  pJRMT2  produced  five  fragments  of  =0.63,  =0.64,  =1.07, 
1.26  and  =1.42  whereas  four  fragments  of  =0.64,  =1.26,  =1.42  and  =1.55 
kb  were  produced  for  plasmids  pJRMT25  and  pJRMT26  because  one  Earl  site 
had  been  removed  from  middle  part  of  aroA  gene.  Digestion  with  ApaLI 
produced  two  fragments  of  =2.1  and  =2.9  kb  for  plasmids  pJRMT1  and 
pJRMT2  whereas  for  plasmids  pJRMT25  and  pJRMT26,  it  produced  two Fig  49:  PCR  analysis  with  AroA  primers  of  P.  multocida  85020  clones 
transformed  with  plasmid  pJRMT23  (size  as  kb) 
A: 
Lanes  1-7:  transformed  clones 
Lane  8:  P.  multocida  85020 
Lane  9:  negative  control 
Lane  M:  1  kb  DNA  marker 
B: 
Transformed  clones  after  10  subcultures: 
Left: 
Lanes  1-3:  transformed  clones 
Lane  4:  P.  multocida  85020 
Lane  5:  negative  control 
Lane  M:  1  kb  DNA  marker 
Right: 
Lane  M:  1  kb  DNA  marker 
Lanes  1-2:  transformed  clones 
Lane  3:  P.  multocida  85020 
Lane  4:  negative  control Fig  49: 
A. 
B. Fig  50:  PCR  analysis  with  AroA  primers  of  P.  multocida  Quetta  clones 
transformed  with  plasmid  pJRMT24  (size  as  kb) 
A: 
Lanes  1-7:  transformed  clones 
Lane  8:  P.  multocida  Quetta  (wild-type) 
Lane  9:  negative  control 
Lane  M:  1  kb  DNA  marker 
B:  Transformed  clones  after  10  subcultures 
Lanes  1-3:  transformed  clones 
Lane  4:  P.  multocida  Quetta  (wild-type) 
Lane  5:  negative  control 
Lane  M:  1  kb  DNA  marker Fig  50: 
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fragments  of  =2.1  and  =2.75  kb  (Fig.  51A).  PCR  analysis  of  plasmid  DNA 
with  aroA  primers  amplified  bands  of  1.2  kb  for  plasmids  pJRMT1  and 
pJRMT2  whereas  bands  of  1.05  kb  were  amplified  for  plasmids  pJRMT25  and 
pJRMT26,  as  predicted  (Fig.  51B). 
3.3.1.4.  Allelic  exchange 
The  plasmids  pJRMT25  and  pJRMT26  were  transformed  into  P.  multocida 
strains  by  electroporation  and  KmR-ApR  clones  selected.  After  PCR  analysis 
with  aroA  primers,  a  few  clones  showed  two  bands,  one  of  the  wild-type  gene 
size  and  the  other  the  size  of  the  mutated  gene  (Fig.  52)  and  these  were 
subcultured  into  BHI  broth  without  any  antibiotic  for  induction  of  a  second 
crossing-over  event.  After  ten  subcultures  some  clones  were  checked  by  PCR, 
but  all  of  them  showed  the  wild-type  gene  pattern. 
The  last  two  experiments  for  construction  of  marker-free  aroA  mutants  were 
found  to  be  unsuccessful  by  the  procedures  used. 
3.3.2.  Construction  of  marker-free  galE  mutants 
In  further  experiments  to  construct  marker-free  mutants  for  use  in  double 
mutation  constructs,  it  was  decided  to  construct  deleted  galE  mutants  without 
any  antibiotic  marker. 
3.3.2.1.  Construction  of  deleted  galE  gene  (250  bp  deletion) 
The  plasmids  pJRMT15  and  pJRMT16  were  digested  with  NsiUEcoRV  to 
remove  a  250  bp  middle  part  of  the  galE  gene  (from  nt.  615-865;  Fig.  38A), 
and  self  ligated  as  pJRMT41  and  pJRMT42  for  P.  multocida  85020  and  Quetta 
galE  gene  respectively  (Fig.  54).  The  recombinants  were  confirmed  with 
restriction  analysis  and  PCR.  PCR  analysis  with  GalE  primers  of  plasmids 
pJRMT15  and  pJRMT16  amplified  a  =1.0  kb  fragment  whereas  a  =0.75  kb 
fragment  was  amplified  for  plasmids  pJRMT41  and  pJRMT42  (Fig.  53B  left). 
When  digested  with  EcoRI,  that  cuts  at  both  ends  of  the  galE  gene  inserted  into Fig  51:  Analysis  of  plasmids  pJRMT25  and  pJRMT26  (size  as  kb) 
A:  Restriction  analysis 
Lanes  1-2:  plasmid  pJRMT25  digested  with  Earl 
Lane  3:  plasmid  pJRMT1  digested  with  Earl 
Lanes  4-5:  plasmid  pJRMT26  digested  with  Earl 
Lane  6:  plasmid  pJRMT2  digested  with  Earl 
Lane  M:  1  kb  DNA  marker 
Lanes  7-8:  plasmid  pJRMT25  digested  with  ApaLI 
Lane  9:  plasmid  pJRMT1  digested  with  ApaLI 
Lanes  10-11:  plasmid  pJRMT25  digested  with  ApaLI 
Lane  12:  plasmid  pJRMT2  digested  with  ApaLI 
Lane  M:  1  kb  DNA  marker 
B:  PCR  analysis  with  AroA  primers 
Lane  1:  plasmid  pJRMT1 
Lane  2:  plasmid  pJRMT25 
Lane  3:  plasmid  pJRMT2 
Lane  4:  plasmid  pJRMT26 
Lane  M:  1  kb  DNA  marker Fig  51: 
A. 
B. Fig  52:  PCR  analysis  with  aroA  primers  of  P.  multocida  85020  clones 
transformed  with  plasmid  pJRMT25  (size  as  kb) 
A: 
Lanes  1-10:  transformed  clones 
Lane  11:  P.  multocida  85020  (wild-type) 
Lane  12:  negative  control 
Lane  M:  1  kb  DNA  marker 
B: 
Lanes  1-8:  transformed  clones 
Lane  9:  P.  multocida  85020  (wild-type) 
Lane  10:  P.  multocida  JRMT1(positive  control) 
Lane  11:  negative  control 
Lane  M:  1  kb  DNA  marker Fig  52: 
A. 
B. Fig  53:  Analysis  of  plasmids  pJRMT41  and  pJRMT42  (size  as  kb) 
A:  Undigested  plasmid  DNA 
Lanes  1-5:  plasmid  pJRMT41  (different  clones) 
Lane  6:  plasmid  pJRMT15 
Lanes  7-  10:  plasmid  pJRMT42  (different  clones) 
Lane  11:  plasmid  pJRMT16 
Lane  M:  supercoiled  DNA  marker 
B: 
Left:  PCR  analysis  with  galE  primers 
Lane  1:  plasmid  pJRMT15 
Lane  2:  plasmid  pJRMT41 
Lane  3:  plasmid  pJRMT16 
Lane  4:  plasmid  pJRMT42 
Lane  M:  1  kb  DNA  marker 
Right: 
Lanes  1-2:  plasmid  pJRMT41  digested  with  EcoRI  (different  clones) 
Lane  3:  plasmid  pJRMT15  digested  with  EcoRl 
Lane  4:  plasmid  pJRMT42  digested  with  EcoRI 
Lane  5:  plasmid  pJRMT16  digested  with  EcoRI 
Lane  M:  1  kb  DNA  marker Fig  53: 
A. 
B. Fig  54:  The  map  of  plasmids  pJRMT41  and  pJRMT42 
The  plasmids  pJRMT15  and  pJRMT16  (see  Fig.  38)  were  digested  with 
NsiI/EcoRV  to  remove  a  250  bp  middle  part  of  the  galE  gene. Fig  54: 
B 
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suicide  vector  pUC19,  two  fragments  of  =1.0  and  =2.7  kb  were  produced  for 
plasmids  pJRMT15  and  pJRMT16  but  for  plasmids  pJRMT41  and  pJRMT42 
two  fragments  of  -0.75  and  =2.7  kb  were  produced  (Fig.  53B  right). 
The  plasmids  pJRMT41  and  pJRMT42  were  transformed  into  P.  multocida 
85020  and  Quetta  strains  by  electroporation  and  bacteria  plated  on  to  BHI  agar 
supplemented  with  5%  (v/v)  sheep  blood  containing  ampicillin.  ApR  clones 
were  picked  and  subcultured  five  times  without  any  antibiotic.  Some  ApS 
clones  were  obtained  but,  by  PCR  analysis,  none  of  them  showed  mutated 
bands. 
3.3.2.2.  Construction  of  deleted  galE  gene  (98  bp  deletion) 
Because  of  unsuccessful  results  in  the  last  experiment,  it  was  again  decided 
to  increase  the  size  of  the  flanking  regions,  by  deleting  a  small  fragment  of  the 
galE  gene. 
The  plasmids  pJRMT15  and  pJRMT16  were  digested  with  EcoRV  and 
BsmI  (at  55  'C  for  8  hrs)  to  remove  a  98  bp  middle  part  of  galE  gene  (from  nt. 
865-963)  (Fig.  38A)  and  self-ligated  as  plasmids  pJRMT27  and  pJRMT28. 
The  recombinants  were  confirmed  with  restriction  analysis  and  PCR. 
Restriction  analysis  of  plasmids  pJRMT15  and  pJRMT16  with  EcoRI  produced 
two  fragments  of  =  1.0  and  =2.7  kb  while  for  plasmids  pJRMT27  and 
pJRMT28  two  fragments  of  =0.9  and  =2.7  kb  were  produced  (Fig.  55A). 
Also,  PCR  analysis  of  plasmid  DNA  with  the  GaIE  primers  amplified 
fragments  at  predicted  size,  =1.0  and  =0.9  kb  for  plasmids  pJRMT15, 
pJRMT16  and  plasmids  pJRMT27and  pJRMT28  respectively  (Fig.  55B). 
The  plasmids  pJRMT27  and  pJRMT28  were  transformed  into  P.  multocida 
85020  and  Quetta  strains  by  electroporation  and  plated  out  on  to  BHI  agar 
supplemented  with  5%  (v/v)  sheep  blood  containing  ampicillin.  ApR  clones 
were  picked  and  checked  by  PCR  but  none  of  them  showed  mutated  bands. Fig  55:  Analysis  of  plasmids  pJRMT27  and  pJRMT28  (size  as  kb) 
A:  Restriction  analysis  digestion  with  EcoRI 
Lane  1:  plasmid  pJRMT27 
Lane  2:  plasmid  pJRMT15 
Lanes  3-4:  plasmid  pJRMT28  (different  clones) 
Lane  5:  plasmid  pJRMT16 
Lane  M:  1  kb  DNA  marker 
B:  PCR  analysis  with  GalE  primers 
Lane  1:  plasmid  pJRMT27 
Lane  2:  plasmid  pJRMT15 
Lane  3:  plasmid  pJRMT28 
Lane  4:  plasmid  pJRMT16 
Lane  M:  1  kb  DNA  marker Fig  55: 
A. 
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Also  when  checked  for  the  presence  of  plasmid,  most  of  the  clones  showed  that 
plasmids  pJRMT27  and  pJRMT28  could  replicate  in  P.  multocida  strains.  In  a 
final  attempt,  the  plasmid  pAKA19  was  tried  as  a  suicide  vector.  To  obtain 
suitable  restriction  sites,  the  deleted  galE  genes  were  amplified  as  a  =0.9  kb 
fragment  by  PCR  with  the  GalE  primers,  using  plasmid  DNA  pJRMT27  and 
pJRMT28  as  templates.  The  purified  fragments  from  agarose  gel  were  cloned 
into  the  pCR®2.1-TOPO  cloning  vector  and  transformed  into  E.  coli  DH5a 
competent  cells.  Recombinant  plasmids  were  confirmed  by  restriction  analysis 
(results  not  shown)  and  were  named  plasmids  pJRMT35  and  pJRMT36  for  P. 
multocida  85020  and  Quetta  respectively  (Fig.  56A). 
3.3.2.3.  Cloning  of  deleted  galE  fragment  into  the  vector  pAKA  19 
The  galE  fragments  were  removed  from  plasmid  pJRMT35  and  pJRMT36 
by  EcoRI  digestion  and  cloned  into  EcoRI-digested  and  dephosphorylated 
pAKA19  and  transformed  into  E.  coli  DH5a  competent  cells.  Recombinant 
plasmids  were  confirmed  by  restriction  analysis  (results  not  shown)  and 
designated  as  plasmids  pJRMT37  and  pJRMT38  for  P.  multocida  85020  and 
Quetta  strains  respectively  (Fig.  56B). 
The  plasmids  pJRMT37  and  pJRMT38  were  transformed  into  P.  multocida 
85020  and  Quetta  strains  by  both  electroporation  and  conjugation  and  bacteria 
plated  onto  BHI  agar  supplemented  with  5%  (v/v)  sheep  blood  containing 
appropriate  antibiotics.  ApR  clones  (for  transformants)  or  ApR-SmR  clones 
(for  transconjugants)  were  analysed  by  PCR.  Some  of  them  showed  some 
differentiation  from  the  wild-type,  but,  for  these  transformed  cells,  the  PCR 
product  with  GaIE  primers  was  bigger  than  the  wild-type  size  (Fig.  57A).  This 
was  not  to  be  expected  from  the  deleted  galE  gene  transformed  into  these  cells. 
When  the  PCR  products  were  digested  with  ApaLI  restriction  enzyme  (the 
ApaLI  site  of  galE  gene  was  removed  by  digestion  with  EcoRV/Bsml)  the 
wild-type  showed  two  bands  around  0.5  kb  and  some  of  the  transformed Fig  56: 
A:  Map  of  plasmids  pJRMT35  and  pJRMT36 
The  deleted  galE  gene  (98  bp  removed)  was  amplified  by  PCR  and  cloned  into 
plasmid  pCR®2.1-TOPO  vector. 
B:  The  map  of  plasmids  pJRMT37  and  pJRMT38 
The  deleted  galE  gene  was  cut  from  plasmids  pJRMT35  and  pJRMT36  with 
EcoRI  and  cloned  into  plasmid  pAKA19  which  had  been  digested  with  EcoRI 
and  dephosphorylated. Fig 
A. 
B. 
CL. 
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Taql  W'ý Fig  57:  PCR  analysis  of  P.  multocida  strains  transformed  with  plasmids 
pJRMT37  and  pJRMT38  (size  as  kb) 
A:  PCR  product  with  GaIE  primers 
Lanes  1-5:  P.  multocida  85020  clones  transformed  with  plasmid  pJRMT37 
Lanes  6-10:  P.  multocida  Quetta  clones  transformed  with  plasmid  pJRMT38 
Lane  11:  P.  multocida  85020  (wild-type) 
Lane  M:  1  kb  DNA  marker 
B:  The  above  PCR  products  after  digestion  with  ApaLI. 
C:  The  above  PCR  products  after  digestion  with  ApaLI,  but  run  for  a  longer 
time. Fig  57: 
A. 
B. 
C. 86 
clones  showed  one  band  but  others  showed  two  bands  but  with  different  sizes 
compared  to  the  wild-type  gene  size  (Fig.  57  B,  Q. 
Compared  to  pasteurella  minimal  medium  (PMM),  the  wild-type  bacteria 
grew  better  in  MT  minimal  medium  (Appendix  5.15).  When  P.  multocida 
strains  85020  and  Quetta  were  inoculated  into  PMM  and  MT  minimal  medium, 
after  incubation  for  24  hrs,  the  OD540nm  in  PMM  was  0.9  and  1.01  whereas 
in  MT  minimal  medium  the  valus  were  1.3  and  1.8  respectively.  Also,  the 
wild-type  bacteria  grew  better  on  MT  minimal  agar  containing  glucose  (0.2% 
w/v)  and  sucrose  (0.2%  w/v)  than  PMM  agar.  When  the  transformed  clones 
were  inoculated  into  MT  minimal  medium  with  glucose  and  sucrose  as  carbon 
source,  all  were  grown  in  similar  values  as  wild-type  parent  strain.  But,  in  MT 
minimal  medium  containing  0.4%  (w/v)  galactose  in  place  of  glucose  and 
sucrose  as  sole  carbon  source,  they  did  not  grow,  whereas  wild-type  did  grow 
(Fig.  58).  These  results  therefore  indicated  that  the  allelic  exchange  with 
pAKA19  was  successful  in  creating  putative  galE  deletion  derivatives  of  the  P. 
multocida  strain  85020.  Similar  results  were  obtained  for  strain  Quetta. 
However,  after  five  subcultures,  when  checked  by  PCR  analysis  with  GalE 
primers,  all  clones  showed  the  wild-type  pattern  and  were  able  to  grow  in  MT 
medium  just  like  the  wild-type  strains. 
3.3.3.  Construction  of  marker-free  cya  mutants 
In  further  work  required  for  the  construction  of  double  mutants,  attempts 
were  made  to  create  a  deleted  cya  derivative  by  removing  the  middle  fragment 
of  cya  gene. 
3.3.3.1.  Construction  of  deleted  cya  mutants 
The  plasmids  pJRMT7  and  pJRMT8  were  digested  with  HpaI  and  a  1168  bp 
middle  fragment  (from  nt.  690-1857)  of  the  cya  gene  removed  (see  Fig.  25). 
The  purified  DNA  fragments  were  self  ligated  and  transformed  into  E.  coli 
XL1Bue  competent  cells  by  electroporation  and  plated  onto  LB  agar  containing Fig  58:  Growth  of  P.  multocida  clones  transformed  with  plasmid  pJRMT37  in 
MT  minimal  medium  containing  0.4%  (w/v)  galactose  as  sole  carbon 
source. 
Lanes  1-10:  different  clones  (galE  mutant)  of  strain  85020 
Lane  11:  P.  multocida  85020  (wild-type) Fig  58: 
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tetracycline  and  chloramphenicol.  Single  colonies  were  checked  by  restriction 
analysis  and  designated  as  plasmid  pJRMT43  and  pJRMT44.  Restriction 
analysis  of  plasmid  pJRMT7  with  EcoRI/Sacl  produced  three  fragments  of 
=0.6,  =1.9  and  =3.5  kb  but  for  plasmid  pJRMT43  it  produced  two  fragments 
of  =1.36  and  =3.5  kb.  For  plasmid  pJRMT8  three  fragments  of  X0.6,  =1.6 
and  =3.5  kb  were  produced  whereas  for  plasmid  pJRMT44  two  fragments  of 
=1.06  and  =3.5  kb  were  obtained,  as  predicted  (results  not  shown). 
In  addition,  plasmids  pJRMT7  and  pJRMT8  were  digested  with  BcgI  and  a 
34  bp  middle  fragment  (from  nt.  1404-1438)  of  the  cya  gene  removed  (see  Fig. 
25).  The  purified  DNA  fragments  were  self-ligated,  transformed  into  E.  coli 
XL1Bue  competent  cells  by  electroporation  and  plated  onto  LB  agar  containing 
tetracycline  and  chloramphenicol.  Single  colonies  were  checked  by  restriction 
analysis.  Recombinants  were  designated  as  plasmid  pJRMT45  and  pJRMT46. 
Digestion  with  AvaI  (the  uniqe  Aval  site  of  cya  gene  was  removed  by  digestion 
with  Bcgl)  for  plasmid  pJRMT7  produced  two  fragments  of  =1.2  and  =4.66 
whereas  for  plasmid  pJRMT45  a  linearised  fragment  of  =5.9  kb  was  produced. 
For  plasmid  pJRMT8,  two  fragments  of  -1.24  and  =4.36  were  produced 
whereas  for  plasmid  pJRMT46  just  one  linearised  fragment  of  5.6  kb  was 
produced  (results  not  shown). 
3.3.3.2.  Allelic  exchange 
The  plasmids  pJRMT43,  pJRMT44,  pJRMT45  and  pJRMT46  were 
transformed  into  the  P.  multocida  strains  by  electroporation  and  plated  onto 
BHI  agar  supplemented  with  5%  (v/v)  sheep  blood  containing  5  µg/  ml 
chloramphenicol.  After  incubation  for  48  hrs  at  370C  no  colonies  were  found 
for  plasmids  pJRMT44  and  pJRMT46'  but  a  few  colonies  grew  for  plasmids 
pJRMT43  and  pJRMT45  derived  from  the  P.  multocida  85020  sequence.  Some 
of  these  were  inoculated  into  BHI  broth  without  any  antibiotic  and  subcultured 
five  times.  The  new  clones  transformed  with  plasmid  pJRMT43  were  checked 88 
by  PCR  with  primers  Cya4  and  CyaS  which  amplified  two  or  three  bands 
representing  wild  type  and  possible  smaller,  mutated  fragments  (Fig.  59A). 
But,  after  further  subculture  for  induction  of  second  cross  over  events  in  BHI 
broth  without  any  antibiotic,  the  transformants  lost  the  mutated  bands.  The 
genomic  DNA  of  the  clones  transformed  with  plasmid  pJRMT45  were  digested 
with  Aval  and  checked  by  Southern  blot  hybridisation.  The  cya  probe 
hybridised  to  two  bands  for  wild-type  and  three  bands  for  the  mutants  strains 
(Fig.  59).  It  was  expected  that  because  of  removing  the  unique  AvaI  site,  the 
cya  probe  should  hybridise  to  one  bigger  band  in  mutant  strains,  but  this  was 
not  found. 
3.4.  Use  of  a  sacB-sacR  cartridge  for  constructing  directed, 
unmarked  mutations  in  Gram-negative  bacteria  by  marker 
exchange-eviction  mutagenesis 
Previous  data  indicated  that,  during  the  allelic  exchange  experiments,  a  first 
crossing-over  to  integrate  the  plasmid  DNA  into  the  chromosome  apparently 
occurred  but  subculture  to  encourage  loss  of  the  plasmid  via  a  second  crossing- 
over  event  did  not  occur  readily.  For  this  reason  a  means  was  sought  to  select 
against  the  plasmid  once  it  had  been  incorporated  into  the  chromosome  via  the 
first  recombination  event  so  as  to  actively  encourage  loss  of  the  plasmid  and 
promote  the  second  recombination  event. 
3.4.1.  Expression  of  sacB  gene  in  E.  coli  DH5a 
The  plasmid  pEG  18.3  (Fig.  60)  conferring  sensitivity  to  sucrose,  kindly 
provided  by  Dr.  Peggy  Cotter,  Department  of  Microbiology,  Immunology  and 
Molecular  Genetics,  UCLA  School  of  Medicine,  University  of  California, 
[unpublished  data,  modified  version  of  plasmid  pEG25,  Tejada  et  al..  (1996)] 
was  transformed  into  E.  coli  . DH5a  by  electroporation  and  plated  onto  LB  agar 
G 
containing  ampicillin  and  kanamycin.  After  incubation  for  24  hrs  at  37  C,  10 
single  KmR-ApR  clones  were  checked  by  restriction  analysis.  Two  of  the  E. Fig  59:  Analysis  of  P.  multocida  clones  transformed  with  plasmids  pJRMT43 
and  pJRMT45  (size  as  kb) 
A:  PCR  analysis  with  Cya4  and  Cya5  primers  of  P.  multocida  85020 
transformed  with  plasmid  pJRMT43 
Lanes  1-3:  transformed  clones 
Lane  4:  P.  multocida  85020  (wild-type) 
Lane  5:  negative  control 
Lane  M:  1  kb  DNA  marker 
B:  Southern  blot  hybridisation  of  P.  multocida  85020  clones  transformed  with 
plasmid  pJRMT45 
Lanes  1-2:  transformed  clones 
Lane  3:  P.  multocida  85020  (wild-type) 
Lane  M:  1  kb  DNA  marker Fig  59: 
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This  plasmid  was  used  as  a  source  of  the  sacB-sacR  genes  from  Bacillus 
subtilis  and  contains  three  antibiotic  resistance  markers  (Ap,  Gm  and  Km). Fig  60: 
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coli  clones  containing  plasmid  pEG18.3  were  inoculated  into  5  ml-volumes  of 
G 
LB  broth  containing  appropriate  antibiotics  and  incubated  at  37  C  overnight 
with  shaking.  10  ml  pre-warmed  LB  broth  was  inoculated  with  0.5  ml  of  the 
G 
overnight  culture  and  incubated  at  37  C.  When  the  OD540nm  reached  =1.0 
(109  C.  F.  U.  /  ml),  lOx  serial  dilutions  in  PBS  were  prepared  and  100  µl 
aliquots  spread  onto  LB  agar  containing  appropriate  antibiotics  with  and 
without  5%  (w/v)  sucrose  and  incubated  at  37*C.  After  48  hrs,  no  colonies 
grew  on  LB  agar  containing  5%  (w/v)  sucrose,  but  on  control  plates  (LB  agar+ 
antibiotics  without  sucrose)  the  predicted  numbers  of  colonies  grew. 
3.4.2.  Expression  of  sacB  gene  in  P.  multocida  strains 
3.4.2.1.  Cloning  of  the  sacB  gene  into  the  pAKA16  vector 
In  marker  exchange-eviction  mutagenesis,  both  parts  of  the  nptl-sacB-sacR 
cartridge  contributed  to  the  construction  on  an  unmarked,  chromosomal 
mutation  through  a  two-step  process.  KmR  is  used  in  the  first  step  to  select  for 
the  exchange  of  the  marked  gene  for  the  wild-type  allele,  as  in  typical  marker- 
exchange  mutagenesis.  Sucrose  sensitivity  is  used  in  the  second  step  to  select 
for  the  eviction  of  the  marked  gene  by  exchange  for  an  unmarked  derivative. 
The  success  of  the  second  step  is  determined  initially  by  growth  in  the  presence 
of  5%  (w/v)  sucrose  and  subsequently  confirmed  by  testing  for  Km  sensitivity. 
The  plasmid  pEG18.3  was  digested  with  BamHI  and  a  =3.8  kb  fragment 
containing  the  KmR-sacB-sacR  cartridge  removed  and  cloned  into  BamHI- 
digested  and  dephosphorylated  pAKA16.  E.  coli  DH5a  competent  cells  were 
transformed  with  the  ligation  mixture  and  plated  onto  LB-X-Gal-IPTG  agar 
containing  ampicillin  and  also  onto  LB  agar  containing  ampicillin  and 
kanamycin.  A  selection  of  white  colonies  from  the  LB-X-Gal-IPTG  agar  and 
also  ApR-KmR  clones  from  the  LB  plates  were  checked  by  restriction  analysis, 
and  for  lack  of  growth  on  LB  agar  containing  5%  (w/v)  sucrose  and  the 
plasmid  in  one  such  clone  was  designated  plasmid  pJRMT29  (Fig.  61A).  Also Fig  61: 
A:  Map  of  plamid  pJRMT29 
The  KmR-sacB-sacR  fragment  was  cut  from  plasmid  pEG  18.3  and  cloned  into 
pAKA16  which  had  been  digested  with  BamHI  and  dephosphorylated. 
B:  Map  of  plamid  pJRMT30 
The  KmR-sacB-sacR  fragment  was  cut  from  plasmid  pEG18.3  and  cloned  into 
pAKA19  which  had  been  digested  with  BamHI  and  dephosphorylated. Dra  raI 
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the  KmR-sacR-sacB  cartridge  was  cloned  into  plasmid  pAKA19  and 
designated  plasmid  pJRMT30  (Fig.  61B).  BamHI-digestion  of  plasmids 
pAKA16  and  pAKA19  produced  just  linearised  DNA  bands  of  =5.0  and  =5.3 
kb  respectively,  whereas  for  plasmids  pJRMT29  and  pJRMT30  it  produced  an 
additional  =3.8  kb  fragment,  as  expected  (results  not  shown). 
3.4.2.2.  Introduction  of  the  sacB  gene  into  P.  multocida  strains 
The  plasmid  pJRMT29  was  transformed  into  P.  multocida  strains  by 
electroporation  and  KmR  clones  selected.  These  new  clones  were  analysed  for 
the  presence  of  plasmid  DNA  and  for  growth  on  BHI  agar  supplemented  with 
5%  (v/v)  sheep  blood  containing  5%  (w/v)  sucrose  and  were  named  P. 
multocida  JRMT8  and  JRMT9  for  P.  multocida  strains  85020  and  Quetta 
respectively.  Single  clones  of  these  P.  multocida  strains  from  BHI  agar  were 
e  inoculated  into  5  ml-volume  of  BHI  broth  and  incubated  overnight  at  37  C  with 
shaking.  10  ml  of  pre-warmed  BHI  broth  were  inoculated  with  0.5  ml  of 
overnight  culture  and  incubated  at  37*C.  When  the  OD540nm  reached  =1 
(=109  C.  F.  U.  /  ml),  IOx  serial  dilutions  were  prepared  in  PBS  and  100.  tl 
aliquots  of  each  sample  spread  onto  BHI  agar  supplemented  with  5%  (v/v) 
sheep  blood  and  5%  (w/v)  sucrose  and  incubated  at  37*C.  After  24  hrs,  single 
0 
colonies  had  grown  up  but  when  these  were  left  for  about  40  hrs  at  37  C  all 
colonies  were  liquefied  because  of  levansucrase  secretion.  The  sacB  phenotype 
was  therefore  expressed  in  P.  multocida  caused  cell  lysis.  Also,  plasmid 
pJRMT30  was  transformed  into  P.  multocida  strains  and  plated  on  BHI  agar 
C 
supplemented  with  5%  (v/v)  sheep  blood.  After  incubation  for  48  hrs  at  37  C, 
a  few  KmR  colonies  grew  but  these  were  assumed  to  be  spontaneous  KmR 
colonies  as  plasmid  DNA  could  not  be  detected  in  them. 91 
3.4.3.  Construction  of  marker-free  aroA  mutants  with  sacB  gene  as  a 
selective  marker 
3.4.3.1.  Insertion  of  deleted  aroA  gene  into  pAKA19  vector 
Direct  cloning  of  the  deleted  aroA  gene  into  plasmid  pJRMT30  was  difficult 
because  of  incompatible  restriction  sits  in  its  multiple  cloning  site  with  plasmids 
pJRMT25  and  pJRMT26.  For  this  reason,  the  deleted  aroA  genes  were  initially 
cloned  into  pAKA19  vector.  The  deleted  aroA  genes  were  cut  from  plasmids 
pJRMT25  and  pJRMT26  with  BamHUXhoI  as  a  =1.05  kb  fragment  and  cloned 
into  BamHl/XhoI-digested  and  dephosphorylated  pAKA19.  The  constructs 
were  transformed  into  E.  coli  DHSa  competent  cells  by  electroporation  and 
plated  onto  LB-X-Gal-IPTG  agar  containing  ampicillin.  White  colonies  were 
picked  and  inoculated  into  LB  broth  containing  ampicillin.  The  recombinant 
plasmids  were  confirmed  by  restriction  analysis  and  designated  as  plasmids 
pJRMT31  and  pJRMT32  for  P.  multocida  strains  85020  and  Quetta 
respectively  (Fig.  62A).  Digestion  of  plasmid  DNA  with  BamHIIXhoI 
linearised  the  plasmid  pAKA19  as  a  =5.0  kb  fragment  but  for  plasmids 
pJRMT31  and  pJRMT32  it  produced  two  fragments,  of  =1.05  kb  as  the  deleted 
aroA  gene  and  =5.0  kb  as  the  vector  alone  (results  not  shown). 
3.4.3.2.  Insertion  of  KmR-sacR-sacB  cartridge  into  plasmids  pJRMT31 
and  pJRMT32 
The  plasmid  pEG18.3  was  digested  with  BamHI  and  the  KmR-sacB-sacR 
cartridge  removed  as  =3.8  kb  fragment.  This  was  cloned  into  the  plasmids 
pJRMT31  and  pJRMT32  which  had  been  BamHI-digested  and 
dephosphorylated  and  these  were  then  transformed  into  E.  coli  DH5a 
competent  cells  by  electroporation.  The  recombinant  plasmids  were  confirmed 
by  restriction  analysis  and  lack  of  growth  on  LB  agar  containing  5%  (w/v) 
sucrose,  and  were  named  plasmids  pJRMT33  and  pJRMT34  (Fig.  62B).  As 
expected,  digestion  of  plasmids  pJRMT31  and  pJRMT32  with  BamHI Fig  62: 
A:  The  maps  of  plasmids  pJRMT31  and  pJRMT32 
The  deleted  aroA  gene  was  cut  from  plasmids  pJRMT25  and  pJRMT26  with 
BamHUXhoI  and  cloned  into  pAKA19  and  were  named  as  plasmids  pJRMT31 
and  pJRMT32. 
B:  The  map  of  plasmid  pJRMT33  and  pJRMT34 
The  KrR-sacB-sacR  fragment  was  cut  from  plasmid  pEG18.3  and  cloned  into 
plasmids  pJRMT31  and  pJRMT32  and  designated  as  plasmid  pJRMT33  and 
pJRMT34. Fig  62 
A. 
Ndel 
Ai 
B. 
BamHl 
of 
Taql 92 
produced  just  one  band  of  =6.0  kb  as  linearised  vector  whereas  another 
fragment  of  =3.8  kb  was  produced  for  plasmids  pJRMT33  and  pJRMT34 
representing  the  inserted  KrR-sacB-sacR  fragment  (results  not  shown).  When 
cells  containing  these  plasmids  were  spread  on  LB  agar  with  and  without  5% 
(w/v)  sucrose,  a  few  colonies  grew  on  LB  agar  containing  sucrose  but 
confluent  growth  was  obtained  on  LB  agar  without  sucrose.  Some  of  the 
colonies  that  grew  on  LB  agar  with  5%  (w/v)  sucrose  were  analysed  for  the 
presence  of  plasmid,  but  the  result  was  negative  indicating  that  they  had  lost  the 
plasmid  and  so  no  longer  expressed  the  sacB  phenotype  with  sucrose.  The 
plasmids  pJRMT33  and  pJRMT34  were  then  transformed  into  E.  coli 
SM10XPir  for  conjugation. 
3.4.3.3.  Allelic  exchange 
The  plasmids  pJRMT33  and  pJRMT34  were  transformed  into  P.  multocida 
strains  by  electroporation  and  transconjugation  and  plated  onto  BHI  agar 
supplemented  with  5%  (v/v)  sheep  blood  containing  kanamycin  or  kanamycin 
0 
and  streptomycin  (for  transconjugants).  After  incubation  for  48  hrs  at  37  C, 
some  single  colonies  were  picked  from  more  than  500  colonies  and  patched 
onto  BHI  agar  supplemented  with  5%  (v/v)  sheep  blood  without  any 
antibiotics.  They  were  then  plated  onto  BHI  agar  supplemented  with  5%  (v/v) 
sheep  blood  with  and  without  kanamycin  and  also  onto  plates  with  5%  (w/v) 
sucrose.  Some  sucrose  resistant  and  KmS  samples  were  selected,  inoculated 
into  BHI  broth  and  checked  by  PCR.  Most  of  them  showed  two  bands,  one 
wild-type  in  size  and  one  with  the  correct  mutated  size  and  some  showed  just 
one  band  of  wild-type  size  (Fig.  63).  However,  a  few  samples  showed  just  one 
band  of  the  mutated  gene  size  (Fig.  63A  lane  7,  B  lane  5  and  C  lane  11)  and 
these  were  selected  and  transferred  to  BA  plates  individually.  Representative 
clones  of  each  new  mutant  were  designated  as  P.  multocida  JRMT12  and 
JRMT13  for  P.  multocida  85020  and  Quetta  strains  repectively. Fig  63:  PCR  analysis  of  P.  multocida  clones  transformed  with  plasmids 
pJRMT33  and  pJRMT34  (size  as  kb) 
A  and  B:  P.  multocida  85020  transformed  with  plasmid  pJRMT33 
A: 
Lanes  1-7:  transformed  clones  after  subculture  (Kms  and  sucroseR) 
Lane  8:  P.  multocida  85020  (wild-type) 
Lane  M:  1  kb  DNA  marker 
B: 
Lanes  1-12:  transformed  clones  after  subculture  (KmS  and  sucroseR) 
Lane  13:  P.  multocida  85020  (wild-type) 
Lane  M:  1  kb  DNA  marker 
C:  P.  multocida  Quetta  transconjugated  with  plasmid  pJRMT34 
Lanes  1-11:  transformed  clones  after  subculture  (KmS  and  sucroseR) 
Lane  12:  P.  multocida  Quetta  (wild-type) 
Lane  M:  1  kb  DNA  marker Fig  63: 
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3.4.3.4.  Confirmation  of  deleted  aroA  mutants 
The  deleted  aroA  mutants  were  confirmed  by  PCR  and  restriction  enzyme 
analysis,  growth  in  PMM  and  also  Southern  blot  hybridization. 
3.4.3.4.1.  PCR 
The  AroA  primers  produced  a  single  band  (=1.0  kb),  smaller  than  the  wild- 
type  band  (1.2  kb)  (Fig.  64A).  When  the  PCR  products  were  digested  with 
Earl  (the  Earl  site  had  been  removed  from  the  aroA  gene  sequence  by  digestion 
with  Af  II/SacII),  the  wild-type  amplimer  showed  two  bands  (=0.45  and  =0.75 
kb)  but  the  mutant  amplimer  showed  only  one  band  (=1.05  kb)  (Fig.  64B). 
3.4.3.4.2.  Growth  in  Pasteurella  Minimal  Medium 
As  described  previously,  aroA  mutants  and  wild-type  strains  were  checked 
for  growth  in  PMM.  Fresh  overnight  cultures  of  the  P.  multocida  strains  were 
0 
inoculated  into  10  ml-volumes  of  PMM  and  incubated  at  37  C  with  shaking. 
After  24  and  48  hrs,  the  OD540nm  was  measured  for  each  strain  (Fig.  65). 
Only  the  wild-type  strains  were  able  to  grow  in  the  minimal  medium, 
confirming  the  phenotype  of  the  aroA  mutants. 
3.4.3.4.3.  Southern  blot  hybridisation 
Genomic  DNA  of  P.  multocida  wild  type  and  the  deleted  aroA  mutant  strains 
was  digested  with  Earl  (the  Earl  site  of  aroA  gene  had  been  removed  by 
digested  with  AflII/  SacII),  electrophoresed  in  a  0.7%  (w/v)  agarose  gel  and 
blotted  to  Hybond  N+  membrane.  The  blot  was  hybridised  with  the  aroA  probe 
which  hybridised  to  two  bands  of  =1.3  and  =1.6  kb  for  wild  type  strains  and 
only  one  band  of  =2.8  kb  for  the  deleted  aroA  mutant  strains  (Fig.  66). 
The  results  of  this  experiment  showed  that  use  of  the  sacB  selection 
procedure  was  successful  in  selecting  for  a  double  cross-over  more  readily  to 
produce  deleted  aroA  derivatives. Fig  64:  PCR  analysis  of  the  deleted  aroA  mutation  in  P.  multocida  strains 
(size  as  kb) 
A:  PCR  products  with  AroA  primers 
Lane  1:  P.  multocida  JRMT12  (AaroA  mutant) 
Lane  2:  P.  multocida  85020  (wild-type) 
Lane  3:  P.  multocida  JRMT13  (AaroA  mutant) 
Lane  4:  P.  multocida  Quetta  (wild-type) 
Lane  M:  1  kb  DNA  marker 
B:  Amplified  aroA  gene  digested  with  Earl 
Lane  1:  P.  multocida  JRMT12  (aroA  mutant) 
Lane  2:  P.  multocida  85020 
Lane  3:  P.  multocida  JRMT13  (aroA  mutant) 
Lane  4:  P.  multocida  Quetta 
Lane  M:  1  kb  DNA  marker Fig  64: 
A. 
B. Fig  65:  Growth  of  P.  multocida  strains  in  Pasteurella  Minimal  Medium  (PMM) 
P.  multocida  strains  85020,  JRMT12  (AaroA  mutant  of  85020),  Quetta 
and  JRMT13  (AaroA  mutant  of  Quetta)  were  inoculated  into  10  ml  of 
PMM  and,  after  shaking  for  24  hrs  and  48  hrs  at  370C  the  ODS40nm  was 
measured. Fig  65: 
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strains  (genomic  DNA  digested  with  Earl)  and  hybridised  with  aroA 
probe  (size  as  kb). 
Lane  1:  P.  multocida  85020  (wild-type) 
Lane  2:  P.  multocida  JRMT12  (DaroA  mutant) 
Lane  3:  P.  multocida  Quetta  (wild-type) 
Lane  4:  P.  multocida  JRMT13  (DaroA  mutant) Fig  66: 
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3.4.4.  Construction  of  marker-free  galE  mutants  with  sacB  gene  as  a 
selective  marker 
3.4.4.1.  Insertion  of  KmR-sacB-sacR  cartridge  into  plasmids  pJRMT37 
and  pJRMT38 
The  plasmid  pGE18.3  was  digested  with  BamHI  to  remove  the  KmR-sacB- 
sacR  cartridge  as  a  =3.8  kb  fragment  and  this  was  cloned  into  BamHI-digested 
and  dephosphorylated  plasmids  pJRMT37  and  pJRMT38  (Fig.  56B).  The 
recombinant  plasmids  were  confirmed  by  restriction  analysis  and  lack  of 
growth  on  LB  agar  containing  5%  (w/v)  sucrose  and  designated  as  pJRMT39 
and  pJRMT40  for  P.  multocida  strains  85020  and  Quetta  respectively  (Fig. 
67). 
3.4.4.2.  Allelic  exchange 
The  plasmids  pJRMT39  and  pJRMT40  were  transformed  to  P.  multocida 
strains  85020  and  Quetta  by  electroporation  or  conjugation  and  plated  onto 
BHI  agar  supplemented  with  5%  (v/v)  sheep  blood  containing  kanamycin  or 
kanamycin  and  streptomycin  (for  transconjugants).  After  incubation  for  48  hrs 
at  37"C,  150  colonies  were  patched  onto  BHI  agar  supplemented  with  5% 
(v/v)  sheep  blood  without  any  antibiotic  for  selection  against  plasmid.  They 
were  plated  then  onto  BHI  agar  supplemented  with  5%  (v/v)  sheep  blood  with 
and  without  kanamycin  and  also  onto  plates  with  5%  (w/v)  sucrose.  Some 
sucrose  resistant  and  KmS  clones  were  selected,  inoculated  into  BHI  broth 
and  checked  by  PCR  with  GaIE  primers.  Most  colonies  showed  one  band  of 
wild-type  size,  but  some  showed  one  band  larger  than  the  wild-type  gene,  as 
seen  before  (see  Fig.  57).  Digestion  of  the  PCR  product  with  ApaLI  (the 
ApaLI  site  had  been  removed  from  the  galE  gene  by  digestion  with 
EcoRVIBsmI)  showed  two  bands  of  =0.5  kb  for  the  wild-type,  as  expected, 
and  the  mutants  showed  two  bands  but  at  different  size  from  the  wild-type 
(Fig.  57),  as  seen  previously.  However,  after  10  subcultures  into  BHI  broth, Fig  67: 
A:  The  map  of  plasmids  pJRMT39  and  pJRMT40 
The  KmR-sacB-sacR  fragment  was  cut  from  plasmid  pEG  18.3  and  cloned  into 
plasmids  pJRMT37  and  pJRMT38  (see  Fig  56). Fig  67: 
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all  clones  showed  wild-type  pattern.  This  experiment  was  repeated  more  than 
30  times  by  electroporation  and  transconjugation,  but  on  no  occasion  was  a 
clone  found  with  the  correct  predicted  PCR  amplimer.  Thus  for  this  locus, 
sacB  selection  was  not  successful. 
3.5.  Mouse  virulence  tests 
3.5.1.  Preparation  of  inoculum 
P.  multocida  strains,  both  the  wild-type  parent  strains  and  mutated  strains, 
grew  readily  in  BHI  broth.  A  maximum  viable  population  of  3-6  x  109  viable 
cells  per  ml  was  achieved  in  the  shaken  cultures  in  4-  6  hrs  at  37  C.  The  culture 
went  into  an  early  decline  phase  so  that  less  than  106  viable  bacteria  per  ml 
could  be  detected  after  18  hrs.  For  this  reason,  overnight  cultures  were  not 
used  to  prepare  challenge  inocula.  Single  colonies  from  a  fresh  BA  plate  were 
u 
inoculated  into  5  ml-volumes  of  BHI  broth  and  incubated  overnight  at  37  C 
with  shaking,  after  which  10  ml  of  pre-warmed  BHI  broth  was  inoculated  with 
0.5  ml  of  overnight  culture.  When  the  OD540nm  reached  =1  (after  4-6  hrs, 
exponential  phase  culture  containing  =3-6  x  109  C.  F.  U.  /  ml),  lOx  serial 
dilutions  in  PBS  were  prepared. 
3.5.2.  Virulence  test  of  P.  multocida  85020  and  its  aroA  mutant,  JRMTI 
(Experiment  1) 
Ten  groups  of  three  mice  were  injected  intraperitoneally  (i.  p.  )  with  0.5  ml  of 
graded  doses  of  these  two  strains.  All  mice  were  weighed  and  checked  for 
illness  every  day  for  5  days  and  the  weight  gain  noted.  According  to  the  results 
of  this  experiment  (Table  11)  LD50  values  for  P.  multocida  85020  of  <20 
C.  F.  U.  /  mouse  was  estimated  and  >_1.7  x  105  C.  F.  U.  /  mouse  for  the  JRMT1 
strain.  Thus,  the  wild-type  strain  was  very  virulent  by  this  route  of  inoculation 
and  could  kill  mice  in  less  than  24  hrs  from  a  very  low  inoculum.  The  aroA 
mutant  strain  JRMT1  appeared  to  be  greatly  attenuated. Table  11:  The  virulence  properties  of  P.  multocida  strain  85020  and  its  aroA  mutant 
JRMT1  by  i.  p.  route  (Experiment  1) 
Treatment  C.  F.  U.  /  mouse  No.  of  survivors 
No.  challenged 
P.  m.  85020 
(wild-type) 
2000  0/3 
it  200  0/3 
20  0/3 
2.0  2/3 
P.  m.  JRMT1 
(85020  aroA  mutant) 
1.75x105  3/3 
it  to  1.75x104  3/3 
it  it  1.75  x  103  3/3 
if  1.75  x  102  3/3 
PBS  0.5  ml  3/3 
BHI  0.5  ml  3/3 96 
In  the  next  experiment  (Experiment  2)  9  groups  of  5  mice  were  injected  with 
higher  doses  of  P.  multocida  JRMT1  and  lower  doses  of  the  wild-type  P. 
multocida  85020  strain  and  the  weight  gain  checked  over  the  following  six  days 
(Table  12;  Fig.  68).  Many  of  the  mice  given  the  wild-type  strain  died  on  the 
first  day  post  injection,  whereas,  mice  injected  with  the  top  dose  of  JRMT1 
(=2.85  x  109  C.  F.  U.  )  died  on  the  second  day.  The  mice  given  =2.85  x  108 
C.  F.  U.  of  P.  multocida  JRMT1  showed  some  toxicity  and  lost  weight  during 
the  first  day  post  inoculation  (PI)  but  by  the  second  day  all  of  them  had 
recovered.  The  results  of  this  experiment  showed  that  the  LD50  of  P.  multocida 
85020  was  <32  C.  F.  U.  /  mouse  but  for  P.  multocida  JRMT1  was  more  than 
2.85  x  108  C.  F.  U.  /  mouse  (Table  12).  As  a  preliminary  protection  test,  the 
surviving  vaccinated  mice  were  challenged  i.  p.  with  =100  LD50  of  P. 
multocida  85020  wild-type  parent  strain  on  7  day  post  inoculation.  In  this 
experiment,  the  mice  given  a  dose  as  low  as  105  C.  F.  U.  of  JRMT1  showed 
some  protection  (data  not  shown).  The  results  of  this  experiment  indicated  that 
a  dose  of  P.  multocida  JRMT1  between  105-108  C.  F.  U.  /mouse  would  confer 
optimal  protection.  Due  to  some  adverse  side  effects  resulting  from  a  dosage  of 
2.85  x  108  C.  F.  U.,  immunisation  with  a  lower  dosage  was  considered.  It  was 
decided  that  a  dosage  of  107  C.  F.  U.  /  mouse  would  be  used,  as  it  offered  good 
protection  and  no  side  effects. 
Finally  for  confirmation  of  these  results  (Exp.  3),  13  groups  of  5  mice  were 
challenged  with  graded  doses  of  P.  multocida  strains  85020,  JRMT1,  Quetta 
and  JRMT2  (aroA  mutant  of  Quetta)  (Table  13).  The  results  of  this  experiment 
confirmed  that  P.  multocida  JRMT1  was  highly  attenuated  with  LD50  >_108 
C.  F.  U.  /  mouse.  Similar  results  were  obtained  with  the  Quetta  strains  and  its 
aroA  derivative  JRMT2  (Table  13).  At  48  hrs  PI,  two  mice  from  the  groups 
given  the  top  dose  of  JRMT1  and  JRMT2  were  sacrificed  and  heart  blood 
0 
plated  onto  BA  and  incubated  at  37  C  for  48  hrs.  No  colonies  were  detected Table  12:  The  virulence  properties  of  P.  multocida  85020  strain  and  its  aroA 
mutant  JRMT1  by  i.  p.  route  (Experiment  2) 
Treatments 
. 
F.  U.  /  mouse 
No.  of  survivors 
No.  challenged 
P.  m.  85020 
(wild-type) 
320  0/5 
to  32.0  0/5 
It  3.2  2/5 
P.  m.  JRMT  1 
(85020  aroA  mutant) 
2.85  x  109  0/5 
it  2.85  x  108  5/5 
It  2.85  x  107  5/5 
it  2.85  x  106  5/5 
PBS  0.5  ml  5/5 Fig  68:  Mean  weight  gain  of  mice  inoculated  i.  p.  with  of  P.  multocida  85020 
and  its  aroA  derivative  JRMT1. 
1.  Control  group  (given  0.5  ml  PBS) 
2.  P.  multocida  85020  (wild  type)  320  C.  F.  U.  /  mouse 
3.  P.  multocida  JRMT1  2.85  x  109  C.  F.  U.  /  mouse 
4.  P.  multocida  JRMT1  2.85  x  108  C.  F.  U.  /  mouse 
5.  P.  multocida  JRMT1  2.85  x  107  C.  F.  U.  /  mouse 
The  mice  given  of  P.  multocida  85020  by  i.  p.  route  (320  C.  F.  U.  /  mouse)  died 
after  24  hrs  (No.  2).  Mice  given  highest  dose  of  P.  multocida  JRMT1  (2.85  x 
109  C.  F.  U.  /  mouse)  died  after  48  hrs  (No.  3).  Mice  given  a  lower  dose 
JRMT1  (2.85  x  108  C.  F.  U.  /  mouse)  showed  some  toxicity  and  lost  weight 
but  had  recovered  by  48  hrs  (No.  4) Fig  68: 
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a123V Table  13:  The  virulence  properties  of  P.  multocida  strains  and  their  aro  A  mutants 
(Experiment  3) 
Treatment  Challenge  dose  i.  p.  No.  of  survivors 
(C.  F.  U.  /  mouse)  No.  challenged 
P.  m.  85020  266  0/5 
(Wild-type) 
26.6  0/5 
of 
' 
2.66  2/5 
P.  m.  JRMT  1  2.11  x  108  5/5 
(85020  aroA  mutant 
it  of 
2.11x107  5/5 
it  it 
2.11  x  106  5/5 
2.11  x  105  5/5 
to  if 
1 
2.11  x  104  5/5 
P.  m.  Quetta  295  0/5 
(Wild-type) 
11 
29.5  0/5 
2.95  1/5 
' 
P.  m.  JRMT2  1.97  x  108  5/5 
(Quetta  aroA  mutant 
1.97  x  107  5/5 
it  ￿ 
to 
1.97  x  106  5/5 
1.97  x  105  5/5 
￿ 
1.97  x  104  5/5 
￿ 
PBS  0.5  ml  5/5 97 
from  these  blood  samples,  indicating  that  the  aroA  strains  had  greatly  reduced 
ability  to  survive  and/or  multiply  in  vivo. 
3.5.3.  Virulence  test  of  cya::  KmR  mutant  of  Quetta  strain  (Experiment  4) 
Six  groups  of  3  mice  were  injected  with  0.5  ml  of  graded  doses  of 
exponential  phase  cells  of  P.  multocida  Quetta  and  the  corresponding  cya 
mutant  JRMT3  (Table  14).  The  results  showed  that  the  P.  multocida  JRMT3 
(cya::  KmR)  strain  was  at  least  103  times  more  attenuated  than  the  wild-type 
strain,  but  not  as  attenuated  for  virulence  as  the  aroA  mutants  strains  (Tables 
11-13). 
3.5.4.  Virulence  test  of  P.  multocida  strains  by  different  routes  of 
inoculation  (Experiment  5) 
For  this  experiment,  36  groups  of  3  mice  were  injected  with  graded  doses  of 
P.  multocida  strains  by  the  i.  p.,  i.  n.  and  s.  c.  routes  (Table  15).  The  results  of 
this  experiment  indicated  that  the  LD50  of  different  strains  varied  by  route  of 
inoculation.  The  LD50  of  P.  multocida  85020  and  Quetta  strains  by  the  i.  p.  and 
s.  c.  routes  was  <50  C.  F.  U.  /  mouse  and  by  the  i.  n.  route  was  >200  and  >5600 
C.  F.  U.  /  mouse  for  85020  and  Quetta  strains,  respectively.  It  was  also  found 
that  the  wild  type  strains  could  kill  the  mice  by  the  i.  p.  challenge  at  24  hrs  post- 
inoculation  (PI),  but  by  the  s.  c.  route  only  after  48-72  hrs  and  by  the  i.  n.  route 
only  after  96  hrs  (5th  day  PI).  After  5  days  PI,  samples  were  taken  for  culture 
from  all  surviving  mice  that  had  been  inoculated  by  the  i.  n.  route  and  from  mice 
that  had  been  inoculated  with  the  top  dose  of  mutant  strains  by  the  s.  c.  and  i.  p. 
routes.  Aliquots  of  heart  blood  and  homogenised  lungs  were  plated  onto  BA 
plates.  A  few  colonies  grew  from  the  blood  and  lungs  of  mice  that  were 
inoculated  by  the  i.  n.  route  with  P.  multocida  85020  strain,  but  no  colonies 
grew  from  the  other  samples.  The  mice  that  inoculated  i.  n.  were  showed 
different  stages  of  hepatisation  and  adhision  of  lungs  to  the  thorasic  cavities. Table  14:  The  virulence  properties  of  P.  multocida  strain  Quetta  and  its  cya  mutant 
by  i.  p.  route  (JRMT3) 
Treatments  C.  F.  U.  /  mouse 
No.  of  survivors 
No.  challen  ged  at  time  (hrs)  PI 
by  L  p.  route  0  18  24  48  72  96  120 
P.  m.  Quetta 
(wild-type)  1330  2/3  0/3  ----  ----  ----  ---- 
"  133 
E3/3] 
1/3  0/3  ----  ----  ----  ---- 
"  13.3  3/3  2/3  0/3 
P.  M.  JRMT3 
(cya  mutant) 
1.2  x  105 
3/3  3/3  3/3  3/3  2/3  1/3  0/3 
It  of  1 
1.2  x  104 
3/3  3/3  3/3  3/3  2/3  2/3  1/3 
If  if 
1 
1200  3/3  3/3  3/3  3/3  3/3  3/3  3/3 
----  mice  dead  after  24  hrs Table  15:  Virulence  test  of  P.  multocida  strains  by  different  routes  of  inoculation 
Treatments 
_ 
Challenge  dose 
(C.  F.  U.  /  mouse) 
Route  of 
inoculation 
No.  of  survivors 
No.  challenged 
P.  m.  8502U 
(wild-type)  2100  i.  p.  0/3  (18  hrs  PI) 
11  it  if  210  0/3  (18  hrs  PI) 
to  21  0/3  (24  hrs  PI) 
"  2100  S.  C.  0/3  (48  hrs  PI) 
210  0/3  (48  hrs  PI) 
21  0/3  (48  hrs  PI) 
It  ""  2100  i.  n.  1/3  (96  hrs  PI) 
I'  210  11  2/3  (96  hrs  PI) 
It  21  3/3  (96  hrs  PI) 
P.  m.  JRMT1 
(85020  aroA  mutant)  2.1  x  109  i.  p.  0/3  (24  hrs  PI) 
11  11  it  2.1  x  108  of  3/3  (96  hrs  PI) 
it  to  of  2.1  x  107  it  3/3  (96  hrs  PI) 
of  of  of  2.1  x  109  S.  C.  3/3  (96  s  PI) 
of  to  it  2.1  x  108  It  3/3  (96  hrs  PI) 
of  If  2.1  x  107  3/3  (96  hrs  PI) 
to  to  2.1  x  109  i.  n.  3/3  (96  hrs  PI) 
11  of  of  2.1  x  108  11  3/3  (96  hrs  PI) 
of  of  2.1  x  107  3/3  (96  hrs  PI) 
P.  m.  Quetta 
(wild-type)  5600  i.  p.  0/3  (18  hrs  PI) 
to  to  "  560  "  0/3  (24  hrs  PI) 
it  it  "  56  "  0/3  (24  hrs  PI) 
of  if  to  5600  S.  C.  0/3  (48  hrs  PI) 
If  560  0/3  (48  hrs  PI) 
56  0/3  (48  hrs  PI) 
"  5600  i.  n.  3/3  (96  hrs  PI) 
"  560  3/3  (96  hrs  PI) 
56  3/3  (96  hrs  P1) Table  15:  (continued) 
P.  m.  JRMT2 
(QuettaaroA  mutant)  3.12  x  109  i.  p.  0/3  (48  hrs  PI) 
o"  3.12  x  108  3/3  (96  hrs  PI) 
3.12  x  107  3/3  (96  hrs  PI) 
3.12  x  109  i.  p.  3/3  (96  hrs  PI) 
3.12  x  108  3/3  (96  hrs  PI) 
3.12  x  107  3/3  (96  hrs  PI) 
"  3.12  x  109  i.  p.  3/3  (96  hrs  PI) 
3.12  x  108  3/3  (96  hrs  PI) 
'"  3.12  x  107  3/3  (96  hrs  PI) 98 
The  results  of  this  experiment  indicated  that  for  P.  multocida  85020  the 
LD50  by  the  i.  n.  route  was  =200  C.  F.  U.  and  for  Quetta  strain  was  >5600 
C.  F.  U.  /  mouse  whereas  for  the  aroA  mutant  strains  the  LD50  by  the  s.  c.  and 
i.  n.  routes  was  more  than  109  C.  F.  U.  /  mouse.  In  the  next  experiment 
(Experiment  6),  7  groups  of  5  mice  were  inoculated  intranasally  with  graded 
doses  of  P.  multocida  85020  and  Quetta  strains  and  observed  for  10  days  PI 
(Table  16).  This  experiment  gave  a  clear  indication  of  the  LD50  by  the  i.  n. 
route.  Again  the  85020  strain  appeared  to  be  more  virulent  by  this  route  (LD50 
1000  C.  F.  U.  /  mouse)  than  the  Quetta  strain  (LD50  =105  C.  F.  U.  /  mouse). 
3.6.  Mouse  protection  tests 
3.6.1.  Vaccination  with  P.  multocida  strains  JRMT1,  JRMT2  and  JRMT3 
(Experiment  7) 
Eight  groups  of  5  mice  were  inoculated  with  0.5  ml  of  culture  diluted  in 
PBS  and  containing  =2-3  x  107  C.  F.  U.  of  P.  multocida  JRMT1  and  JRMT2 
and  -3.65  x  103  C.  F.  U.  of  JRMT3  strains  by  the  i.  p.  route.  Two  weeks  later 
all  mice  were  challenged  with  different  doses  of  P.  multocida  85020  or  Quetta 
wild  type  strains.  The  uninoculated  control  groups  were  challenged  with  100 
LD50  of  the  wild-type  strains  (Table  17). 
The  results  of  this  test  showed  that  the  P.  multocida  JRMT1  and  JRMT2 
strains  completely  protected  the  mice  against  all  the  challenge  doses  with  the 
wild-type  strains,  but  P.  multocida  JRMT3  did  not  show  any  protective  effects 
at  the  vaccination  dose  used. 
3.6.2.  Effects  of  different  doses  and  different  time  intervals  between 
vaccination  and  challenge  (Experiment  8) 
Groups  of  6  mice  were  inoculated  with  107  C.  F.  U.  of  P.  multocida  JRMT1 
or  JRMT2  strains  by  i.  p.  route.  Two  weeks  later  all  groups  were  inoculated 
again  as  before.  After  two  further  weeks  all  mice  were  challenged  with  1000 Tablel6:  Virulence  properties  of  P.  multocida  strains  by  i.  n.  inoculation 
Treatments  C.  F.  U.  /  mouse  Route  of  inoculation 
No.  of  survivors 
No.  challenged 
P.  m.  85020 
(wild-type) 
1.23  x  104  i.  n.  1/5  (after  10  days) 
it  "  1.23  x  103  i.  n.  3/5  (after  10  days) 
of  it  1.23  x  102  i.  n.  5/5  (after  10  das) 
P.  m.  Quetta 
(wild-type) 
2.23  x  106  i.  n.  1/5  (after  10  days) 
to  of  2.23  x  105  i.  n.  3/5  (after  10  days) 
to  it  2.23  x  104  i.  n.  4/5  (after  10  days) 
Control  PBS  50  1  i.  n.  5/5  (after  10  days) Table  17:  Protection  properties  of  P.  multocida  strains 
Vaccination  Challenge  dose  i.  p.  No.  of  survivors 
Treatments  C.  F.  U.  /  mouse  route  (strain)  No.  challenged 
1000  LD50 
P.  m  . 
JRMT1  2.12  X  107  I.  P.  5/5  (by  6  days) 
(wild-type  85020) 
(85020  aroA  mutant) 
10,000  LD50 
if  2.12  X  107  i.  p.  5/5  (by  6  days) 
(wild-type  85020) 
1000  LD50 
P.  m.  JRMT2  3.24  X  107  I.  P.  5/5  (by  6  days) 
(wild-type  Quetta) 
(85020  aroA  mutant) 
10,000  LD50 
It  3.24  X  107  I.  P.  5/5  (by  6  days) 
(wild-type  Quetta) 
100  LD50 
P.  m.  JRMT3  3.65  X  103  I.  P.  (wild-type  85020) 
0/5  (by  2  days) 
(Quetta  cya  mutant) 
100  LD50 
It  3.65  x  103  i.  p.  0/5  (by  3  days) 
(wild-type  Quetta) 
100  LD50 
Control  PBS  i.  p.  (wild-type  85020) 
0/5  (by  36  hrs) 
100  LD50 
Control  PBS  i.  p.  (wild-type  Quetta) 
0/5  (by  36  hrs) 99 
and  10,000  LD50  of  wild  type  strains  (Table  18).  The  results  of  this 
experiment  again  showed  that  the  P.  multocida  JRMT1  and  JRMT2  strains 
could  protect  the  mice  against  challenge  with  either  wild-type  strain  and  no 
differences  were  observed  between  one  or  two  vaccine  doses. 
3.6.3.  Effect  of  different  routes  of  vaccination  (Experiment  9) 
Since  the  presumed  route  of  natural  infection  by  P.  multocida  is  via  the 
respiratory  tract,  it  is  assumed  that  local  defence  mechanisms  are  important  in 
preventing  establishment  of  infection.  To  determine  whether  P.  multocida  aroA 
mutant  could  function  as  an  effective  live  respiratory  vaccine,  we  attempted  to 
see  which  route  of  immunisation  would  provide  better  protection. 
Groups  of  4  mice  were  inoculated  with  graded  doses  of  P.  multocida 
JRMT1  or  JRMT2  by  the  i.  n.  or  s.  c.  routes  and  JRMT3  via  the  i.  p.  route. 
After  two  weeks  all  mice  were  inoculated  again  with  the  same  doses  of  the 
same  strains,  except  the  control  groups.  Two  weeks  later  mice  were  challenged 
with  different  doses  of  the  wild-type  strains  by  the  i.  p.  route.  The  mice  that 
were  given  two  doses  of  P.  multocida  JRMT1  or  JRMT2  strains  i.  n.  were 
completely  protected  against  i.  p.  challenge  but  this  was  not  the  case  for  a  single 
dose.  The  mice  given  two  doses  of  P.  multocida  JRMT1  or  JRMT2  strains  s.  c. 
showed  some  protection,  with  JRMT1  performing  bettter  than  JRMT2,  but 
protection  was  not  as  good  as  via  the  i.  n.  route.  Mice  that  were  given  P. 
multocida  JRMT3  strain  i.  p.  again  did  not  show  any  protection  (Table  19). 
The  mice  given  two  doses  of  the  strains  JRMT1  or  JRMT2  by  the  i.  n.  route, 
were  protected  against  heterologous  challenge  with  strains  Quetta  or  85020  by 
the  i.  p.  route. Table  18:  Protective  properties  of  aroA  mutants  of  P.  multocida  strains  85020  and 
Quetta  by  the  i.  p.  route 
1st  immunization  2nd  immunization  Challenge  dose  No.  of  survivors 
dose  (C.  F.  U.  /  mouse)  dose  (C.  F.  U.  /  mouse)  (strain)  No.  challenged 
2.3  x  107  P.  m.  JRMTI  1.1  x  107  P.  m.  JRMT1  100  LD50  6/6 
(85020  aroA  mutant)  (85020  aroA  mutant)  (  wild-type  85020) 
1000  LD50  6/6 
file  fill  fill  will  (wild-type  Quetta) 
1000  LD50  6/6 
""  ""  (  wild-type  85020) 
2.3  x  107  P.  m.  JRMT1  10,000  LD50  6/6 
(85020  aroA  mutamt)  ""  ""  (  wild-type  85020) 
6/6 
toff  fill  till  till 
3.0  x  107  P.  m.  JRMT2 
.4  x107  P.  m.  JRMT2  1000  LD50  6/6 
(Quetta  aroA  mutant)  (Quetta  aroA  mutant)  (  wild-type  85020) 
1000  LD50  6/6 
""  ""  ""  ""  (wild-type  85020) 
1000  LD50  6/6 
""  ""  (wild-type  Quetta) 
3.0  x  107  P.  m.  JRMT2  10,000  LD50  6/6 
(  Quetta  aroA  mutant)  ""  ""  (wild-type  Quetta) 
6/6 
f,,,  fill  fill  ,,,, 
100  LD50  0/  6  (by  24  hrs) 
Control  (wild-type  85020) 
100  LD50  0/  6  (by  24  hrs) 
Control  (wild-type  Quetta) Table  19:  protective  properties  of  P.  multocida  strains  JRMT1,  JRMT2  and 
JRMT3  by  different  routes 
1st  immunisation  2nd  mmunisation  Vaccination  Challenge  doses  i.  p.  No.  of  survivors 
dose  (C.  F.  U.  /  mouse)  dose  (C.  F.  U.  /  mouse)  route  (strain)  No.  challenged 
2.35  x  107  JRMT1  2  15  x  107  JRMR1  i.  n.  1000  LD50  4/  4  (by  day  6  PI) 
(85020  aroA  mutant) 
. 
(85020  aroA  mutant) 
(wild-type  85020) 
10000  LD50  4/  4  (by  day  6  PI) 
(wild-type  85020) 
-----  1000  LD50  1/  4  (by  day  6  PI) 
(wild-type  85020) 
-----  10000  LD50  0/  4  (by  day  6  PI) 
(wild-tvpe  85020) 
2.35  x  107  JRMTI  2.15  x  107  JRMT1  1000  LD50  3/  4  (by  day  6  PI) 
(85020  aroA  mutant)  (85020  aroA  mutant)  (wild-type  Quetta) 
2.35  x  107  JRMT1  2.35  x  107  JRMTI  1000  LD50  2/  4  (by  day  PI) 
(85020  aroA  mutant)  (85020  aroA  mutant)  S.  C.  (wild-type  85020) 
10000  LD50  1/  4  (by  day  6  PI) 
it  of  to  It  "  (wild-type  85020) 
-----  1000  LD50  0/  4  (by  day  3  PI) 
if  of  of  (wild-type  85020) 
-----  10000  LD50  0/  4  (y  day  2  PI) 
to  it  to  (wild-type  85020) 
2.35  x  107  JRMT1  2.15  x  107  JRMT  1  1000  LD50  1/  4  (by  day  4  PI) 
(85020  aroA  mutant)  (85020  aroA  mutant) 
(wild-type  Quetta) 
2.35x  107  JRMT2  2.42  x  107  JRMT2  1000  LD50  4/4  (by  day  6  P5 
(Quetta  aroA  mutant)  (Quetta  aroA  mutant) 
i.  n.  (wild-type  Quetta) 
10000  LD50  4/  4  (by  day  6  PI) 
(wild-type  Quetta) 
-----  1000  LD50  214  (by  day  6  PI) 
(wild-type  uetta 
-----  10000  LD50  1/4  (by  day  6  PI) 
(wild-type  Quetta) 
2.35  x  107  JRMT2  2.42  x  107  JRMT2  1000  LD50  4/  4  (by  day  6  PI) 
(Quetta  aroA  mutant)  (Quetta  aroA  mutant)  wild-type  85020) 
2.35  x  107  JRMT2  2.42  x  107  JRMT2  1000  LD50  0/  4  (by  day  3  PI) 
(Quetta  aroA  mutant)  (Quetta  aroA  mutant)  S.  C.  (wild-type  Quetta) 
10000  LD50  1/  4  (by  day  3  PI) 
of  if  it  of  It 
wild-  uetta 
-----  1000  LD50  0/  4  (by  day  3  PI) 
to  to  if  (wild-type  Quetta) 
-----  10000  LD50  0/  4  (by  day  2  PI) 
it  it  ff  (wild-type  Quetta) 
2.35  x  107  JRMT2  2.42  x  107  JRMT2  1000  LD50  0/  4(by  day  3  PI) 
(Quetta  aroA  mutant)  (Quetta  aroA  mutant) 
(wild-type  85020) Table  19:  (continued) 
2.67  x  107  JRMT3  2.67  x  107  JRMT3  100  LD50  0/  4  (by  day  3  PI) 
(Quetta  cya  mutant)  (Quetta  cya  mutant)  t"P"  (wild-type  Quetta) 
1000  LD50  0/  4  (by  day  2  PI) 
it  It  of  (wild-type  Quetta) 
-----  100  LD50  0/  4  (by  day  2  PI) 
wild-  Quetta) 
-----  1000  LD50  0/  4  (by  day  2  PI) 
(wild-type  Quetta) 
2.67  x  107  JRMT3  2.67  x  107  JRMT3  100  LD50  0/  4  (by  day  2  PI) 
(Quetta  cya  mutant)  (Quetta  cya  mutant)  (wild-type  85020) 
100  LD50  0/  4  (by  day  2  PI) 
PBS  PBS  i.  (wild-type  85020) 
100  LD50  0/  4  (by  day  2  PI) 
PBS  PBS  i.  (wild-type  Quetta) 100 
3.6.4.  Effect  of  different  vaccination  intervals  and  vaccination  route 
(Experiment  10) 
Eight  groups  of  5  mice  were  vaccinated  with  P.  multocida  JRMT1  by  the 
i.  p.,  i.  n.  and  s.  c.  routes.  After  2  weeks,  4  groups  were  challenged  i.  p.  with 
1000  LD50  of  P.  multocida  85020  and  rest  of  them  were  challenged  2  weeks 
later  by  the  i.  p.  route. 
The  results  of  this  experiment  (Table  20)  showed  that  the  mice  given  the 
vaccine  i.  p.  were  protected  against  i.  p.  challenge,  but  mice  vaccinated  by  the 
i.  n.  route  were  not  fully  protected  against  challenge  at  either  2  or  4  weeks  after 
vaccination.  Vaccination  by  the  s.  c.  route  gave  little  or  no  protection. 
3.6.5.  Effect  of  different  vaccination  and  different  challenge  routes 
(Experiment  11) 
Twelve  groups  of  3  mice  were  vaccinated  with  a  single  dose  of  P.  multocida 
JRMT1  by  different  routes  (i.  p.,  i.  n.  and  s.  c.  ) 
After  2  weeks,  1  group  vaccinated  by  each  route  was  challenged  with  100 
LD50  of  P.  multocida  85020  either  by  the  i.  p.,  i.  n.  or  s.  c.  routes.  The  strategy 
for  this  experiment  is  shown  below. 
Vaccination  route  Challenged  route 
1.  p. 
1.  p. 
1.  n. 
i.  n. 
S.  C. 
S.  C. 
Control Table  20:  Effect  of  different  vaccination  intervals  and  vaccination  routes 
Treatments  Vaccination  C.  F.  U.  /  mouse  Challenge  date  No.  of  survivors 
route  i.  p.  (PI)*  No.  challenged 
P.  m.  JRMTI 
(85020  aroA  mutant)  i.  p.  3.2  x  107  2  weeks  5/5 
P.  m.  JRMTI 
(85020  aroA  mutant)  i.  n.  3.2  x  107  2  weeks  3/5 
P.  m.  JRMTI 
(85020  aroA  mutant)  S.  C.  3.2  x  107  2  weeks  0/5 
Control  -----  -----  2  weeks  0/5 
P.  m.  JRMT1 
(85020  aroA  mutant)  i.  p.  3.2  x  107  4  weeks  5/5 
P.  m.  JRMTI 
(85020  aroA  mutant)  i.  n.  3.2  x  107  4weeks  2/5 
P.  m.  JRMT  1 
(85020  aroA  mutant)  S.  C.  3.2  x  107  4  weeks  1/5 
Control  -----  -----  4  weeks  0/5 
*  All  mice  challenged  with  100  LD50  of  P.  multocida  85020  wild-type  strain 
and  checked  for  6  days 101 
The  results  of  this  experiment  (Table  21)  showed  that  the  mice  given 
vaccine  i.  p.  were  completely  protected  against  challenge  by  all  routes,  but  the 
mice  given  vaccine  i.  n.  showed  complete  protection  against  in  challenge  but 
only  some  protection  against  i.  p.  and  s.  c.  challenge,  whereas  the  mice 
vaccinated  s.  c.  did  not  show  any  protection  against  challenge  by  any  route. 
These  results  suggested  that  the  best  way  for  vaccination  with  these  live 
attenuated  strains  was  i.  p.  or  i.  n.  routes. 
3.7.  Spread  of  the  bacteria  into  different  organs 
This  part  of  the  work  was  designed  to  compare  the  spread  of  the 
microorganisms  to  different  organs  when  inoculated  by  different  routes. 
For  this  experiment,  8  groups  of  8  mice  were  inoculated  with  P.  multocida 
strains  (85020,  Quetta,  JRMT1  and  JRMT2)  by  i.  p.  and  i.  n.  routes.  All  mice 
were  weighed  and  identified  individually.  Every  day,  2  mice  from  each  group 
were  sacrificed  and  the  liver,  lungs  and  spleen  of  each  mouse  were  removed 
aseptically  and  transfered  to  pre-weighed  Universal  bottles.  Also  0.1  ml  of 
heart  blood  from  each  mouse  was  collected  aseptically  and  diluted  into  5  ml 
sterile  PBS.  The  samples,  0.1  ml  of  neat  and  lOx  serial  dilutions  for  each 
0 
organ  were  plated  out  onto  BA  and  incubated  overnight  at  37  C.  The  colonies 
on  each  plate  were  counted  and  final  C.  F.  U.  of  microorganism  per  gram  of 
each  organ  and  per  ml  of  blood  were  calculated  (Tables  22-25). 
The  results  of  this  experiment  showed  that  i.  p.  inoculation  allowed 
proliferation  of  the  wild-type  parent  strains  in  all  of  the  tissues  by  24  hrs,  and 
mice  developed  a  fatal  peritonitis  and  septicaemia  and  died  by  36  hrs. 
Inoculation  i.  n.  also  led  to  proliferation  of  the  parent  strains  in  all  tissues,  but  to 
a  lower  level.  By  48  hrs  the  parent  strain  were  apparently  beginning  to  be 
cleared,  but  proliferation  had  increased  again  by  72  hrs.  An  initial  challenge 
dose  of  =104  C.  F.  U.  of  P.  multocida  85020  increased  to  more  than  1013 
organisms  per  gram  of  lung  in  72  hrs  in  one  instance.  Interestingly,  the  Quetta Table  21:  Effect  of  different  vaccination  and  different  challenge  routes 
Vaccination  Challenge  No-of  survivors 
Treatments  route  C.  F.  U.  /  mouse  route*  No.  challenged 
P.  m.  JRMT  1  2.6  x  107 
(85020aroA  mutant)  i.  p.  i.  p.  3/3  (by  day  6  PI) 
2.6  x  107 
i.  n.  3/3  (by  day  6  PI) 
2.6  x  107 
S.  C.  3/3  (by  day  6  PI) 
P.  m.  JRMT1  2.6  x  107 
(85020  aroA  mutant)  i.  n.  I.  P.  1/3  (by  day  6  PI) 
2.6  x  107 
i.  n.  3/3  (by  day  6  PI) 
2.6  x  107 
S.  C.  0/3  (by  day  3  PI) 
P.  m.  JRMT1  2.6  x  107 
(85020  aroA  mutant)  S.  C.  i.  p.  0/3  (by  day  3  PI) 
2.6  x  107 
of  if  it  it  in  0/3  (by  day  3  PI) 
2.6  x  107 
it  it  it  of  S.  C.  0/3  (by  day  3  PI) 
Control  ----  ------  I.  P.  0/3  (by  36  hrs  PI) 
Control  ----  ------  i.  n.  0/3  (by  day  4  PI) 
Control  ----  ------  S.  C.  0/3  (by  day  2  PI) 
*  Two  weeks  after  vaccination  all  mice  were  challenged  with  the  appropriate 
dose  of  P.  multocida  85020  wild-type  strain  (100  LD50) Table  22:  Viable  counts  of  bacteria  in  different  organs  after  24  hrs 
Mouse  Challenge  Challenge  dos  Route  of  Hrs  PI  C.  F.  U.  per  Gram  of: 
No.  Strain  C.  F.  U.  /mouse  inoculation  Liver  Lung  Spleen  Blood 
1  P.  m.  85020  723  i..  24  hrs  8.52X  1010  1.54X  1011  4.74X  1012  1.03X  109 
2  11  ..  ..  1.65X1010  7.33X1010  6.9X1011  1.33X109 
3  P.  m.  JRMTI  4.1  X  107  120  Neg  7000  1.55X104 
4 
H  of  it  to  It  80  to  1.3  X  104  500 
5  P.  m.  Quetta  337  1.2  X  1011  1.49X1010  1.45X1013  . 
0X1010 
6  .,  "  of  It  ..  '  2.15X  1010  3.85X1011  1.62X1013  1.0x1010 
7  P.  m.  JRMT2  6.68  X  107  of  360  Neg  1200  550 
8  if  of  of  of  it  120  3000  400 
9  P.  m.  85020  7.23  X  104  i.  n.  24  hrs  180  9900  5.2  X  105  1500 
10  of  to  1.  "  to  2.76  X104  7.26  X106  4.2  X104  1500 
11  P.  m.  JRMTI  4.1X  109  of  it  Neg  7.92  X  104  Neg  50 
12  it  of  to  It  of  of  "  3.63  X  104  30 
13  P.  m.  uetta  3.37X  106  "  11  1200  3.47  X  104  1.9X  105  5.0  X  104 
14  of  it  It  1140  1650  1000  500 
15  P.  m.  JRMT2  6.68X109  "  Neg  8.35  X104  Neg  1000 
16  to  to  I  to  of  I  of  240  7.69  X  105  of  500 
Neg=  No  colonies  detected Table  23:  Viable  counts  of  bacteria  in  different  organs  after  48  hrs 
Mouse  Challenge  Challenge  dos  Route  of  Hrs  PI  C.  F.  U.  per  Gram  of: 
No.  Strain 
. 
F.  U/  mouse  inoculation  Liver  Lung  Spleen  Blood 
1  P.  m.  85020  723  i..  48  ------  -------  -------  ------ 
2 
11  11  11  11  11  11 
-------  ------- 
3  P.  m.  JRMT  1  4.1  X  107  It  of  Neg  Neg  Neg  Neg 
4 
N  of  11  11  1/  $1  11  tl  of  11 
5  P.  m.  Quetta  337  to  Of  -------  -------  ------- 
6 
11  11  11  of  1.  11 
-------  -------  ------- 
7  P.  m.  JRMT2  6.68X  107  of  it  Neg  Neg  1000  Neg 
8 
11  11  11  11  11  11  60  11  Ne  11 
9  P.  m.  85020  7.23X  104  i,  n.  11  Ne  6.2X  108  1000  Neg 
10  11  11  11  10  ,1  11  11  9.9  X  105  Neg  100 
11  P.  m.  JRMT  1  4A  X  109  is  so  Neg  2.64X  104  Ne 
12  of  M  to  ,1  ,1  11  It  9900  01 
13  P.  m.  Quetta  3.37X106  Neg  3.48X  106  to 
14  11  ,1  11  10  of  2.18X  104  N  11 
15  P.  m.  JRMT2  6.68X  109  of  11  Neg  2.64X  104 
16  of  It  1.1.  11  11  11 
2.31)<!  04  11  1" 
Neg=  No  colonies  detected 
----  =  Mouse  died  before  48  hrs Table  24:  Viable  counts  of  bacteria  in  different  organs  after  72  hrs 
Mouse  Challenge  Challenge  dos  Route  of  Hrs  PI  C.  F.  U.  per  Gram  of: 
No  Strain 
. 
F.  U.  /mouse  inoculation  Liver  Lung  Spleen  Blood 
I  P.  m.  85020  723  i.  p.  72  hrs  -------  -------  -------  ------ 
2 
"  it  to  of  -------  -------  ------ 
3  P.  m.  JRMT  1  4.1X107  Neg  Neg  Neg  Neg 
4 
of  it  of  ￿  of  ￿  it 
5  P.  m.  Quetta  337  -------  -------  -------  ------ 
6 
to  it  of  .,  ,.  ,. 
-------  -------  ------- 
7  P.  m.  JRMT2  6.68X  107  Neg  Neg  Neg  Neg 
8 
.,  "  11  to  ￿  It  of  It 
9  P.  m.  85020  7.23X  104  i.  n.  72  hrs  2.77  X  1011  2.58X  1013  6.28  X  1010  2.23X  107 
10  of  to  it  7200  .9X 
1010  1000  163 
11  P.  m.  JRMT  1  4.1  X  109  "  Neg  . 
39  X  104  Neg  Neg 
12  ￿  It  ￿￿  ￿  "" 
. 
85  X  104  to  ￿ 
13  P.  m.  Quetta  3.37X106  it  . 
32  X  104  1.18  X  05  4.3  X  103  210 
14  to  of  It  it  It  of  . 
68  X  103  . 
67  X  105  2.2  X  104  3.1  X  104 
15  P.  m.  JRMT2  6.68X109  to  of  Neg  330  Neg  Neg 
16  of  of  to  of  It  of  «  2970  of  of 
Neg=  No  colonies  detected 
----  =  Mouse  died  before  72  hrs Table  25:  Viable  counts  of  bacteria  in  different  organs  after  96  hrs 
Mouse  Challenge  Challenge  dos  Route  of  Hrs  PI  C.  F.  U.  per  Gram  of. 
No.  strain  . 
F.  U/mouse  inoculation  Liver  Lung  Spleen  Blood 
1  P.  m.  85020  723  i..  96  hrs  -------  -------  -------  ------ 
2  of  .,..  it  ------ 
3  P.  m.  JRMT1  4.1  X  107  to  It  Neg  Neg  Neg  Neg 
4  "  of  of  of  of  to  of  to  to  if 
5  P.  m.  Quetta  337  ------ 
6  to  ,00.  of  to 
-------  -------  -------  ------ 
7  P.  m.  JRMT2  6.68  X  107  of  Neg  Ne  Neg  Neg 
8 
to  to  IT  u  of  to  of 
9  P.  m.  85020  7.23  X  104  i..  96  hrs  9.6  X  109  8.28  X  108  5.0  X  109  . 
78X104 
10  of  to  of  to  7.2  X  107  5.81  X  109  2.0  X  106  1.23X104 
11  P.  m.  JRMTI  4.1  X  109  of  Neg  Neg  Neg  Ne 
12  of  It  i,  of  of  it  it  ..  ..  .. 
13  P.  m.  Quetta.  3.37  X  106  It  Neg  Neg  Neg  Neg 
14  of  of  of  of  of  to  It  to 
15  P.  m.  JRMT2  6.68  X  109  "  Ne  99  Neg  Neg_j 
16  to  01  to  i,  11  11  1.  165  to  11 
Neg=  No  colonies  detected 
----  =  Mouse  died  before  96  hrs 102 
strain  was  cleared  by  96  hrs,  but  strain  85020  persisted.  For  the  aroA  mutants, 
inoculation  i.  p.  allowed  proliferation  into  all  tissues  except  the  lungs  by  24  hrs, 
although  at  a  much  reduced  level  compared  to  the  wild-type  parent  strains.  The 
bacteria  were  essentially  cleared  by  48  hrs  and  the  mice  survived.  Inoculation 
i.  n.  allowed  some  proliferation  in  the  lungs,  which  still  persisted  at  96  hrs  for 
the  Quetta  strain.  Low  numbers  of  bacteria  were  also  detected  in  blood  and  liver 
at  24  hrs  post-inoculation  but  not  at  later  times. 
3.8.  Phagocytosis  assay 
The  capacity  of  the  B:  2  P.  multocida  strains  to  invade  and  survive  within 
macrophage-like  cells  was  studied.  Prolonged  survival  of  the  organism  within 
macrophage,  a  feature  exhibited  by  pathogens  such  as  Salmonella 
typhimurium,  would  indicate  that  cell-mediated  immune  response  would  be 
needed  to  eliminate  the  organism  from  this  intracellular  niche. 
Table  26  and  27  shows  the  assay  protocol  and  results.  From  the  digitonin- 
treated  RAW  cells,  IOx  serial  dilutions  were  prepared  from  each  sample  in  PBS 
0 
and  100  µl  portions  spread  on  BA  and  incubated  at  37  C for  48  hrs.  The  viable 
count  results  are  shows  in  Table  27.  Taking  the  data  from  the  control  plates 
first,  exposure  of  the  RAW  cells  mixed  with  P.  multocida  to  digitonin  without 
first  removing  the  antibiotic,  resulted  in  no  colonies  detected  (wells  11  and  12). 
This  indicates  that  no  bacteria  survived  exposure  to  the  antibiotic.  Only  bacteria 
which  were  able  to  take  up  an  intracellular  location  could  survive  the  antibiotic 
treatment,  as  long  as  the  antibiotic  was  removed  by  washing  before  lysis  of  the 
mammalian  cells  with  digitonin.  No  antibiotic  treatment  gave  surviving  colonies 
at  10-4  dilution  (well  9  and  10)  indicating  that  washing  cells  did  not  remove  all 
the  bacteria.  The  remainder  of  the  wells  gave  results  for  wells  where  the  RAW 
cells  had  been  exposed  to  the  P.  multocida  strain  for  2  hrs,  followed  by 
washing  and  antibiotic  treatment  to  remove  extracellular  bacteria.  A  further  3 
washes  was  followed  by  exposure  to  digitonin  at  time  intervals  to  release A  W  N  :  --'  O 
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a Table  27:  Viable  counts  from  the  phagocytosis  assay 
No  Treatments  Neat  Dil.  10-1,  Dil.  10-2  Dil.  10-3  il.  10-4 
1  P.  m.  85020+  cells  Non  countable  2.19  x  104  1.11  x  104  ---- 
2  it  to  of  if  2.18  x  104  2000  ---- 
3  7.88  x  104  1.14  x  104  1700  ---- 
4  4.74  x  104  7800  800  ---- 
5  P.  m.  JRMT1+  cells  Non  countable  8.74  x104  1.31  x  104  600 
6  9.24  x  104  1.88  x  104  1700 
7  7.28  x  104  7500  1000 
8  5.20  x  104  3700  500 
9  P.  m.  85020  +  cells  Confluent  Non  countable  1.08  x  104  1400  200 
10  P.  m.  JRMT1+  cells  Non  countable  4.35  x  104  3800  400 
11  P.  m.  85020  +  cells  ----  ---- 
12  P.  m.  JRMT1+  cells  ----  ---- 
13  P.  m.  85020  -----  ----  ---- 
14  P.  m.  JRMT1  ----  ----  ---- 
----  =  No  colonies  detected 103 
intracellular  bacteria.  The  results  indicate  that  the  wild-type  parent  strain  85020 
could  enter  RAW  cells  and  survive  for  at  least  2  hrs.  Interestingly,  the  aroA 
mutant  became  intracellular  to  a  greater  extent  than  its  parent  strain,  but  its 
number  decreased  in  a  similar  manner  over  a  period  of  2  hrs.  This  experiment 
was  repeated  and  gave  essentially  similar  results. 104 
4.  DISCUSSION 
4.1.  Construction  of  defined  mutants  of  P.  multocida  strains 
Despite  the  availability  of  different  vaccines,  including  killed  whole-cell  and 
live-attenuated  vaccines,  the  control  of  haemorrhagic  septicaemia  in  cattle  and 
buffalo  still  remains  problematic  because  the  current  vaccines  are  not 
sufficiently  effective  and  require  repeated  adminstration.  The  ideal  and  more 
preferred  live  vaccine  for  HS  should  mimic  the  natural  infection  and  be  capable 
of  surviving  for  a  period  of  time  within  the  host  sufficient  to  stimulate 
protective  immunity.  It  should  contain  a  genetically-defined  mutation(s)  which 
renders  the  vaccine  strain  unable  to  establish  continued  growth  in  vivo  and 
which  minimises  the  risk  of  reversion  to  the  wild-type.  Rationally-attenuated 
aro  mutants  of  several  bacterial  species  provide  some  of  these  criteria  and  have 
been  demonstrated  to  be  strongly  immunogenic  and  to  confer  solid  protection 
against  experimental  challenge  at  least  in  the  mouse  model,  but  also  in  some 
instances  in  cattle  (Ramos  et  al.  1998)  (Table  3). 
In  this  section  we  have  reported  the  molecular  cloning  of  the  aroA  gene  of 
P.  multocida  B:  2  as  well  as  the  construction  of  mutant  strains  of  P.  multocida 
strains  85020  and  Quetta,  by  insertional  inactivation  of  the  aroA  gene  with  a 
KmR  cassette.  Additional  data  indicated  that  the  aroA  strains  have  potential  as 
effective  live  vaccines. 
The  aroA  mutant  strains  were  functionally  evaluated  by  EPSP  synthase 
assay  and  animal  tests.  In  comparison  to  P.  multocida  85020  and  Quetta,  the 
wild-type  parent  strains,  JRMT1  and  JRMT2,  the  aroA  mutant  strains,  did  not 
show  any  detectable  activity  for  EPSP  synthase.  EPSP  synthase  occurs  at 
relatively  low  levels  in  bacteria;  for  example,  for  Escherichia  coli  it  must  be 
purified  over  2000-fold  to  achieve  homogeneity  (Lewendon  and  Coggins, 
1983).  As  reported  by  Lewendon  and  Coggins  (1983)  it  was  very  difficult  to 105 
estimate  the  amount  of  enzyme  in  crude  extracts  of  E.  coli  (ATCC  14948),  but 
after  (NH4)2  S04  fractionation  EPSP  synthase  activity  was  located  in  the  50- 
70%  saturation  fraction  as  0.021  units/  mg.  Also  in  a  report  by  Duncan  et  al. 
(1994)  the  specific  activity  of  E.  coli  K12  (ATCC  14948)  was  cited  as  0.004 
units/  mg. 
Survival  of  mice  and  the  LD50  values,  demonstrated  that  the  P.  multocida 
aroA  mutants  are  highly  attenuated  for  prolonged  colonisation  and  infection  of 
internal  organs  relative  to  the  wild-type  parent  strains.  The  persistence  of  the 
mutant  strains  in  mouse  tissues,  as  determined  by  the  recovery  of  viable 
bacteria  was  shorter  than  that  described  by  Dougan  et  al.  (1989)  for  a 
genetically  attenuated  Salmonella  typhimurium  aroA  mutant.  The  more  rapid 
clearance  of  P.  multocida  aroA  mutants  may  be  related  to  possible  different 
colonisation  sites  in  the  tissues  and  to  difference  between  the  species  in  their 
ability  to  survive  intracellularly.  Clearance  of  P.  multocida  aroA  mutants  from 
the  lung  was  similar  to  that  described  for  a  Bordetella  pertussis  aroA  mutant 
where  Roberts  et  al.  (1990)  found  that  the  number  of  Bordetella  pertussis  aroA 
bacteria  decreased  daily  until  they  were  cleared  from  the  lungs  between  days  5 
and  8. 
As  noted  by  Tacket  et  al.  (1992),  pathogenic  Salmonella  typhimurium, 
Salmonella  dublin  and  Salmonella  typhi  have  been  successfully  attenuated  by 
insertional  inactivation  or  deletion  of  aroA  genes.  Such  aroA  strains  of  S. 
typhimurium  used  as  live  oral  vaccines  are  safe  in  mice  and  calves  and  protect 
these  animals  against  lethal  challenge  with  virulent  parent  strains.  Homchampa 
et  al.  (1992)  constructed  an  aroA  mutant  of  P.  multocida  serotype  A:  1,  a  fowl 
cholera  agent,  and  they  found  that  it  was  highly  attenuated  and  protected  mice 
against  wild-type  challenge. 
The  behaviour  of  aroA  mutants  is  not  necessarily  the  same  in  all  bacterial 
species.  Oyston  et  al.  (1996)  found  that  the  aroA  mutant  of  Yersinia  pestis  was 106 
attenuated  in  the  guinea-pig  but  still  remained  virulent  in  mice.  In  guinea-pigs, 
immunity  was  induced  with  a  single  low  dose  of  the  aroA  mutant  and  protected 
them  against  challenge  with  wild-type  virulent  strain.  The  aroA  mutant  was  still 
virulent  in  mice  although  there  was  an  increased  time  to  death.  In  comparison 
to  the  aroA  mutant  of  Yersinia  enterocolitica  that  is  attenuated  in  mice,  Y.  pestis 
produces  a  toxin,  which  is  active  in  mice.  This  may  go  some  way  towards 
explaining  the  observed  host-dependent  nature  of  the  attenuation. 
The  present  data  confirm  the  use  of  rational  attenuation  as  a  means  of 
constructing  non-reverting,  live  vaccine  strains  of  P.  multocida.  When  injected 
into  mice,  the  aroA  mutant  strains  described  here  showed  considerable  loss  of 
virulence  and  no  illness  was  observed  following  injection  of  107  or  109 
C.  F.  U.  /  mouse  by  the  i.  p.  or  i.  n.  routes  respectively.  This  compares  with  an 
LD50  of  less  than  50  and  103  C.  F.  U.  /  mouse  for  the  parent  strains  by  the  i.  p. 
or  i.  n.  routes,  respectively.  Inability  to  isolate  the  aroA  mutants  from 
peripheral  blood  of  mice  at  48  hrs  after  i.  p.  injection  indicated  that  these 
strains  had  greatly  reduced  ability  to  survive  in  vivo. 
Live  fowl  cholera  vaccine  administered  in  drinking  water  was  reported  to 
stimulate  cross-immunity  to  a  heterologous  strain  in  chickens  (Heddleston  et 
al.,  1975),  but  Adler  et  al.  (1996)  reported  that  the  aroA  mutant  of  P. 
multocida  A:  1  strain  could  not  protect  mice  against  heterologous  challenge  by 
i.  p.  route  and  they  suggested  that  this  may  be  depend  either  an  excessive 
attenuation  or  that  host-specific  cross-protective  antigens  induced  in  the 
chicken  were  not  expressed  in  mice  due  to  differing  environmental  conditions 
such  as  body  temperature.  Finally  they  suggested  that  the  cross-immunity  is 
manifested  only  when  vaccination  and/or  challenge  occurs  by  alternative  oral  or 
i.  n.  routes.  In  the  experiments  reported  here  i.  p.  immunisation  with  one  dose 
of  P.  multocida  JRMT1  (aroA  mutant  of  strain  85020)  and  JRMT2  (aroA 
mutant  of  strain  Quetta)  completely  protected  mice  against  homologous  and 107 
heterologous  challenge  with  1000  LD50  of  the  wild-type  strains  (Tables  18  and 
19).  As  reported  by  Adler  et  al.  (1999)  it  has  been  speculated  that  the  in  vivo 
expression  of  cross-protective  antigens  may  be  induced  by  the  low 
concentration  of  iron  in  the  host  tissues.  Iron,  essential  for  bacterial  growth,  is 
largely  unavailable  in  vivo  as  a  result  of  binding  by  host  proteins  such  as 
transferrin  and  lactoferrin.  Pathogenic  bacteria,  such  as  P.  multocida, 
overcome  these  iron  limitations  by  expressing  of  iron  regulatory  proteins.  The 
mechanism  of  in  vivo  iron  acquisition  by  P.  multocida  is  not  clear,  but  some 
high  molecular  weight  outer  membrane  proteins  (OMPs)  (Snipes  et  al.,  1988; 
Choi  et  al.,  1991)  were  identified  when  P.  multocida  was  grown  under  iron 
limiting  conditions.  Adler  et  al.  (1999)  found  that  these  outer  membrane 
proteins  appear  to  be  expressed  in  vivo  and  it  has  been  speculated  that  these 
iron-regulated  OMPs  may  be  involved  in  cross-protective  immunity.  Glisson  et 
al.  (1993)  showed  that  whole-cell  bacterins  grown  under  iron  limiting 
conditions  could  stimulate  cross-immunity  in  mouse  model.  Ruffolo  et  al. 
(1998)  demonstrated  that  OMPs  of  P.  multocida  produced  under  iron-limiting 
conditions,  which  mimic  the  concentration  of  iron  in  vivo,  could  induce  cross- 
protective  immunity  in  mice  whereas  OMPs  produced  under  iron  replete 
conditions  stimulated  only  homologous  protection. 
Since  the  route  of  natural  infection  by  P.  multocida  is  probably  via  the 
respiratory  tract,  we  evaluated  the  effect  of  i.  n.  vaccination.  One  dose  of  in 
live  aroA  vaccine  of  either  strain  induced  relatively  poor  levels  of  protection 
against  an  i.  p.  challenge  with  the  homologous  wild-type  P.  multocida  strains. 
However,  after  a  second  dose  of  live  cells,  there  was  a  sharp  increase  in  the 
number  of  survivors  of  a  lethal  homologous  or  hetrologous  challenge  (Table 
19).  As  was  found  by  Collins  (1973),  one  dose  of  formalin  killed  P.  multocida 
strain  when  used  by  the  in  route  produced  partial  protection  in  the  mouse 
model  against  i.  p.  challenge  whereas  two  doses  of  i.  n.  vaccine  produced 
strong  immunity  against  the  wild-type  strains.  Smith  et  al.  (1981)  reported  that 108 
i.  n.  immunisation  with  a  P.  multocida  bacterin  protected  the  mice  from  an  i.  p. 
P.  multocida  challenge.  In  the  work  of  Collins  and  Woolcock  (1976),  mice 
were  protected  from  an  i.  p.  challenge  if  immunised  i.  p.  with  formalin-killed  P. 
multocida,  but  i.  p.  immunised  mice  responded  poorly  to  an  i.  n.  challenge  and 
some  mice  died  as  a  result  of  the  challenge.  Thus,  according  to  the  results 
obtained  on  Table  18,  the  local  defence  mechanisms  may  have  a  significant  role 
in  preventing  establishment  of  infection. 
In  aro  mutants,  the  attenuation  might  be  either  as  a  result  of  unavailability  of 
metabolites  derived  from  the  biosynthetic  pathway  due  to  inhibition  of  a  key 
enzymatic  step  (downstream  effect)  or  because  of  accumulation  of  toxic 
substrate  or related  metabolite  due  to  enzyme  inhibition  (upstream  effect).  As 
mentioned  by  Gunel-Ozcan  et  al.  (1997),  shikimate  pathway  inhibition  studies 
on  plants  and  the  original  studies  on  attenuation  of  Salmonella  typhimurium 
aroA  mutant  suggest  that  downstream  effects  are  probably  responsible  for  the 
attenuation  of  aroA  mutants.  For  the  Bordetella  pertussis  aroA  mutant,  Roberts 
et  al.  (1990)  proposed  that  attenuation  was  probably  due  to  starvation  in  vivo 
of  an  essential  aromatic  metabolite  rather  than  indirect  effects  on  the  expression 
of  virulence  factors.  Our  finding  confirmed  these  suggestions,  because  when 
P.  multocida  strains  JRMT1  and  JRMT2  (the  aroA  mutants  of  strains  85020 
and  Quetta  respectively)  were  inoculated  into  aromix  supplemented  PMM,  they 
grew  to  an  OD450nm  =0.5-0.6,  in  comparison  to  OD  =0.03-0.04  in  PMM 
without  aromix  supplementation  (Fig.  22) 
4.2.  Construction  of  double  mutants 
As  cited  by  Curtiss  (1990),  a  difficulty  with  auxotrophs  is  the  potential  to 
reverse  the  attenuating  mutation  phenotypically  by  inclusion  of  the  required 
nutrient  in  the  diet  of  animäls  inoculated  with  the  auxotrophic  mutant.  Thus 
ideally  the  mutated  vaccine  strains  should  have  two  or  more  attenuating 
deletion  mutations  to  preclude  loss  of  the  attenuation  traits  by  reversion,  gene 109 
transfer  or  growth  supplements.  This  is  critical  for  the  safety  of  live  vaccine 
strains  and  is  an  essential  requirement,  because  live  vaccine  strains  used  for 
protection  of  animals  might  sometimes  be  transmitted  through  the  food  chain  to 
humans.  Also,  Curtiss  (1990)  reported  that  phenotypic  reversion  occurred 
readily  for  pab  and  pur  mutants  of  Salmonella  typhimurium.  Thus  strains  with 
two  or  more  mutations  conferring  auxotrophy  have  been  constructed. 
However,  as  noted  by  Levine  et  al.  (1987),  a  construct  of  Salmonella  typhi 
with  two  mutations  in  the  aroA  and  purA  genes  was  not  immunogenic  in 
humans  because  of  the  severe  attenuation  imposed  by  this  combination  of 
mutations.  A  similar  observation  was  made  by  O'Callaghan  et  al.  (1988)  for 
AaroA,  ApurA  mutations  of  Salmonella  typhimurium  which  were  not 
immunogenic  in  mice.  On  the  other  hand,  Hone  et  al.  (1991)  constructed  a 
double  aroD  aroC  mutant  of  Salmonella  typhi  and  found  that  the  mutant  strains 
were  highly  attenuated  and  were  protective  in  a  mouse  model  against  wild-type 
challenge.  Tacket  et  al.  (1992)  constructed  double  mutation  strains  such  as 
aroA,  aroD  and  cya,  crp  of  Salmonella  typhi  that  were  highly  attenuated  and 
yet  immunogenic  in  human.  Thus,  double  mutations  affecting  the  same  broad 
physiological  function  retain  immunogenicity,  but  retain  the  potential  problem 
of  phenotypic  reversion. 
An  attempt  was  made,  therefore,  to  construct  double  mutations  in  P. 
multocida  strains.  For  this  purpose  the  cya  gene  was  chosen  and  inactivated  by 
deletion  and  insertion  of  a  KmR  cassette,  and  also  by  deletion  and  insertion  of 
an  ApR  cassette,  because  the  recipient  strains  contained  an  aroA  mutation  with 
a  Km1  insertion.  No  reports  were  found  in  which  a  defined  P.  multocida  cya 
mutant  was  constructed  and  tested  for  virulence  and  protection  properties.  This 
locus  was  chosen  for  study  because  Tacket  et  al.  (1992)  reported  that  a  strain 
of  Salmonella  typhi  carrying  a  deletion  in  the  cya  gene  had  reduced  virulence, 
but  was  immunogenic  in  humans.  Unfortunately,  allelic  exchange  in  the  cya 
locus  proved  to  be  very  difficult.  Using  this  strategy,  it  was  possible  to 110 
introduce  plasmids  pJRMT10,  containing  the  KmR  inactivated  cya  gene  of  P. 
multocida  strain  85020,  and  pJRMTI  1,  containing  the  KmR  inactivated  cya 
gene  of  P.  multocida  strain  Quetta,  into  wild-type  P.  multocida  strains.  The 
results  of  subsequent  Southern  blot  analysis  were  consistent  with  integration  of 
the  vector  into  the  cya  gene,  but  the  size  of  the  resulting  restriction  fragments 
which  hybridised  to  the  cya  gene  probe  suggested  duplication  in  this  region. 
Such  an  event  could  occur  through  homologous  recombination  of  daughter 
genomes  at  the  intact  and  mutated  alleles  of  the  cya  locus  during  DNA 
replication  under  kanamycin  selection  pressure.  Donnenberg  and  Kaper  (1991) 
reported  duplication  of  the  eae  gene  of  E.  coli  under  ampicillin  selection 
pressure.  The  Southern  blot  results  with  the  P.  multocida  transformants, 
showed  that  KmR  clones  had  a  different  pattern  to  the  wild-type  parent  strains, 
and  indicated  that  the  first  crossing-over  event  happened  with  high  frequency 
and  the  plasmid  containing  the  KmR-interrupted  cya  gene  integrated  into  the 
genome,  but  for  unknown  reasons  the  second  crossing-over  event  never 
happened  except  in  one  clone.  This  cya::  KmR  strain  (JRMT3),  when  tested  in 
mice  for  virulence  and  protection  properties  by  the  i.  p.  route,  showed  some 
attenuation  with  a  LD50  of  about  1000  C.  F.  U.  /  mouse  in  comparison  to  the 
wild-type  parent  strain  with  a  LD50  less  than  50  C.  F.  U.  /  mouse,  but  it  did  not 
induce  protection.  The  possible  reason  for  this  may  be  that  the  low  number  of 
organisms  inoculated  to  avoid  toxicity  was  not  enough  for  stimulation  of  the 
immune  system.  Curtiss  and  Kelly  (1987)  reported  that  a  Salmonella 
typhimurium  cya  mutant  was  highly  attenuated  in  the  mouse  model  by  oral 
administration  with  more  than  109  C.  F.  U.  and  protected  the  mice  against 
challenge  with  10000  LD50  of  the  wild-type  parent  strain  by  the  oral  route. 
Because  the  cya  construct  JRMT3  was  only  slightly  attenuted  it  was 
considered  that  introduction  of  cya  and  aroA  mutations  into  the  same  P. 
multocida  strain  might  create  a  vaccine  candidate  that  retained  good 
immunogenicity  but  which  might  have  lost  the  problem  of  toxicity.  Data presented  here  indicated  that,  at  high  doses,  the  aroA  mutant  strains  exhibited 
some  toxicity  (Table  12)  which  might  be  reduced  by  the  introduction  of  a 
second  attenuating  cya  mutation. 
For  construction  of  double  mutant  strains,  P.  multocida  strains  JRMT  1  and 
JRMT2  (aroA  mutants)  were  used  as  recipients  and  repeated  attempts  were 
made  to  introduce  the  ApR-interrupted  cya  gene  by  electroporation.  Again  the 
cya  locus  showed  problems  for  allelic  exchange  with  just  the  first  cross-over 
event  apparently  occurring,  and  when  ApR  clones  were  checked  by  Southern 
blottting,  they  showed  both  wild-type  and  mutated  hybridisation  patterns  at  the 
cya  locus.  Harman  and  Dobrogosz  (1983)  noted  that  a  cya  mutant  of  E.  coli 
was  difficult  to  manipulate  because  it  had  a  tendency  to  revert  to  a  wild-type 
phenotype  at  high  frequency  in  liquid  or  on  agar  culture.  They  proposed  that, 
in  E.  coli,  one  mechanism  for  cya  suppression  is  the  formation  of 
compensatory  mutations  in  the  crp  gene. 
Another  possibility  that  was  explored  was  the  construction  of  a  second 
mutation  site  in  the  P.  multocida  chromosome  by  targetting  the  galE  gene.  As 
demonstrated  by  Germanier  and  Furer  (1975)  the  galE  mutants  of  Salmonella 
typhimurium  and  Salmonella  typhi,  which  are  unable  to  synthesise  the  enzyme 
UDP-galactose-4-epimerase,  were  avirulent  and  immunogenic  in  the  mouse 
model  by  the  i.  p.  route.  It  is  not  clear,  however,  whether  it  is  the  sensitivity  to 
galactose  (resulting  in  cell  lysis)  or  the  inability  to  synthesise  complete  LPS 
which  renders  the  cells  susceptible  to  non-specific  host  defense  mechanisms, 
leads  to  avirulence  in  vivo.  Unfortunately,  the  KmR-interrupted  galE  gene 
again  presented  problems  for  allelic  exchange  in  P.  multocida  strains.  One  of 
the  main  problems  was  multiplication  of  suicide  vectors,  pJRMT17, 
pJRMT  18,  pJRMT  19  and  pJRMT20,  in  P.  multocida  strains,  because  the 
plasmids  with  ColE  I  origin  were  maintained  in  the  presence  of  kanamycin  and 
actually  did  not  appear  to  act  as  suicide  vectors  in  P.  multocida  strains.  The 112 
same  phenomenon  has  been  described  in  other  strains  of  P.  multocida. 
Homchampa  et  al.  (1992,1994)  and  Henestrosa  et  al.  (1997)  reported  that  the 
suicide  vectors  pMEC  124  and  pMEC200  (pUC18-base  plasmids)  and 
pUA659  (a  pGP704-base  plasmid)  respectively  were  able  to  replicate  in  P. 
multocida  serotypes  A:  1,  P.  haemolytica  serotype  A:  1  and  P.  multocida 
serotype  D:  12  strains  respectively.  It  is  possible  that  the  frequency  of  gene 
recombination  at  the  galE  locus  in  P.  multocida  is  relatively  low,  since  only  a 
few  transconjugants  were  obtained  with  either  P.  multocida  85020  or  Quetta 
strains  from  the  huge  number  of  colonies  screened.  When  these  colonies  were 
subcultured  for  selection  of  the  deleted  galE  mutants,  no  colonies  of  the 
correct  genotype  were  obtained. 
The  behavior  of  galE  mutant  strains  in  different  bacterial  species  is  not  the 
same.  In  contrast  to  galE  mutants  of  E.  coli  and  Haemophilus  influenzae,  galE 
mutants  of  Neisseria  meningitidis  (Jennings  et  al.,  1993)  and  Neisseria 
gonorrhoeae  (Robertson  et  al.,  1993),  although  they  produced  rough  LPS, 
were  not  galactose  sensitive,  because  they  did  not  utilise  galactose  as  a  carbon 
source.  In  Yersinia  enterocolitica,  mutation  in  the  galE  gene  eitherdid  not 
affect  the  Leloir  pathway  or  the  organism  has  an  alternative  pathway  for 
galactose  utilisation,  because  when  this  mutants  was  grown  in  media 
containing  glucose  or  galactose,  neither  sugar  had  any  effect  on  the  LPS 
profile  of  the  mutant  (Pierson  and  Carlson,  1996).  In  Bacillus  subtilis,  as 
reported  by  Krispin  and  Allmansberger  (1998),  glucose  is  able  to  alleviate  the 
effects  of  galactose,  as  it  dose  in  galE  mutants  of  enterobacteria,  but  causes 
cell  death  during  late  log  phase.  Thus,  one  task  of  the  GalE  protein  is 
therefore  to  protect  the  cell  from  the  toxic  effects  of  galactose  and  glucose  or 
derivatives  of  both  sugars  which  accumulate  in  its  absence.  As  was  found  by 
Henestrosa  et  al.  (1997),  a  P.  multocida  galE  mutant  of  serotype  D:  12  that 
they  constructed  showed  some  slight  attenuation  and  delay  in  time  to  death  of 113 
mice  and  they  proposed  that  the  galE  mutation  could  be  useful  as  part  of 
double  mutant  strains  for  construction  of  live  vaccines.  The  reasons  why  the 
experiments  reported  here  failed  to  achieve  the  required  galE  construct  are  not 
clear,  as  the  procedures  adopted  were  essentially  similar  to  those  reported  by 
Henestrosa  et  al.  (1997). 
4.3.  Construction  of  marker-free  P.  multocida  strains 
Because  the  properties  of  the  aroA  derivatives  JRMTI  and  JRMT2 
suggested  that  attenuation  of  the  aroA  locus  would  provide  a  good  vaccine 
candidate,  it  was  decided  to  construct  a  marker-free  derivative  more  suitable  for 
use  as  a  vaccine. 
In  this  part  of  the  work,  the  construction  of  P.  multocida  strains  with  a 
deletion  mutation  in  aroA  gene  were  described  and  also  their  virulence  and 
protection  properties,  using  i.  p.  challenge  of  mice.  An  improved  procedure  for 
allelic  exchange  was  developed  using  the  Bacillus  subtilis  sacB  gene  as  a 
positive  selective  marker. 
Most  currently  available  gene  cloning  vectors  for  bacteria  are  based  on 
multicopy  plasmids  carrying  antibiotic  resistance  markers.  Although 
recombinant  plasmids  may  be  readily  maintained  in  bacteria  cultivated  in 
culture  under  controlled  environmental  conditions,  they  are  frequently  unstable 
within  host  organisms  when  grown  in  the  absence  of  antibiotics.  Furthermore, 
antibiotic  resistance  markers  are  generally  perceived  as  undesirable  in 
organisms  designed  for  release  in  large  quantities,  such  as  live  vaccines  or 
bacteria  developed  to  degrade  chemical  pollutants. 
Construction  of  deleted  aroA  mutants  according  to  the  procedure  of 
Homchampa  et  al.  (1997),  by  a  combination  of  repeated  subculture  and 
auxotrophic  enrichment,  proved  unsuccessful.  When  selected  KmR  clones 
were  checked  by  PCR,  they  showed  the  wild  type  pattern.  In  another  attempt, 114 
screening  for  sensitivity  to  ampicillin  or  kanamycin  carried  by  the  vectors  was 
attempted.  When  the  resulting  colonies  were  checked  by  PCR,  it  was  found 
that  most  clones  contained  both  wild-type  and  mutated  alleles  and  repeated 
subculturing  in  the  absence  of  antibiotic  to  promote  loss  of  the  integrated 
plasmid  via  a  second  crossing-over  was  not  successful.  After  further 
subculture,  the  clones  lost  the  mutated  allele  and  reverted  to  the  wild-type. 
Finally,  for  first  time  in  Pasteurella  spp.,  the  sacB  gene  of  Bacillus  subtilis 
was  used  as  a  positive  selective  marker  and  was  found  to  be  more  effective  in 
P.  multocida  for  induction  of  the  double  cross-over  event.  The  sacB  locus 
encodes  the  enzyme  levan  sucrase,  which  is  toxic  for  Gram-negative  bacteria 
only  in  presence  of  sucrose  (Gay  et  al.,  1985).  The  sacB  gene  was  included  in 
to  the  suicide  vector  pAKA19  to  provide  a  conditionally  lethal  phenotype,  but 
was  first  cloned  into  plasmid  pAKA16  to  check  expression  of  the  sucrose 
sensitivity  phenotype  in  P.  multocida  strains.  When  P.  multocida  strains 
JRMT8  (  85020  containing  the  sacB  gene)  and  JRMT9  (Quetta  containing  the 
sacB  gene)  were  plated  on  BHI  agar  supplemented  with  5%  (v/v)  sheep  blood 
O 
containing  5%  (w/v)  sucrose,  after  overnight  incubation  at  37  C,  the  predicted 
0 
number  of  colonies  had  grown  up,  but  when  left  for  about  40  hrs  at  37  C,  all 
colonies  were  liquified.  This  indicated  that  the  sacB  gene  phenotype  was 
expressed  in  P.  inultocida  strains  and  rendered  them  sensitive  to  sucrose,  and 
that  it  could  be  used  as  a  positive  selection  marker  in  these  strains  of  P. 
multocida.  Jost  et  al.  (1997)  used  the  Bacillus  subtilis  sacB  gene  as  a  counter- 
selectable  marker  in  serogroups  A:  1  (PBA-100  and  X-73),  A:  3  (P-1059),  A:  4 
(P-1662)  and  B:  2  (M1404)  strains  of  P.  multocida.  But  they  found  that 
expression  of  the  sacB  gene  failed  to  render  any  of  the  strains  sensitive  to 
sucrose,  and  they  reported  that  the  sacB  gene  cannot  be  used  as  a  positive 
selection  system  for  allelic  exchange  in  P.  multocida  strains.  They  suggested 
that,  because  fructose  is  a  major  component  of  the  capsule  of  P.  multocida 
strains  (Rimler  and  Rhoades,  1989)  the  lack  of  cell  death  as  a  result  of 115 
expression  of  sacB  gene  may  be  attributed  to  the  ability  of  this  organism  to 
utilise  the  activated  fructose  for  inclusion  into  capsular  material.  The  reason  for 
this  discrepancy  between  the  work  reported  here  and  that  of  Jost  et  al.  (1997) 
is  unclear.  Perhaps  Jost  et  al.  did  not  leave  their  plates  long  enough  to  see 
expression  of  the  sucrose-sensitive  phenotype. 
The  P.  multocida  strains,  after  transformation  of  the  suicide  vector  and 
integration  of  the  mutated  version  of  aroA  gene  into  the  aroA  locus,  were 
exposed  to  sucrose  to  directly  select  for  organisms  that  had  undergone  a 
second  recombination  event  resulting  in  the  loss  of  the  suicide  vector.  As 
reported,  different  non-antibiotic  markers  have  been  used  in  Gram-negative 
bacteria  for  induction  of  marker-free  mutations.  Herrero  et  al.  (1990)  reported 
successful  results  with  three  different  markers  such  as  resistance  to  the 
herbicide  bialphose,  to  mercuric  salts  and  organomercurial  compounds  and  to 
arsenite  in  Pseudomonas  putida  and  Klebsiella  pneumoniae.  Also  Donnenberg 
and  Kaper  (1991)  used  the  sacB  gene  of  Bacillus  subtilis  to  construct  an  eae 
deletion  mutant  in  enteropathgenic  E.  coli.  In  addition  to  plasmids  pJRMT31 
and  pJRMT32  containing  the  aroA  deletion  allele,  we  developed  a  sacB- 
containing  suicide  vector  for  general  use  and  designated  this  as  pJRMT30. 
However,  for  construction  of  a  marker-free  galE  mutant,  again  there  were 
problems  during  the  allelic  replacement  event.  After  transfer  of  suicide 
plasmids  containing  the  deleted  galE  allele,  with  or  without  the  sacB  gene, 
into  P.  multocida  strains  by  electroporation  or  transconjugation,  PCR  analysis 
demonstrated  an  unexpected  amplimer,  larger  than  the  wild-type  galE  gene 
(Fig.  57).  However,  inoculation  of  the  strains  into  minimal  medium 
containing  galactose  showed  suppression  of  growth  compared  to  the  wild  type 
strains  (Fig.  58).  These  data  indicated  that  the  suicide  vectors  containing  the 
deleted  galE  allele  integrated  into  the  P.  multocida  chromosome  as  a  first 
cross-ever  event  but,  in  a  second  cross-over  event,  part  of  galE  locus  was 116 
duplicated.  After  subculture,  the  galE  mutation  reverted  to  the  wild-type  or,  as 
reported  by  Germanier  and  Furer  (1971),  the  frequency  of  secondary 
mutations  in  the  galE  locus  was  sufficiently  high  in  vitro  to  select  for  the  wild- 
type  genotype. 
4.4.  Spread  of  P.  multocida  into  different  organs  of  the 
mouse 
The  BALB/c  mice  were  highly  susceptible  to  infection  by  P.  multocida 
whether  introduced  i.  p.  or  i.  n..  The  growth  of  the  challenge  organism  in  the 
liver,  lung,  spleen  and  blood  was  quantitated  daily  for  up  to  4  days.  P. 
multocida  parent  strains  were  able  to  multiply  very  rapidly  in  vivo,  so  that  the 
introduction  of  a  small  number  of  viable  bacteria  into  the  peritoneal  cavity  of 
non-vaccinated  mice  quickly  resulted  in  an  in  vivo  population  of  more  than  109 
viable  organisms  per  gram  of  liver,  lung,  spleen  and  blood  resulting  in  death  of 
the  mice  within  24  hrs.  As  suggested  by  Collins  (1973),  it  is  probable  that 
unrestricted  extracellular  growth  of  the  unopsonised  organisms  occurs  within 
the  peritoneal  cavity.  This  is  due  to  the  virtual  absence  of  phagocytosis  and 
inactivation  of  the  challenge  inoculum  by  the  host  macrophages,  which  allows 
this  organism  to  grow  in  the  tissue  at  rates  normally  only  achievable  in  vitro.  In 
contrast,  for  the  P.  multocida  JRMT  1  and  JRMT2  aroA  mutant  strains,  after 
high  challenge  dose  (107  C.  F.  U.  /  mouse),  the  bacteria  were  able  to  spread 
into  the  liver,  spleen  and  blood  after  24  hrs,  but  at  greatly  reduced  numbers  of 
viable  bacteria  compared  to  the  parent  strains.  In  the  lungs,  however,  no 
colonies  were  detected.  After  48  hrs,  all  mice  given  =700  C.  F.  U.  of  the  wild- 
type  parent  strains  had  died  but  the  aroA  mutant  strains  even  at  doses  of  107 
C.  F.  U.  had  been  cleared  and  no  colonies  were  detected  in  any  of  the  internal 
organs  except  for  a  few  bacteria  detected  in  the  liver  of  one  mouse  inoculated 
with  107  C.  F.  U.  of  the  JRMT2  (Table  23). 117 
When  mice  were  given  P.  multocida  strains  i.  n.  at  an  initial  challenge  dose 
of  104  C.  F.  U.,  after  24  hrs,  the  wild-type  strain  85020  decreased  but  after  48 
hrs  had  increased  more  than  100  times  in  the  lungs  and  also  the  infection  had 
spread  to  the  liver,  spleen  and  blood.  In  contrast,  the  initial  challenge  dose  of 
strain  Quetta  had  decreased  by  48  hrs.  A  similar  situation  was  reported  by 
Collins  (1973)  where  wild-type  P.  multocida  strains  serotype  5:  A  isolated  from 
turkey  when  inoculated  i.  n.  replicated  rapidly  in  unvaccinated  mice,  and  after 
24  hrs,  the  bacteria  had  spread  into  the  internal  organs.  However,  in  the 
present  work,  the  number  of  the  aroA  mutant  strains  in  the  lungs  was  reduced 
by  about  105  times  after  24  hrs  and  only  a  few  colonies  were  detected  in  blood 
and  in  the  liver.  Interestingly,  the  aroA  mutants  did  persist  in  the  lungs  for  up 
to  96  hrs,  but  appeared  to  be  largely  confined  to  this  location.  It  was  clear, 
however,  that  this  degree  of  persistence  was  sufficient  to  engender  a  protective 
immune  response  because  i.  n.  vaccination  of  JRMTI  and  JRMT2  fully 
protected  mice  against  challenge  with  the  virulent  parent  strains  if  a  two  dose 
vaccination  schedule  was  used  (Table  19). 
4.5.  Phagocytosis  assay 
Until  recently,  the  Pasteurellae  were  generally  considered  to  be  extracellular 
pathogens  associated  predominantly  with  the  respiratory  tract  of  animals  and 
birds,  and  accordingly,  it  was  assumed  that  humoral  immunity  played  the 
principal  role  in  control  of  P.  multocida  infections.  However,  some 
investigations  have  shown  that  avian  strains  of  P.  multocida  serotypes  A:  3  and 
3,4:  A  can  enter  and  survive  within  eukaryotic  cells  (Collins,  1973;  Lee  et  al., 
1994;  Rabier  et  al.,  1997).  Collins  (1973)  found  that  mouse  alveolar  and 
peritoneal  macrophages  killed  80-90%  of  those  P.  multocida  taken  up  within 
about  60  min  in  vitro,  but  the  surviving  organisms  multiplied  extensively  and 
complete  sterilisation  was  never  achieved  in  their  experiments. 118 
When  we  exposed  P.  multocida  85020  and  its  aroA  mutant,  strain  JRMT  I 
strains  to  macrophage-like  cells,  both  strains  entered  RAW  cells  and  survived 
for  at  least  2  hrs  and  the  number  of  intracellular  bacteria  decreased  over  2  hrs. 
According  to  the  Table  25,  the  number  of  phagocytosed  aroA  mutant  bacteria 
was  more  than  that  of  its  wild-type  parent  strain  but  the  reason  for  this  is  not 
clear.  Truscott  and  Hirsh  (1988)  proposed  that  P.  multocida  produces  a 
substance(s)  that  interferes  with  the  function  of  phagocytic  cells.  Toxins  with 
similar  activity  have  been  demonstrated  in  P.  (Mannheimia)  haemolytica 
isolated  from  cattle  (Kaehler  et  al.,  1980;  Baluyut  et  al.,  1981;  Chang  et  al., 
1985)  and  in  P.  multocida  isolated  from  rabbits  (Anderson  et  al.,  1984;  Chang 
et  al.,  1985;  Chanter  et  al.,  1986).  Also  Lee  et  al..  (1994)  noted  that  the 
virulent  strain  of  P.  multocida  serotype  3,4:  A  consistently  attained  invasion 
levels  in  turkey  epithelial  monolayer  at  least  one  log  greater  than  avirulent 
strains.  Intracellular  survival  of  recombinant,  bioluminecent  Bordetella 
bronchiseptica  was  evaluated  by  Forde  et  al.  (1998).  They  found  that  B. 
bronchiseptica  could  survive  for  at  least  4  days  in  mouse  macrophage-like 
cells  and  that  a  critical  population  size  appeared  to  be  for  intracellular 
persistence.  The  potential  for  cell  invasion  and  intracellular  survival  of  P. 
multocida  B:  2  strains,  in  macrophage  and  other  cell  types,  deserves  further 
study,  perhaps  with  the  use  of  bioluminecent  derivatives. 
4.6.  Conclusion 
The  results  presented  here  have  shown  that  aroA  derivatives  of  the  P. 
multocida  B:  2  strains  may  represent  excellent  candidates  for  an  attenuated  live 
vaccine  against  HS.  Attenuated  strains  of  P.  multocida  B:  2  have  been 
constructed  by  interruption  or  deletion  of  the  aroA  and  cya  genes.  The  safety 
and  efficacy  of  these  strains  has  been  demonstrated  in  a  mouse  model  of 
infection.  The  next  requirement  is  to  evaluate  the  kinetics  of  antibody 
responses  following  adminstration  of  live  aroA  vaccine  and  antibody  classes 
after  inoculation  by  different  routes,  such  as  i.  n.  and  i.  p.  Vaccine  trials  in  the 119 
target  species,  either  cattle  or  buffaloes,  will  however  be  needed  in  order  to 
establish  that  the  safety  and  protective  properties  demonstrated  in  the  mouse 
are  reflected  in  similar  properties  in  cattle  or  buffaloes. 
Although,  both  KmR  and  deletion  derivatives  of  the  aroA  locus  were 
obtained  in  this  work,  the  other  two  loci  tested,  cya  and  galE,  were 
remarkably  intractable  to  allelic  exchange.  The  reasons  for  this  are  not 
obvious.  One  explanation  would  be  that  P.  multocida  B:  2  has  more  than  one 
chromosome  carrying  duplications  of  the  cya  and  galE  genes.  This  would 
explain  why  both  wild-type  and  mutant  alleles  were  detected  in  recombinant 
colonies.  Increasing  numbers  of  microorganisms  have  been  shown  to  contain 
more  than  one  chromosome  (Kolsto,  1997;  Yamaichi  et  al.,  1999;  Heidelberg 
et  al.,  2000),  for  example,  Heidelberg  et  al.  found  105  genes  with  copies  on 
both  Vibrio  cholerae  chromosomes,  but  whether  this  represents  a  reason  for 
the  problems  found  with  allelic  exchange  in  P.  multocida  must  await  the 
sequencing  of  the  genome  of  this  important  veterinary  pathogen. 120 
5.  APPENDICES 
5.1.  Brain  Heart  Infusion  (BHI)  broth  or  agar 
Brain  Heart  Infusion,  dehydrated  (Oxoid)  37.0  g 
Distilled  water  to  1  litre 
The  medium  dissolved  in  distilled  water  and  sterilised  by  autoclaving  for  20 
0  min  at  121  C.  For  solid  medium,  1.2%  (w/v)  agar  (Technical  No.  3,  Oxoid) 
was  added  before  autoclaving.  The  5%  (v/v)  sheep  blood  (B&E  laboratories, 
Scotland)  supplement  was  added  to  solid  medium  after  it  was  allowed  to  cool 
G 
to  50  C. 
5.2.  Luria-Bertani  (LB)  broth  or  agar 
Tryptone  (Oxoid)  10.0  g 
Yeast  extract  (Oxoid)  5.0  g 
NaC1(Analar,  BDH)  10.0  g 
Distilled  water  to  1  litre 
The  solutes  were  dissolved  in  distilled  water  by  shaking  and  the  pH 
was  adjusted  to  7.0  with  1M  NaOH.  For  solid  medium,  1.2%  (w/v)  agar 
was  added  before  autoclaving. 
5.3.  Preparation  of  LB-X-Gal-IPTG  plates 
20  mg of  X-Gal  (5-bromo-4-chloro-3-indolyl-(3-D-galactoside,  Sigma) 
was  dissolved  per  ml  in  dimethyl  formamide  (Sigma)  and  stored  at 
. 
-20  C. 
200  mg  of  IPTG  (isopropyl-ß-D-thiogalactopyranoside,  Sigma)  was 
G 
dissolved  per  ml  in  distilled  water  and  stored  at  -20  C. 121 
One  ml  of  X-Gal  and  100  [il  of  IPTG  stock  solutions  (it  give  100  µg 
ml-1  final  concentration  of  each)  were  added  to  200  ml  of  melted  LB  agar, 
mixed  by  gentle  rotation  or  inversion  of  the  bottle  and  poured  into  petri 
dishes. 
5.4.  Preparation  of  antibiotic  solutions 
Stock  solutions  of  antibiotics  were  made  at  the  following  concentrations 
(%w/v):  ampicillin  (1%),  kanamycin  (1%),  chloramphenicol  (1%), 
carbenicillin  (3%),  tetracycline  (1.2%).  tetracycline  and  chloramphenicol 
were  dissolved  in  ethanol.  Kanamycin,  ampicillin,  carbenicillin  were 
dissolved  in  distilled  water  and  filter  sterilised  by  passing  the  solution 
through  an  Acrodisc  of  0.45  pm  pore  size  (Milipore).  All  antibiotic 
0  solutions  were  stored  at  -20  C. 
5.5.  Tris-EDTA  (TE)  buffer,  pH  8.0 
Per  L  of  dH2O  Final  conc. 
Tris  1.212  g  10  mM 
EDTA  0.372  g  1.0  mm 
Dissolved  in  H2O,  the  pH  adjusted  to  8  with  HCI,  sterilised  by 
00 
autoclaving  at  121  C  for  20  min  and  stored  at  4  C. 
5.6.  Tris-Boric  acid-EDTA  (TBE)  buffer  (lOx  stock  solution): 
Per  L  of  dH2O  Final  conc. 
Tris  107.8  g  89  mM 
Boric  acid  55.0  g  89  mM 
EDTA  1.488  g2  mM 
Dissolved  in  distilled  water  by  gently  stirring  with  a  magnetic  stirrer  and 
stored  at  room  temperature. 122 
5.7.  SOC  medium 
A)  SOC  base 
Per  L  of  dH2O  Final  conc. 
Tryptone  20.0  g  2%  (w/v) 
yeast  extract  5.0  g  0.5%  (w/v) 
NaC1  0.58  g  10  mm 
KC1  0.18  g  2.5  mM 
The  solutes  were  dissolved  by  shaking  and  the  pH  was  adjusted  to  7.0 
C 
with  NaOH.  The  broth  was  sterilised  by  autoclaving  and  stored  at  4  C. 
B)  SOC  Additive  (lOx  concentration): 
Per  100  ml  dH2O  Final  conc. 
glucose:  2.0  g  20  mM 
MgCl2,6H20  2.03  g  10  mm 
MgSO4,7H20  2.46  g  10  mm 
The  solutes  were  dissolved  by  using  a  magnetic  stirrer,  filter  sterilised 
and  stored  at  40C.  The  SOC  additive  was  added  to  SOC  base  in  a  ratio  of 
1:  10  just  before  use. 
5.8.  Terrific  broth 
A)  Basal  medium 
To  900  ml  of  distilled  water  were  added: 
Tryptone  12.0  g 
Yeast  extract  24.0  g 
Glycerol  4.0  ml 
B)  Additive 
To  100  ml  of  distilled  water  were  added: 123 
KH2PO4  2.31  g 
K2HPO4  12.54  g 
Both  basal  medium  and  additive  were  made  up  separately,  sterilised  by 
autoclaving  and  mixed  together  before  use. 
5.9.  Gel-loading  buffer 
Sucrose 
Bromophenol  blue 
40%  (w/v) 
0.25%  (w/v) 
Dissolved  and  mixed  well  in  sterile  distilled  water  and  stored  in  aliquots  at 
C 
-20  C. 
5.10.  Pasteurella  Minimal  Medium  (PMM): 
Composition: 
Components  mm  g/  L 
1.  Glucose  11.1  1.999 
2.  Sucrose  7.3  2.4988 
3.  Na2SO3  1.6  0.2016 
4.  K2HPO4  23.0  4.006 
5.  FeS04,7H20  0.01  0.0028 
6.  NH4C1  9.5  0.5082 
7.  K2SO4  0.28  0.0488 
8.  CaC12,2H20  5x10-4  7.35x10-5 
9.  M902,6H20  0.53  0.1078 
10.  NaCl  50.0  2.922 
11.  L-Cysteine  2.9  0.457 
12.  L-Methionine  4.5  0.6714 
13.  L-Leucine  5.0  0.656 
14.  L-Glutamic  acid  4.5  0.6621 
15.  Nicotinamide  24.6  3.0037 
16.  Ca.  Pantothenate.  5.9  1.41 
17.  Thiamine  HCl  4.5  1.5178 124 
Reagents  3-10  were  dissolved  in  distilled  water  and  autoclaved,  reagents  1 
and  2  were  dissolved  separately  in  distilled  water  and  filter  sterilised  and 
reagents  11-  17  were  dissolved  in  distilled  water  and  filter  sterilised  and 
0 
stored  at  4C.  All  reagents  were  mixed  together  just  before  use.  When 
required,  an  "aromix"  supplement  consisting  of  L-tryptophan  and  L- 
phenylalanine  (Sigma),  each  to  a  final  concentration  of  40  µg/  ml,  and  2,3 
dihydroxybenzoic  acid  and  p-hydroxybenzoic  acid  (Sigma)  each  at  10  µg/  ml 
were  added. 
S.  11.  Southern  blot  hybridisation  reagents 
a.  Maleic  acid  Buffer: 
Per  L  of  dH2O  Final  conc. 
Maleic  acid  11.6  g  0.1  M 
NaCl  8.76  g  0.15  M 
The  pH  was  adjusted  to  7.0  with  concentrated  or  solid  NaOH,  the  solution 
autoclaved  and  stored  at  room  temperature. 
b.  Blocking  reagent  (stock  solution): 
Blocking  reagent  (Boehringer  Mannheim,  Germany)  was  dissolved  in 
maleic  acid  buffer  to  a  final  concentration  of  10%  (w/v)  with  shaking  and 
heating. 
c.  20x  SSC 
Per  L  of  dH2O  Final  conc. 
NaCl  175.32  g  3.0  M 
Tri  sodium  citrate  88.0  g  0.3  M 
The  pH  was  adjusted  with  HCI  to  =7.0 
d.  Standard  hybridisation  solution 
In  5x  SSC  was  added: 125 
N-laurylsarcosine  (from  10%  stock  solution) 
SDS  (from  10%  stock  solution) 
Blocking  reagent  (from  10%  stock  solution) 
e.  Washing  buffer 
Add  0.3%  (v/v)  Tween  20  to  the  maleic  acid  buffer. 
0.1%  (v/v) 
0.02%  (v/v) 
1%  (v/v) 
f.  Blocking  buffer 
Dilute  blocking  reagent  stock  solution  1:  10  with  maleic  acid  buffer. 
g.  Detection  buffer 
Per  L  of  dH2O 
Tris-HCI  12.1  g 
NaCl  5.85  g 
h.  2x  washing  solution 
Into  2x  SSC  add  0.1%  (v/v)  SDS 
i.  0.5x  washing  solution 
Into  0.5x  SSC  add  0.1%  (v/v)  SDS 
j.  Probe  stripping  solution 
Into  0.2  N  NaOH  was  added  0.1%  (v/v)  SDS 
Final  conc. 
100mM 
100  mM 
5.12.  Denaturation  solution  (for  agarose  gel) 
Per  L  of  dH2O  Final  conc. 
NaOH  20.0  g  0.5  N 
NaCl  87.66g  1.5M 
Dissolved  and  stored  at  room  temperature. 
5.13.  Neutralisation  solution  (for  agarose  gel) 
Per  L  of  dH2O  Final  conc. 
Tris-HCI  60.57  0.5  M 126 
NaCl  87.66  3.0  M 
Dissolved,  adjast  pH  to  7.5  with  concentrared  HCl  and  stored  at  room 
temperature. 
5.14.  Assay  buffers  and  reagents 
A.  Reagents  for  protein  assay: 
Reagent  A:  2%  (w/v)  Na2CO3  in  0.1  N  NaOH 
Reagent  B:  0.5%  (w/v)  CuSO4,5H20  in  1%  (w/v)  sodium 
tartarate 
Reagent  C:  Mix  50  ml  of  reagent  A  with  1  ml  of  reagent  B, 
daily  prepared  fresh 
Reagent  D:  Commercial  Folin-  Ciocalteu  reagent  (Sigma) 
diluted  with  distilled  water  1:  1 
B.  2x  EPSP  assay  buffer 
Potassium  phosphate  buffer  1M  (pH  7.0) 
ADP  25  mM 
MgC121  M 
H2O 
C.  One  mM  stock  EPSP 
Barium  EPSP  (white  solid) 
Di-potassium  sulphate  (K2SO4)  0.5M 
H2O 
20  ml 
20  ml 
0.5  ml 
to  100  ml  (=59.5  ml) 
3.5  mg 
50  µl 
5.  O  ml 
Stir  until  a  milky  suspension  results,  then  spin  off  precipitate  and 
collect  supernatant  carefully. 127 
5.15:  Mohammad  Tabatabaei  (MT)  minimal  medium 
Composition: 
Components  /gL 
1.  Na2HPO4  5.8 
2.  KH2PO4  3.0 
3.  NaCl  0.5 
4.  NH4C1  1.0 
5.  MgSO4.7H20  0.247 
Vitamin  additives: 
1.  Thiamine  HCl  1.5 
2.  L-Cysteine  0.09 
3.  L-Methionine  0.13 
4.  L-Leucine  0.13 
5.  L-Glutamic  acid  0.13 
6.  Nicotinamide  0.6 
7.  Ca.  pantothenate  0.28 
The  reagents  1-  4  were  dissolved  in  an  appropriate  volume  of  distilled 
water  and  autoclaved  and  before  use  filter  sterilised  vitamin  additives,  MgSO4 
solution  (5  ml  from  200  mM  solution/  L)  and  sugars  (0.2-0.4%  w/v)  were 
added.  For  making  solid  media,  1.2%  (w/v)  bacteriological  agar  plus  reagents 
1-4  were  dissolved  in  an  appropriate  volume  of  distilled  water  and  autoclaved. 
Then,  before  pouring,  filter  sterilised  vitamin  additives,  MgSO4  solution  (5 
ml  from  200  mM  solution  /  L)  and  sugars  (0.2-0.4%  w/v)  were  added. 
5-  16.  Bordet-Gengou  medium 
Bordet-Gengou  agar  base  (Difco):  30.0  g 
Bacteriological  agar  (Oxoid)  15.0  g 
Distilled  water:  to  1  litre 128 
Boiled  to  dissolve  in  distilled  water  containing  10  g  glycerol  and 
C 
sterilised  by  autoclaving  for  15  min  at  121  C.  The  20%  (v/v)  defibrinated 
horse  blood  (B&E  laboratories,  Scotland)  supplement  was  added  to  solid 
0  medium  after  it  was  allowed  to  cool  to  =50  C. 
S.  17:  Cyclodextrin  liquid  (CL)  medium: 
Compositins: 
Components  g/  L 
1.  Sodium  L-glutamate  10.7 
2.  L-Proline  0.24 
3.  NaCl  2.5 
4.  KH2PO4  0.5 
5.  KCl  0.2 
6.  MgC12.6H20  0.1 
7.  CaC12  0.02 
8.  Tris  6.1 
9.  Casamino  acids  10.0 
10.  MeßCD  1.0 
11.  L-Cysteine  0.04 
12.  FeSO4.7H20  0.01 
13.  Niacin  0.004 
14.  Glutathione  (reduced)  0.15 
15.  Ascorbic  acid  0.4 
Reagents  1-10  were  dissolved  in  950  ml  of  distilled  H2O  and  pH  adjust  to 
7.6  with  3.0  N  HCl  then  autoclaved  at  121*C  for  15  min.  Reagents  11-  15 
dissolved  in  50  ml  distilled  H20,  filter  sterilised  and  added  to  the  autoclaved 
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